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Tricellulin (Tric) is a tight junction protein at tricellular contacts; however its exact structure, 
function and regulation are unclear. Tric contributes to the paracellular tightening by intercellular 
trans-interactions between its extracellular loops 2 (ECL2). Consequently, trictide, a peptide 
derived from the Tric ECL2 was designed as a potential drug enhancer to specifically overcome 
tissue barriers. This work is aimed to investigate the functional and molecular modulations of 
tricellular contacts caused by trictide and to understand essential elements and protein interactions 
of tricellular tight junctions (tTJ) for barrier formation.  
Trictide increased the passage of ions, small and larger molecules up to 10 kDa in a concentration 
dependent manner over duration from 16 h to 47 h after application to human colon epithelial cells. 
Under normal conditions, lipolysis-stimulated lipoprotein receptor (LSR) and Tric localized at tTJs 
while occludin (Occl), claudin-5 (Cldn5) and claudin-1 (Cldn1) localized at bicellular TJs (bTJ). 
After trictide treatment, Tric and LSR moved from tTJs to bTJs, and the bTJ proteins Cldn1 and 
Occl were internalized. Trictide also decreased the transcellular resistance of brain endothelial cells 
after 14 h and caused enrichment of Cldn5 around the tri-cellular area. Trictide down-regulated 
Occl, Tric, Cldn1, Cldn5 in epithelial cells and LSR, Occl, Cldn1 in mouse brain endothelial cells. 
Trictide-initiated opening of the tricellular sealing tube revealed a Tric-free area at the tricellular 
region as demonstrated by super resolution microscopy. In different cells, cis-interactions of Tric–
Tric (tTJs), Tric–Cldn1, Tric–marvelD3, and Occl–Occl (bTJs) were strongly reduced by trictide 
treatment. In normal brain capillaries of different species, Tric was localized both at bTJs and tTJs 
while LSR was found exclusively at tTJs. In vivo, trictide did not increase the uptake of small 
molecules by mouse kidney and liver but tended to enhance brain uptake. Circular dichroism 
spectroscopy and molecular modelling suggested that trictide consists of 50% β-sheet structure 
resulting in an elongated conformation. Contrarily, scrambled trictide has a globular shape. 
Molecular docking models of trictide support the assumption that outward-directed aromatic amino 
acids are involved in a binding to tricellulin.  
In conclusion, trictide is a novel and promising tool for overcoming cellular barriers at bTJs and 
tTJs with the potential to improve permeation of small molecules. Moreover, after targeting the 
cellular junctions, a connection has been disclosed between the disturbances of mutual interactions 






Tricellulin (Tric) ist ein in trizellulären Kontakten lokalisiertes tight junction (TJ)-Protein; 
seine genaue Struktur, Funktion und Regulation sind jedoch nicht bekannt. Tric trägt zur 
parazellulären Dichtheit durch die Ausbildung interzellulärer trans-Interaktionen zwischen 
seinen zweiten extrazellulären Schleifen (ECL2) bei. Daher wurde mit Trictid ein aus dem 
ECL2 von Tric abgeleitetes Peptid entwickelt, das als potentieller Wirkungsverstärker die 
spezifische Überwindung von Gewebsbarrieren ermöglichen soll. In der vorliegenden Arbeit 
werden Trictid-induzierte funktionelle und molekulare Veränderungen trizellulärer Kontakte 
untersucht um zum Verständnis essentieller Elemente und Proteininteraktionen von 
trizellulären tight junc-tions (tTJ) für die Ausbildung von Barrieren beizutragen. 
In Abhängigkeit von seiner Konzentration erhöhte Trictid die Passage von Ionen und Mole-
külen mit mM < 10 kDa innerhalb von 16 h bis 47 h nach Zugabe zu Kulturen humaner 
Darmepithelzellen. Unter Normalbedingungen lokalisierten der Lipolyse-stimulierte Lipopro-
teinrezeptor (LSR) und Tric in den trizellulären tTJs, während Occludin (Occl), Claudin-5 
(Cldn5) und Claudin-1 (Cldn1) in den bizellulären TJs (bTJs) gefunden wurden. Nach Trictid-
Behandlung erfolgte die Relokalisation von Tric und LSR zu den bTJ, und Cldn1 und Occl 
wurden internalisiert. Darüber hinaus verringerte sich der transzelluläre Widerstand von Ge-
hirnendothelzellen 14 h nach Trictide-Zugabe, und eine Anreicherung von Cldn5 im trizellulä-
ren Bereich wurde beobachtet. Trictid-Applikation führte zur Herabregulation von Occl, Tric, 
Cldn1, Cldn5 in Epithelzellen und von LSR, Occl und Cldn1 in murinen Gehirnendothelzel-
len. Untersuchungen mit superauflösender Mikroskopie zeigen, dass die Trictid-induzierte 
Proteinrelokalisation die Ausbildung eines Tric-freien Bereichs in der trizellulären Region be-
wirkte. Die cis-Interaktionen Tric-Tric (tTJs), Tric–Cldn1, Tric–marvelD3 und Occl–Occl 
(bTJs) wurden durch Trictid-Behandlung stark reduziert. 
In normalen Gehirnkapillaren verschiedener Spezies lokalisierte Tric in den bTJs und tTJ, 
während LSR ausschließlich in den tTJ gefunden wurde. In vivo wurde die Aufnahme kleiner 
Moleküle durch Niere und Leber der Maus nicht durch Trictid beeinflußt, jedoch eine ten-
denziell erhöhte Aufnahme in das Gehirn beobachtet. Circulardichroismus-Spektroskopie und 
molekulares Modelling lassen darauf schließen, dass Trictid zu 50% eine β-Faltblattstruktur 
annimmt und in einer gestreckten Konformation vorliegt. Molekulares Docking von Trictid 
legt nahe, dass auswärts gerichtete Aminosäuren für eine Bindung an Tric von Bedeutung sind. 
 Die durchgeführten Untersuchungen lassen den Schluß zu, dass Trictid ein neuartiges und 
vielversprechendes Werkzeug für die Überwindung zellulärer Barrieren von bTJ und tTJ dar-
stellt und das Potential besitzt, als Permeationsverstärker für kleine Moleküle zu dienen. Dar-
über hinaus wurde durch die zielgerichtete Einflußnahme auf die zellulären Junctions ein Zu-
sammenhang zwischen der Störung der gegenseitigen Interaktionen und der daraus resultie-
renden Umverteilung der TJ-Proteine und den funktionalen Veränderungen der Barriere auf-
gedeckt. 
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It is essential to have separate compartments with different molecular compositions for the 
development and maintenance of multicellular organisms. These compartments are defined 
by various cellular sheets which function as barriers that maintain the distinct internal 
environments of each compartment within the organs. For instance, renal tubules and blood 
vessels are lined with epithelial and endothelial cellular sheets, respectively (Tsukita et al., 
2001). Tissue-specific intercellular junctions where individual cells are linked to each other 
are a critical part of tissue barriers for maintaining the structural integrity. The intercellular 
space between adjacent cells is sealed to prevent diffusion of solutes through the 
intercellular space within these sheets. Tissue barriers constitute a line of defense against 
microorganisms, toxins, and allergens (Chaplin, 2010). The junctional complex of simple 
epithelial cells is located at the most-apical part of the lateral plasma membrane and 
consists of three components: tight junctions, adherens junctions, and desmosomes in 
vertebrates (Farquhar and Palade, 1963). Various human diseases are related to epithelial 
or endothelial barrier dysfunctions caused by dismodulation of barrier properties like 
stroke (Luissint et al., 2012; Marchiando et al., 2010) and brain tumors (Tiwary et al., 
2018). This causes loss of stromal homeostasis and alters fluid-electrolyte balance between 
compartments. Disrupted barriers also permit bacterial invasions and allow metastatic cells 
to break in and out of blood vessels (Mullin et al., 2005).  
 
1.1. ORGANIZATION AND FUNCTION OF EPITHELIUM AND 
ENDOTHELIUM 
Epithelial tissues cover the inner and outer surfaces of the body and act as cellular 
boundaries. Epithelium is one of the four basic tissue types covering muscle, nerve and 
connective tissues. Epithelial cells has role in barrier formation, transcellular transport, 
secretion and selective absorption between the compartments. Epithelia provide protection 
against mechanical damage, entry of microorganisms, and dehydration. Epithelia have no 
blood vessels, so it is dependent on the underlying connective tissue for nutrition by 





exposed to the lumen and basolaterally they are in contact with laterally adjacent epithelial 
cells and the basement membrane (Fig. 1.1A). The cells of the epithelium are usually in 
close proximity to each other and are rich in cell-cell contacts (Denker and Nigam, 1998; 
Rodriguez-Boulan and Macara, 2014).  
 
Fig. 1.1 The junctional complex in epithelial cells and endothelial cells. (A) Tight junction (purple) is 
positioned at the apical part of epithelial cells. Adherens junctions (green) is located below the tight 
junctions. The orange-belt in the middle is a part of the intracellular actin cytoskeleton that constitute 
polarized epithelium. (B) In endothelium both tight junctions (purple) and adherens junctions (green) are 
present but intermingled through the junctions. (Modified from Zihni et al., 2016) 
 
Single layered endothelial cells cover blood and lymphatic capillaries and also cover the 
myocardium. Endothelial cells adhere to one another through junctional structures formed 
by transmembrane adhesive proteins that are responsible for homophilic cell-to-cell 
adhesion (Fig 1.1B). In turn, the transmembrane proteins are linked to specific intracellular 
partners that mediate anchorage to the actin cytoskeleton and, as a consequence, stabilize 
junctions. Endothelial junctions control permeability to plasma solute, leukocyte 
extravasation, and infiltration into inflamed areas. Junctional proteins can also transfer 
intracellular signals, which modulate endothelial cell growth and apoptosis (Bazzoni, 
2004).  
Endothelial and epithelial cell junctions share common components. Both cell types have 
two major types of junctions that are responsible for cell-to-cell adhesion: adherens 
junctions (AJ) and tight junctions (TJ) (Fig. 1.1). Additionally, epithelial cells form 
desmosomes (which are absent in the endothelium) and gap junctions that facilitate cell-to-
cell communication (Fig 1.2). Gap junctions are formed by connexions that are expressed 
in the endothelium and function as channels for the intercellular passage of ions and small-






Fig. 1.2 The localization of tight junctions relative to other junctional components of epithelial cells. 
Schematic illustration of intestinal epithelial cells. The junctional complex containing TJs is circled. TJs are 
located at the most apical position of lateral membrane. (B) Electron micrograph of the junctional complex in 
mouse intestinal epithelial cells. The tight junction is circled. (Mv, microvilli; TJ, tight junction; AJ, adherens 
junction; DS, desmosome.) Scale bar, 200 nm. (Modified from Tsukita et al., 2001)  
 
In epithelial cells, junctions are better organized, with TJ and AJ following a well-defined 
spatial distribution along the intercellular cleft. TJ (or zonula occludens) are concentrated 
at the apical side of the rim, while AJ (or zonula adherens) are located below the TJ. In 
contrast, the junctional architecture in endothelial cells is less defined and AJ are 
intermingled with TJ along the cleft (Fig 1.1) (Bazzoni, 2004; Tsukita et al., 2001; Zihni et 
al., 2016). 
 
1.2. TIGHT JUNCTIONS 
The tight junctions (TJ) were discovered by freeze-fracture electron microscopy, decades 
before its molecular identification (Staehelin et al., 1969; Staehelin, 1973; Stevenson et al., 
1986). TJ strands were observed as a set of continuous or discontinues lines surrounding 
the apical part of adjacent epithelial cells. The TJ strands can be seen on both sides of the 
fracture plane. On the P-face, the protoplasmic side of the fracture, the TJ strands are 
clearly visible. On the E-face, the exoplasmic side, empty grooves complementary to those 
strands are detectable (Fig. 1.3A) (Shoichiro Tsukita et al., 2001). TJs appear as a series of 





leaflets of the plasma membranes of neighboring cells (Fig. 1.3C). In simple epithelium, 
AJs and desmosomes mechanically connect adjoining cells, whereas TJs are responsible 
for intercellular sealing. The intercellular space between opposing membranes in AJs and 
desmosomes is 15–20 nm apart while this space is completely removed at the “kissing 
points” (Gumbiner, 1993; Schneeberger and Lynch, 2004). 
Fig. 1.3. The structure of tight junctions. (A) An image of intestinal epithelial cell taken by freeze-fracture 
replica electron microscopy. Tight junctions can be observed as continuous, intramembranous strands 
o(arrowheads) on the P-face with complementary empty grooves on the E-face (arrows). (Mv, microvilli; Ap, 
apical membrane; Bl, basolateral membrane.) Scale bar, 200 nm.  (B) The kissing points: tight junctions 
(arrowheads) seal intercellular space between two cells. (C) Three dimensional structural scheme of tight 
junctions. Tight junction strands from membrane of two opposing cells interact to form the kissing points that 
tighten intercellular space. (Modified from Tsukita et al., 2001) 
 
There are two permeation pathways through cell barriers: the transcellular pathway passes 
through the cell, crossing the apical and basolateral cell membranes, while the paracellular 
pathway passes between the cells through the TJ. TJs function as a barrier for paracellular 
diffusion of water, ions, metabolites and macromolecules. They also function as a fence, 
separating apical from basolateral parts of the cell membrane. However, TJs are not simply 
impermeable barriers. They show ion as well as size selectivity, and differ in tightness 
depending on the cell type. Generally, the proximal segments in epithelia-forming tubules 
such as intestine, nephron and sweat gland are more permeable; in comparison with TJs at 
distal segments, which are categorized as slightly permeable. The tightest TJs are found in 
skin and urinary bladder. Thus the sealing or permeability function of the TJ is strongly 
determined by its molecular composition (Fromter and Diamond, 1972). TJ meshwork of 
strands is formed by transmembrane proteins that play a role in the paracellular barriers. 
TJs are also associated with cytosolic scaffolding proteins that form the platform between 





Mainly, TJ transmembrane proteins consist of claudins (Cldns) with 27 members in 
mammals (Morita, et al., 1999) and TJ-associated MARVEL (MAL and related proteins 
for vesicle trafficking and membrane link) proteins (TAMPs) (Blasig et al., 2011; Sánchez-
Pulido et al., 2002). TAMP family proteins are occludin (Occl) (Furuse et al., 1993), 
tricellulin (Tric) (Ikenouchi et al., 2005) and marvelD3 (MD3) (Steed et al., 2009). 
Cytosolic scaffolding proteins, such as zonula occludens protein (ZO)-1 to -3 belong to the 
membrane-associated guanylate kinase (MAGUK) family (Stevenson et al., 1986). 
 
1.2.1. Bicellular and tricellular tight junctions 
In endothelial or epithelial cell sheets, TJs are located between two cells (bicellular TJs) or 
where three cells (tricellular TJs) meet. These points are called either bicellular or 
tricellular contacts. At tricellular contacts, apically localized bicellular TJ (bTJ) strands 
meet and turn into basolateral direction to connect three cells. These triple pair structures 
firmly attach and extend to form a structure called central sealing tube (Staehelin, 1973) 
(Fig. 1.4A). Other bTJ strands connect to this central sealing tube laterally in order to 









Fig. 1.4 Structure of tricellular and bicellular tight junctions. (A) A schematic illustration of tricellular 
and bicellular tight junctions. The central sealing tube in the middle is formed by tricellular tight junction 
proteins; tricellulin and lipolysis-stimulated lipoprotein receptor (LSR) and elongates through basal direction. 
(bTJ, bicellular tight junctions; tTJ, tricellular tight junctions). (Modified from Krug et al., 2017). (B) Freeze-
fracture replica electron microscopic image of tricellular tight junctions of neighbouring epithelial cells (from 
mouse renal cortical collecting duct). Tricellullar TJ strands turn to extend basolaterally. Claudin-based tight 
junctions can be observed at the bicellular area. (Modified from Staehelin et al., 1973) 
 
Staehelin and his colleagues initially proposed the tricellular cell-cell TJ model in 1973. 
Today the model is still valid and evolving with additional discoveries. Tric and LSR 
(Lipolysis-stimulated lipoprotein receptor or Angulin-1) are the main actors of central 
sealing at tricellular contacts (Krug et al., 2009; Masuda et al., 2011). The composition of 
TJ proteins varies between bicellular and tricellular junctions. Bicellular TJs regulate 
passage of small ions, water and constitute a barrier against other molecules while 
macromolecules can pass through tricellular TJs (tTJ). The length of the central sealing 
tube is about 1 µm, depending on the type of cell. Its radius is estimated as 5 nm, which 
allows transfer of macromolecules up to 10 kDa (Krug et al., 2009; Staehelin, 1973; Wade 






1.3. TIGHT JUNCTION PROTEINS 
1.3.1. Claudins 
Cldn1 and Cldn2 were the earliest discovered members of the Cldn family as integral 
membrane proteins at TJs ( Furuse et al., 1998). Cldns are a large family of TJ proteins 
with 26 members currently identified in human. Their molecular masses are between 21-34 
kDa (Günzel and Yu, 2013; Mineta et al., 2011). Cldns belong to the tetraspan proteins, 
thus possessing four transmembrane domains: an intracellular short N-terminal, an 
intracellular longer C-terminal region, a small intracellular loop and two extracellular two 
loops (ECL), of which the first loop is larger than the second. The first crystal structures of 
Cldns provided more insight about spatial organization and ion homeostasis across TJs 
(Suzuki et al., 2014). Cldn family includes a signature sequence (GLW) within ECL1 and 
COOH-terminal PDZ-binding motif, through which most of the Cldns interact with tight-
junction associated scaffolding or adaptor proteins (Günzel and Yu, 2013).  
According to phylogenetic analysis, Cldns with higher sequence similarity were grouped as 
classical Cldns: 1-10, 14, 15, 17 and 19. Cldn 11, 16, 18, 21, 25 were accepted as non-
classic Cldn. (Krause et al., 2008; Mineta et al., 2011, Günzel and Fromm, 2012). Cldns 
are also classified based on their physiological role in paracellular transport, complete 
sealing (Cldn1, 3-6, 8, 9, 11, 14, 18, 19) and formation of channels that are permeable for 
anions (Cldn10a and 17), cations (Cldn2, 10b and 15) or water (Cldn2) (Günzel and 
Fromm, 2012). There is still not much information about the exact function of the rest of 
the Cldn family (12, 13, 20, 22-27).  
Homophilic and heterophilic interactions can take place between Cldns (Furuse et al., 
1999). If the interaction occurs between two Cldns within the plasma membrane of the 
same cell, a cis-interaction prompts Cldn oligomerization (Piontek et al., 2008). The 
interaction via the paracellular space between two cells is called trans-interaction (Fig. 
1.5). Residues in the ECL1 are  involved in the formation of  paracellular ion pores and the 
determination of their charge selectivity (Alexandre et al., 2007). ECL2 of Cldn5 
contributes to trans-interaction between Cldn oligomers from two opposing plasma 
membranes and generates polymerization of TJ strands within the paracellular space 





tighten the BBB for molecules <800 Da (Nitta et al., 2003). The combination of Cldns 
expressed in tissues determines the barrier properties of the respective tissue (Kiuchi-
Saishin et al., 2002). 
 
Fig. 1.5 Schematic illustration of claudin structure and their way of interaction. Claudins are tetraspan 
membrane proteins with two extracellular loops (ECL), cytosolic N- or C-terminal tails and a short intra 
cellular loop (ICL). Claudins can make cis- and trans- interactions through cytosolic N- or C-terminal tails 
and through extracellular loops, respectively. Furthermore these interactions can occur between identical 
proteins (homophilic, yellow dotted circle) or between two different proteins (purple dotted circle). 
(Modified from Krause et al., 2008) 
 
For instance, the knock-out model of Cldn1 demonstrated that lack of Cldn1 causes 
massive transepidermal dehydration. So Cldn1 is an essential component of epidermal 
barrier (Furuse et al., 2002). Cldn5 also has a barrier-forming function as it was confirmed 
by Cldn5 deficient mice and stable transfection of cell lines (Amasheh et al., 2005; Nitta et 
al., 2003). Cldn2 was shown to reduce transepithelial resistance (Furuse et al., 2001) by 
forming paracellular channels for small cations (Amasheh et al., 2002). It is typically found 
in leaky, proximal segments of tubular epithelia such as proximal tubule (Kiuchi-Saishin et 
al., 2002) and small intestine (Markov et al., 2010). There are contradictory statements 
about Cldn4: its overexpression leads to a strong decrease in cation permeability, while the 
permeability for anions remains unchanged (Van Itallie et al., 2001). In addition, the 
presence of Cldn4 increases the TJ complexity (Colegio et al., 2002). On the other hand, 
Hou and his colleagues claim that Cldn4 has a sodium channel function (Hou et al, 2010). 





functions as pore-forming Cldn with anion-selective (Cldn10a) (Van Itallie et al., 2006) or 
cation-selective (Cldn10b) (Günzel et al., 2009) properties (Olinger et al., 2018). Claudin 
domain containing (CLDND) 1 (Cldn25) is a non-classical Cldn (Mineta et al., 2011). It 
was recently found that Cldn25 mRNA levels decreased transiently 24 h after cerebellar 
hemorrhage. Moreover, Cldn25 knockdown increased the permeability of human bronchial 
epithelial cells (HBECs) by small molecules (Ohnishi et al., 2017).This large functional 
spectrum of Cldns is also reflected in specific expression patterns in the various endothelia 
and epithelia.  
 
1.3.2. Tight junction associated MARVEL proteins 
The TAMP family shares a conserved tetra-spanning MARVEL domain, which is mostly 
responsible for membrane apposition and is concentrated in cholesterol-rich microdomains 
(Sánchez-Pulido et al., 2002). Members of the TAMP family are Occl  (Furuse et al., 
1993), Tric (Ikenouchi et al., 2005) and MD3 (Steed et al., 2009) (Fig. 1.6A). The structure 
of the TAMP family consists of four transmembrane domains, cytosolic N- and C-
terminus, an intracellular and two extracellular loops similar to Cldns (Raleigh et al., 
2010).  
TAMPs have heterophilic (Occl-MD3, Tric-MD3) and homophilic (Occl, Tric, MD3) cis 
interactions and homophilic trans interactions (Occl) (Cording et al., 2013; Raleigh et al., 
2010). TAMPs form TJ strands in the presence of another tight junction protein like a 
Cldn. For instance, Cldn1 and Cldn5 improved enrichment of Occl and Tric at cell–cell 
contacts. The membrane mobility of Occl and Tric was reduced when they were co-
expressed with Cldn1 (Cording et al., 2013). TAMP knockdowns cause greater reductions 
in transepithelial electrical resistance (TER) compared to when TAMPs are knocked down 
as combinations. This suggests that TAMPs make both overlapping and unique 






Fig. 1.6 Classification of tight junction associated MARVEL domain containing proteins (TAMPs) and 
the organization of TAMPs together with other junctional proteins. (A) Human TAMPs are marked as 
red within the phylogenetic tree of the MARVEL domain containing protein superfamily. (B) The scheme 
illustrates a tricellular tight junction area with tricellulin (green balls) localizing at three cell meeting points 
and elongating at basal direction. Claudins form the backbones of bicellular tight junctions and they are 
represented as black balls within continuous strands here. Occludin (blue balls) is primarily found in 
bicellular junctions. MarvelD3 (orange balls) can be observed at both bicellular and tricellular tight junctions. 




The first identified integral TJ membrane protein was Occl (65 kDa) (Furuse et al., 1993). 
Occl has four transmembrane domains, two extracellular loops and three intracellular 
domains consisting of a short intracellular loop, a short N-terminal and a long C-terminal 
tail (Fig. 1.7A). There is also a conserved MARVEL domain (Raleigh et al., 2010) that 
facilitates self-association and directs Occl to locate in basolateral membrane (Yaffe et al., 
2012). The extracellular regions may interact with other TJ proteins of the opposing cells 
in so-called trans interaction (Cording et al., 2013). The first extracellular loop is rich in 
tyrosine and glycine and plays a role in the cell-cell junction. The second extracellular loop 
has a role in integrating Occl in the TJ complex and in formation of the paracellular barrier 
(Citi and Cordenosi, 1998; Medina et al., 2000). The second extracellular loop has two 
conserved cysteine residues that form an intramolecular disulfide bond that play a role in 





The C-terminus has an ELL domain consisting of an antiparallel coiled-coiled hairpin 
structure (also called coiled-coil-domain). This conserved domain is originally found in the 
RNA polymerase II elongation factor ELL. This domain may interact with other proteins 
belonging to the MAGUK family (Li et al., 2005). This includes the proteins ZO-1, ZO-2 
and ZO-3 (Tsukita and Furuse, 1998), as well as F-actin of the cytoskeleton (Wittchen et 
al., 1999). The C-terminal tail of Occl and TRIC-a demonstrate considerable homology 
(Ikenouchi et al., 2005).  
To what extent Occl is essential for the TJ, is controversial. On the one hand, knockout 
mice show no impairment of barrier function. On the other hand an essential barrier 
function of Occl is demonstrated within the TJ strands (Schulzke et al., 2005). Moreover 
postnatal growth retardations, like histological abnormalities in several tissues and male 
sterility, are found in knockout mice (Saitou et al., 2000). In order to explain this weak 
phenotype, a compensatory mechanism is proposed to maintain barrier integrity. For 
instance, knockdown of Occl altered the localization of Tric from tTJs to bTJs. The 
presence of Occl should exclude Tric from bTJs and support Tric’s tricellular localization 
(Ikenouchi et al., 2008). This interplay between Occl and Tric supports the argument that 
members of TAMP family have distinct but also overlapping functions enabling them to 
compensate for each other (Raleigh et al., 2010). Last of all, Occl is accepted as a general 




MD3 was discovered as the third member of TAMP family (Steed et al., 2009). The human 
MD3 has two isoforms: MD3 isoform-1 contains 401 amino acids (44.9 kDa); isoform-2 
comprises 410 amino acids (45.9 kDa). Two isoforms differ in the sequence of the 
MARVEL domain and size of cytosolic C-terminal tail but are identical in N-terminal tail. 
The C-terminal tail of MD3 does not have coiled coil domain unlike Occ and Tric. Since 
the C-terminal tail is the binding site of Occl and Tric to ZO-1, it is assumed that MD3 
does not interact with ZO-1 (Raleigh et al., 2010; Steed et al., 2009). It is expressed in 





1) differentially (Raleigh et al., 2010). It localizes mostly at bicellular apical regions of 
cells co-localizing with Occl and ZO-1 (Raleigh et al., 2010; Steed et al., 2009).  
Depletion of MD3 does not have any effect on formation of functional paracellular barrier. 
It does not cause mislocalization of other TJ proteins like Occl. Interestingly, TER is 
increased after depletion of MD3 (Steed et al., 2009). It was demonstrated that MD3 is 
transported to TJs immediately after synthesis and in accordance with TER development 
(Raleigh et al., 2010). Taken together, MD3 is not essential for junctional association but 
still a determinant of paracellular permeability. 
In 2014, it was reported that MD3 is a dynamic junctional regulator of the MEKK1–c-Jun 
NH2-terminal kinase (JNK) pathway (Steed et al., 2014). This pathway is responsible for 
cell proliferation and migration. Expression levels of MD3 oppositely linked with JNK 
activity, because MD3 recruits MEKK1 to junctions, causing for down-regulation of JNK 
phosphorylation and inhibition of JNK-regulated transcriptional mechanisms. This 
interplay between MD3 internalization and JNK activation is important for cell survival 
and prevention of tumor formation (Steed et al., 2014).  
 
1.3.5. Tricellulin 
Tric (MarvelD2) is the first TJ protein discovered as a component of tTJs (Ikenouchi et al., 
2005). The genes encoding for both human Occl and Tric are located in human 
chromosome 5. To date, four human isoforms of Tric have been described: TRIC-a is the 
longest form with 558 amino acids (64 kDa) and is the most common point of reference 
when Tric is mentioned. TRIC-a has four transmembrane regions: two extracellular loops 
and three intracellular regions consisting of a short loop, a short N-terminal and a long C-
terminal region (Fig, 1.7A). It is composed of seven exons and has a C-terminal CC-
domain that is 32% identical to that of Occl (in total 51% similar) (Fig. 1.7B) (Riazuddin et 
al., 2006). Tric N-terminal domain is suggested to be involved in guiding Tric to tricellular 
contacts while the C-terminus is responsible from the basolateral translocation of Tric 
(Westphal et al., 2010). The first extracellular loop is similar to Occl, rich in glycine and 





contacts. Mutations within TRIC-a lead to non-syndromic deafness (DFNB49) (Riazuddin 
et al., 2006).  
The isoform Tric-a1 (62 kDa TRIC-a1) is very similar to TRIC-a but lacks the third of the 
seven exons. Tric-b (TRIC-b) is a shorter isoform (458 amino acids, 51 kDa) that is highly 
different in the C-terminus of TRIC-a (Fig. 1.7B). The crystal structure of C-terminal 
coiled-coil part has been recently reported as a potential component in dimeric 
arrangement (Schuetz et al., 2017).  
 
 
Fig. 1.7 Scheme of predicted structure of tricellulin and occludin and isoforms of human tricellulin. (A) 
Both tricellulin and occludin are tetraspan membrane proteins with two extracellular loops, cytosolic N- and 
C-terminal tail and a short intracellular loop. Tricellulin has a longer N-terminal tail while occludin has 
longer extracellular loop. Their C-terminal tail is 32% identical to each other (Ikenouchi et al., 2005). (B) 
The isoforms of human Tric. The numbers indicate the order of exons. The black bars of exon two mark the 
predicted transmembrane domains, the red line marks the occludin coiled-coil domain, grey areas symbolize 
untranslated segments (Riazuddin et al., 2006). 
 
It was well known that bTJ proteins like Cldns (Furuse et al., 2002; Nitta et al., 2003) or 
Occl (Schulzke et al., 2005) are tightening the cell barriers. However tricellular contacts 





understood that Tric is the tightening component of epithelial cell barrier at tricellular 
junctions (Ikenouchi et al., 2005). When Tric is expressed in an endogenously low Tric 
expressing cell line, paracellular electrical resistance is increased and permeability to ions 
and larger solutes is decreased (Krug et al., 2009). Tric knockdown experiments exhibited 
that, in the absence of Tric, epithelial barrier tightness is not maintained in parallel with 
cell confluency and the continuity of TJ network is considerably disturbed (Ikenouchi et 
al., 2005). On the other hand, overexpression of Tric is decreasing permeability for 
macromolecules (4-10 kDa) but not affecting the ion permeability (Krug et al., 2009). This 
paradox suggested the tTJ central tube as a pathway for macromolecules based on its 
calculated radius that can enable this passage (Krug et al., 2009; Staehelin, 1973). After 
strong overexpression, tricellulin was detected at both tri- and bicellular contacts equally 
(Krug et al., 2009). The systemic deletion of Tric in mice (Tric
-/-
) causes progressive 
hearing loss linked to the degeneration of cochlear hair cells (Kamitani et al., 2015).  
It has already been stated that Tric has strong interactions with other TAMP members and 
Cldns in addition to its compensatory functions. It was observed that under reducing 
conditions, Occl weakens at bTJ and Tric shows co-localization with ZO-1 and partly with 
Occl Two important information proceed. First Tric should compensate for Occl’s function 
even though Occl and Tric do not interact directly (Cording et al., 2013; Raleigh et al., 
2010). Second, Tric trimerization at tricellular contacts should be disrupted so that it can be 
shifted to bTJs (Cording et al., 2015). The Cys residues in ECL2 of Tric are important for 
trans-interactions and paracellular sealing because trans-association is interrupted in the 
absence of those residues as well as under reducing conditions. This relates the ECL2 
region of Tric with extracellular binding of three Tric proteins at tTJs. The trimerization 
and tightening effect of Tric between three cells is superimposed on tricellular cis-
interaction along one plasma membrane (Cording et al., 2015).  
Tric is strongly expressed in epithelial-derived tissues like kidney, small intestine, stomach 
and lung (Ikenouchi et al., 2005). It is expressed at medium levels in liver. Tric expression 
is lower in organs having less epithelial tissue: spleen, lymph nodes, testis, brain 
(Ikenouchi et al., 2005; Raleigh et al., 2010). Tric localization is also reported in brain 
endothelial regions (cerebrum, cerebellum, retina, choroid plexus) and brain microvessels 





expression in peripheral nervous system (sciatic nerve) is more abundant then in the central 
nervous system (Kikuchi et al., 2010). 
There is limited information about the regulatory mechanism over TJ formation and 
maintenance. Tric might be phosphorylated (Ikenouchi et al., 2005). Even though c-Jun N-
terminal kinase is associated with Tric phosphorylation, it has not been clearly identified 
(Kojima et al., 2010). Recently a mechanism pointing out the relation between Tric down-
regulation and ulcerative colitis (UC) was reported. It is found that in UC interleukin 13 
receptor α2, a proinflammatory cytokine, downregulates Tric and increases luminal uptake 
of antigens resulting from barrier defects (Kojima et al., 2010). Moreover, it was also 
shown that posttranslational modifications like ubiquitination plays a role in down-
regulation of Tric at protein level after forming a complex with Tric (Jennek et al., 2017). 
 
1.4. TIGHT JUNCTION SCAFFOLDING PROTEINS 
The membrane-associated guanylate kinase (MAGUK) family proteins of TJs include the 
ZO proteins that have three N-terminal PDZ domains, one Src homology 3 (SH3) domain 
and a guanylate kinase (GUK) domain (Itoh et al., 1999). PDZ domain is a protein 
interaction module that plays role in attaching receptor proteins in the membrane to 
cytoskeletal components and regulates signal transduction complexes (Lee and Zheng, 
2010). ZO-1 (Stevenson et al., 1986), ZO-2 (Gumbiner et al., 1991) and ZO-3 (Balda et al., 
1993) are members of ZO proteins. The ZO proteins are scaffold proteins, which on the 
one hand bind directly to transmembrane proteins of the TJs and on the other hand are 
connected with signalling and structural proteins for the regulation of TJ structure and 
function (Fanning and Anderson, 2013). ZO-1 is the first junctional protein identified at 
TJs (Stevenson et al., 1986) and ZO-1 deficient mice are embryonic lethal (Katsuno et al., 
2008). ZO-1 comprises N-terminal protein binding domain (PDZ1) for the main 
transmembrane barrier proteins Cldns (Furuse et al., 1998), Occl (Fanning et al., 1998; 
Furuse et al., 1994) and Tric through its conserved C-terminal CC-domain (Ikenouchi et 
al., 2005; Riazuddin et al., 2006) and links TJ proteins directly to the actin cytoskeleton. 
Knockdown of ZO-1 in epithelial cells caused delay in barrier formation (McNeil et al., 





in ZO-1 and-2 double negative cells (Ikenouchi et al., 2007). However once TJs are formed 
in the ZO-1 lacking cells, TER and passage of large molecules were stated at normal levels 
(Umeda et al., 2004). ZO proteins play an important role at the formation and function of 
adherens junctions (Ikenouchi et al., 2007) and gap junctions (Giepmans and Moolenaar, 
1998) in addition to TJs. ZO-1 is accepted as general marker for cell junctions. 
 
1.5. THE ANGULIN-PROTEIN FAMILY 
The angulin-proteins are single-pass transmembrane proteins, which localize at tTJs. The 
family consists of LSR (angulin-1), immunoglobulin (Ig)-like domain-containing receptor 
(ILDR)1 (angulin-2) and ILDR2 (angulin-3) proteins (Higashi et al., 2013; Masuda et al., 
2011). They are expressed in several epithelial tissues at different degrees (Higashi et al., 
2013). At least one splice isoform of angulin proteins localize at tTJs and scarcely at bTJs 
(Higashi et al., 2013; Reaves et al., 2017). Immunoreplica of electron microscopy have 
revealed LSR at the central sealing elements of tTJs. LSR is an important protein for 
barrier function because knockdown of LSR in epithelial cells causes decrease in TER and 
increase in macromolecular passage (Masuda et al., 2011). The expression of angulin-2 
protein reverses the effect of LSR knockdown cells on TER and permeability of 
macromolecules (Higashi et al., 2013). Moreover, knockout of angulin-2 protein causes 
deafness with progressive cochlear hair cells degeneration (Higashi et al., 2015). 
LSR knockdown cells also exhibited bicellular membrane localization of Tric instead of 
tTJs. Contrarily LSR keeps its tricellular position at Tric knockdown cells (Masuda et al., 
2011). When angulin binding deficient mice is generated, it was observed that Tric is not 
present at tTJs while angulin-2 can still localize at tTJs (Nayak et al., 2013). This suggests 
that angulins are the foundation of tTJs at tricellular contacts and recruit Tric to tTJs. The 
interaction between conserved cytoplasmic C-terminal tails of Tric and angulins is 
necessary for recruitment of Tric to tTJs (Higashi et al., 2013; Masuda et al., 2011).  
It is reported that LSR is a BBB enriched protein, expressed in parallel with BBB 
development and specifically expressed at tTJs of CNS blood vessels. Thus, LSR knockout 





neurological disorder models that lack functional BBB showed down-regulation of LSR. 
However LSR knockout mice have no impact on ultrastructure of TJ and the knockout also 
does not affect expression and localization of other junctional proteins like Occl, Cldn5 
and ZO-1 (Sohet et al., 2015). 
Recently, a cancer protective role of LSR has been suggested. Hence LSR deficient 
epithelial cancer cells show increased cell proliferation in vitro and larger cysts in 3D 
cultures (Czulkies et al., 2016). Furthermore, knockdown of LSR causes increased cell 
migration, proliferation and invasion in endometrial cancer cell lines (Shimada et al., 
2016).  
1.6. TRICELLULAR TIGHT JUNCTIONS IN BLOOD-BRAIN BARRIER 
The blood-brain barrier (BBB) is formed by endothelial cells lining brain microvessels. It 
constitutes a barrier between circulating blood and central nervous system (brain and spinal 
cord) (Fig. 1.8). The permeability through BBB is strictly controlled by several 
mechanisms that include BBB specific proteins (transporters) responsible from 
transcellular pathway and TJ proteins limiting the passage between adjacent endothelial 
cells (Abbott, 2013; Greene and Campbell, 2016). This way BBB maintains the ionic 
composition of the interstitial fluid bathing the neurons and also shields the gentle neuronal 
tissue from blood borne agents like pathogens and immune cells. Through BBB, there is 
low rate of vesicular transport and channels that provide rapid exchange of molecules are 
not present (Greene and Campbell, 2016).  
 
Fig. 1.8 Schematic illustration of brain microvascular endothelial cells and position of tricellular tight 
junctions (tTJ). Single layered endothelial cells cover the blood capillaries and form a barrier between blood 
circulation and brain. Since endothelial cells are more flat compared to epithelial cells, the structure of the 
tTJs are also different. That is why, an exemplary tTJ of a brain capillary is illustrated above. EC, Blood 






Cldn5 is the dominant tight-junction protein of the BBB because it is highly expressed in 
capillary endothelial cells and seals the paracellular spaces (Nitta et al., 2003; Ohtsuki et 
al., 2007). For the first time, Tric is found to be expressed in tTJs but also in bTJs of brain 
microvascular endothelial cells  (Mariano et al., 2013). Furthermore, both Tric and LSR 
were specifically concentrated at TJs of brain and retina endothelial cells that contribute to 
formation of BBB and brain-retinal barrier (BRB) (Iwamoto et al., 2014). Importance of 
LSR - a tricellular tight junction protein - for sealing of BBB during embryonic 
development has already been described in previous chapter (Sohet et al., 2015). Even 
though tTJ in endothelial cells is not well-characterized yet, recent studies emphasize 
presence of tTJs in brain endothelial cells and evidenced their role in the BBB formation 
and tightness.  
 
1.7. THE IMPORTANCE OF TRICELLULAR TIGHT JUNCTIONS IN 
PATHOLOGICAL EVENTS 
It was already explained that mutation of Tric causes non-syndromic deafness in humans 
(Riazuddin et al., 2006). Angulin-family proteins and their functional importance have also 
been discovered rather recently (chapter 1.5). LSR (angulin-1) was identified first as a 
lipoprotein receptor (Yen et al., 1999) and liver-specific knockdown resulted with 
hypertriglyceridemia in mice  (Narvekar et al., 2009). In addition, human angulin-3 is 
linked with type 2 diabetes (Dokmanovic-Chouinard et al., 2008), which might have 
developed due to hypertriglyceridemia.  
Numerous bacteria attack tricellular junctions to infect epithelial cells. For instance, S. 
flexneri organizes extending pseudopodia at tricellular junctions in a Tric-dependent way 
(Fukumatsu et al., 2012). On the other hand, group A Streptococcus bacteria is reported to 
target tricellular junctions specifically by interaction with Tric to overcome the epithelial 
barrier (Sumitomo et al., 2016). In pancreatic cancer cell lines, Tric is distributed from 
membrane to nucleus with decreasing differentiation order. Tric expression in nucleus is 
assumed to stimulate cell proliferation and finally related to lymph node metastasis 





1.8. DRUG DELIVERY BY MODULATION OF TIGHT JUNCTIONS 
Most drugs cannot pass tissue barriers properly because of their size or hydrophilicity. 
Hence, there are two ways of passage through cell sheets for drugs: transcellular and 
paracellular routes. Several strategies have been developed to enhance drug passage 
through tissue barriers via these routes. First strategy is to introduce prodrugs that are 
inactive compounds by changing the transcellular permeability or increasing lipophilicity. 
Passage can also be achieved by drugs coupled with specific ligand of transporters 
(Brandsch et al., 2008). Those inactive compounds are activated by enzymatic reactions. 
Recently liposomes (El Maghraby et al., 2008), filled with nanoparticles (Dai, Jiang, and 
Lu, 2018; Kreuter and Gelperina, 2008) are also used for passage via BBB. The 
paracellular strategies are mainly based on ultrasound (Burgess and Hynynen, 2014) and 
mannitol (Kobrinsky et al., 1999). Other paracellular routes with small molecules are 
sodium caprate (Lindmark et al., 1998), peptides (Nusrat et al.,2005) and small interfering 
ribonucleic acid (siRNA)(Campbell et al., 2009) as promising ways of transiently 
modulating the TJs. Thus, TJ proteins responsible from the paracellular tightening can be 
modulated by TJ protein specific peptides. 
 
1.9. TIGHT JUNCTION PEPTIDOMIMETICS 
Peptides are derived from parts of TJ proteins specifically to target barriers and enhance 
passage of small and large molecules. To date, Occl and Cldn derived peptides are more 
common due to the fact that they are the most studied TJ proteins. The most related and 
important Occl and Cldn derived peptides and their effects are summarized in Table 1 and 
Table 2. Peptides are designed based on target tissue and its Cldn composition. Parts of 
target TJ protein that is maintaining the paracellular tightness are explicitly selected. So far 
all peptidomimetic methods are focused on opening bTJ areas. But recently tricellular TJ 
proteins are discussed as a target molecule to enable passage of macromolecules (Cording 






Table 1. Occludin peptidomimetics 
Derived 
from 
Target Effect Literature 











- ↑ permeability, ↓ TER <5 
µM. 
- no changes in cell 
morphology 
- ↓ Occl in TJs and totally 
in cells. 
- ZO-1, ZO-2, cingulin, E-
cadherin not affected. 











- ↓ in TER 
-ZO-1 localization is not 
changed 
 Lacaz-Vieira 








Sertoli cells (EC) 
- Disturbs assembly of 
Sertoli cells 
- Interferes with Occl-Occl 
interactions 
- ↓ in TER 
Intratesticular injection 
- Antispermatogenic effect 
- Disruption of BTB 
- Reversible infertility 









- ↑ permeability by A after 
2 h but not B. 
- Lipoamino acid addition 
to N-term, protects the 
peptide from degradation 
and aggregation  rapid 
apical effect 




HUVEC - Disorganized junctional 
Occl 
- Increase neutrophil 
chemotaxis time and dose 
independently 













- Two peptides exhibited 
different conformation 
- ECL2: selectively 
interacted with Occl, 
Cldn1 and JAM-A  
- ECL2: Disabled recovery 
of TJ strands 
-ECL1: Filed to associate 
with protein components 










- Rapid ↓ TER dose-
dependently, permeable for 
≤2000 kDa 
- Redistribution of Occl 
and ZO-1 6h after peptide 
administration 
- Cldn1 and-4 unchanged 










 Intraperitoneal injection 
- Transient and reversible 
disruption of BTB 
-  Partial germ cell loss 
from testis 
- Specific to only BTB 
because peptide was 
inserted into mutant FSH 






↓, decrease; ↑, increase; ECL, extracellular loop; TER, transcellular electrical resistance; TJ, tight junctions; 
HUVEC, human umbilical vein endothelial cells; Occl, occludin; ZO-1, zonula occludens protein-1; ZO-2, 
zonula occludens protein-2; FSH, follicle stimulating hormone; EC, epithelial cells; Caco-2, human colon 
carcinoma epithelial; Cldn1, claudin-1; JAM-A, junctional adhesion molecule-A. 
 
 
Table 2. Claudin peptidomimetics 
Derived 
from 
Target Effect Literature 








- Reversibly interferes with 
TJ structure and function 




- ↑ permeability across 
gastric epithelium, little 
effect on small intestinal 
epithelium 








- Paracellular opening of 
different epithelial barriers  
-Redistributes Cldn1 and 
Occl 
- Peptide internalized by 
clathrin pathway 
-TJ morphology is altered 
in a more parallel way 
Perineurial injection in rats 
- ↑ permeability ≤66 kDa 
- ↓ Cldn1 mRNA, protein 
expression 
- Opening of blood-nerve 
barrier, drug delivery 
facilitation 
Sauer et al., 










Brain endothelial and 
Cldn5 transfected EC) 
- ↑ permeability ≤40 kDa 
- Cldn5 down-regulated 
and redistributed from cell 
contacts to cytosol  
- Drug delivery enhanced 
iv injections in mouse tail 
- ↑ Brain uptake of small 
molecules  
 







- ↑ permeability ≤ 66 kDa, 
↓ TER, ↓ of Occl, ZO-1 
(Caco-2) 
 
Rat jejunum epithelium 
- ↑ permeability ≤ 20 kDa 
Katahira et 
al., 1997; 
Kondoh et al., 
2006; Winkler 
et al., 2009; 
Veshnyakova 
et al., 2012 
↓, decrease; ↑, increase; ECL, extracellular loop; TJ, tight junctions; Occl, occludin; EC, epithelial cells; 
Cldn1, claudin-1, Cldn5, claudin-5; Cldn3, claudin-3; Cldn4, claudin-4; iv, intravenous; cCPE, c-terminal 
region of Clostridium perfringens enterotoxin; ZO-1, zonula occludens protein-1; Caco-2, human colon 
carcinoma epithelial; 
 
1.10. STATE OF RESEARCH 
Tric is a unique TJ protein due to its tricellular localization and important role in maintain-
ing paracellular tightness. To date, most studies have focused on Tric’s barrier forming 
function and interaction with other TJ proteins. However, it is necessary to have expression 
profile of Tric in all organs and specific tissues. For instance, we lack clear information 





investigation of endothelial cell barriers. Tric is located at the central of TJ network and it 
interacts with both bicellular and tricellular TJ proteins because it extends through the ba-
solateral part. Certainly advancing technology and microscopy techniques will help to re-
veal the interaction and localization of TJ proteins establishing complicated TJ organiza-
tion.  
It is known that TJ proteins compensate for each other when any one of them is knocked 
down or modulated. Nevertheless, it is not possible to make detailed explanations without 
the information about the signalling pathway that regulates transcription of Tric. The com-
plete crystal structure of Tric is unavailable. Likewise there is not much information about 
the link between pathologies and altered Tric expression, structure and function. Most im-
portantly, Tric can be targeted in the course of developing a peptide-based barrier opening 
approach like Cldn and Occl peptidomimetics. This would be a more specific therapeutic 








There is limited knowledge about structure, function and regulation of tricellular contacts. 
This study focused therefore on understanding the tricellular organization of TJ proteins 
which is involved in tissue barriers. To modulate tricellular structure and paracellular 
tightness, a tricellulin ECL2 derived peptide called “trictide” was designed. Tric ECL2 
region plays a role in interactions of Tric between adhering cells and contributes to 
paracellular tightness. The aim was to specify a peptidomimetic approach to tricellular 
junctions by modulating tricellulin and to develop trictide as a potential drug enhancer to 
overcome tissue barriers. Thus, functional and molecular alterations caused by trictide 
were investigated. 
Time- and concentration dependency of trictide on paracellular passage towards different 
markers will be examined to demonstrate function of trictide as barrier opener. To 
recognize the molecular basis of functional changes in barriers, the alterations in 
localization of Tric and several Tric interacting TJ proteins will be inspected after trictide. 
In addition, changes in the localization, disruption of cis-interactions between TJ proteins 
within the plasma membrane, up- or down-regulation of protein and mRNA expressions 
will be studied. After cellular studies, trictide administration in mice are planned to prove 
the impact of trictide in vivo. Tracer uptake of major organs, mRNA expressions of TJ 
proteins in brain and kidney and also stability of the peptide in blood plasma will be 
investigated. In order to understand the molecular function of trictide, the tertiary structure 
and secondary structural elements should be elucidated. The structure of non-functioning 
control peptide (scrambled trictide) will also be analyzed to visualize structural differences 
relevant to the effectiveness of the trictide. Finally, tricellular TJ morphology in brain 
capillaries will be examined. In order to fully comprehend the functional consequences of 
trictide treatment, localization and amount of TJ proteins within brain capillaries will be 
inspected. 
Overall, the functional and molecular modifications caused by trictide will enable to 
realize necessary components and protein interactions of tricellular TJs for a functional 
barrier. Moreover, trictide will be tested as a novel peptidomimetic by targeting the 
tricellular TJs and opening the tissue barriers that can be considered as a drug enhancer in 
future studies.  




3.  MATERIALS AND METHODS 
3.1. MATERIALS 
The tables below summarize the chemicals and consumables used in this study, with the 
supplier listed as well. Unless stated otherwise, all basic chemicals were purchased from 






















Table 3. Chemicals 
Substance Supplier 
2-Methylbutane Carl Roth, Karlsruhe, Germany 
Acetic acid VWR Chemicals, Darmstadt, Germany 
Acetone VWR Chemicals, Darmstadt, Germany 
Acetonitril J. T. Baker, Deventer, The Netherlands 
Acrylamid/Bisacrylamid mixture 40% Carl Roth, Karlsruhe, Germany 
Agarose   Serva Electrophoresis GmbH, Heidelberg, Germany   
Albumin Fraction Carl Roth, Karlsruhe, Germany 
Ammoniumperoxidsulfate (APS) Bio-Rad Laboratories GmbH, Munich, Germany 
Ampicillin  Carl Roth, Karlsruhe, Germany 
Collagen (rat tail) Roche, Mannheim, Germany 
Dimethyl Sulphoxide(DMSO) Sigma-Aldrich, Steinheim, Germany 
dNTP (Deoxynucleotide) mix(10 mM) Fermentas Life Science, St. Leon-Rot, Germany 
Dulbecco's modified eagle medium Life Technologies, Darmstadt, Germany 
Dulbecco's phosphate buffered saline Life Technologies, Darmstadt, Germany 
Ethanol VWR Chemicals, Darmstadt, Germany 
Ethylenediaminetetraacetic acid Carl Roth, Karlsruhe, Germany 
Ethylenglykol Carl Roth, Karlsruhe, Germany 
Fetal calf serum albumin Life Technologies, Darmstadt, Germany 
Geneticin (G418) Carl Roth, Karlsruhe, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
Hank's balanced salt solution Life Technologies, Darmstadt, Germany 
Hoechst 33342 Life Technologies, Darmstadt, Germany 
Isopropanol Chemicals, Darmstadt, Germany 
Kanamycin   Carl Roth, Karlsruhe, Germany 
L-cysteine Carl Roth, Karlsruhe, Germany 
MEM Non-Essential Amino Acids Solution (100X) Life Technologies, Darmstadt, Germany 
Methanol VWR Chemicals, Darmstadt, Germany 
Milk powder Carl Roth, Karlsruhe, Germany 
Opti-minimal-essential-medium Life Technologies, Darmstadt, Germany 
Paraformaldehyde (PFA) Sigma-Aldrich, Steinheim, Germany 
Penicillin/streptomycin Carl Roth, Karlsruhe, Germany 
Polyethylenimine (PEI) Polyscience, Eppelheim, Germany 
Poly-L-lysine (PLL) Sigma-Aldrich, Steinheim, Germany  
Ponceau Sigma-Aldrich, Steinheim, Germany 
Rotiphorese Gel 30 Carl Roth, Karlsruhe, Germany 
Sodium- Dodecyl sulfate Sigma-Aldrich, Munich, Germany 
Tetramethylethylenediamine Carl Roth, Karlsruhe, Germany 
Trichloroacetic acid Carl Roth, Karlsruhe, Germany 
Tricin Carl Roth, Karlsruhe, Germany 
Tris Base Carl Roth, Karlsruhe, Germany 
Triton X-100 Carl Roth, Karlsruhe, Germany 
Trypsin/Ethylenediaminetetraacetic acid-solution Life Technologies, Darmstadt, Germany  











Table 4. Devices 
Device Supplier 
Agarose gel chamber   Agagel Mini  Biometra GmbH, Göttingen, Germany   
Analytical scale, AT21 Comparator  Metler Toledo, Gießen, Germany 
Blotting system Mini Trans-Blot® Cell Bio-Rad Laboratories GmbH, Munich, Germany   
Centrifuge  5415C   Eppendorf, Hamburg, Germany  
Centrifuge  5810R Eppendorf, Hamburg, Germany 
Clean bench  S-1200   BDK Luft- und Raumtechnik, Sonnenbühl-
Genkingen, Germany  
Confocal spinning disk microscope Nikon_CSU Nikon GmbH, Düsseldorf, Germany 
Cryocontainer, CryoTherm Bio-Safe Cryotherm GmbH Kirchen/Sieg, Germany 
Cryostat, CM 3000 Leica Leica Microsystems, Wetzlar, Germany   
Direct Detect Spectrometer Merck Chemicals GmbH, Darmstadt, Germany 
Dounce tissue grinder set     Sigma-Aldrich Chemie GmbH, Steinheim, Germany   
Electric cell-substrate impedance sensing (ECIS) 
instrument  ECIS 1600R + 16 well array station  
Applied Biophysics Inc, Troy, NY, USA  
 
Electrophoresis power supply  (SDS-PAGE), 
Powerpac 1000  
Bio-Rad Laboratories GmbH,  Munich, Germany   
Electrophoresis power supply (agarose gel)  Consort 
E835   
Sigma-Aldrich Chemie GmbH,  Steinheim, Germany   
Flow cytometer,  FACSAria Becton Dickinson, Heidelberg, Germany 
Fluorescence microscope, Zeiss Axiovert 135 TV  Carl Zeiss Jena GmbH, Jena, Germany   
Fluorescence Scanner, FLA-5000   Fujifilm, Tokio, Japan 
Glass plates (SDS-PAGE)  Hoefer, vertical slab gels   Hoefer, Pharmacia Biotech Inc. San Francisco, CA, 
USA 
Hand electrode, EVOM Voltohmmeter  WPI WPI, Sarasota, USA 
Heating block, Thermomixer 5436 Eppendorf, Hamburg, Germany 
Hemocytometer Carl Roth GmbH, Karlsruhe, Germany   
Incubator for cell culture  CB210   Binder GmbH, Tuftlingen, Germany  
Laminar Flow Hood, S-1200 BDK Luft- und Raumtechnik, Sonnenbühl-
Genkingen, Germany 
Laser scanning microscope  LSM 780 &710 Carl Zeiss Jena GmbH, Jena, Germany   
Laser scanning microscope 510 META-NLO  Carl Zeiss Jena GmbH, Jena, Germany   
Leica SP8 TCS STED microscope  Leica Microsystems, Wetzlar, Germany 
Light microscope, IMT-2   Olympus Europa GmbH, Hamburg, Germany 
Magnetic stirrer, IKAMA ® RCT IKA®-Labortechnik, Staufen, Germany 
Monochromator-based microplate detection system, 
Safire   
Tecan Group Ltd, Männedorf, Switzerland 
PCR-thermocycler, DNA Engine   Bio-Rad Laboratories GmbH, Munich, Germany 
pH-meter, CG 840   Schott AG, Mainz, Germany 
Real Time PCR system  StepOne TM  Real-Time 
PCR system, 48/96 well 
Life Technologies GmbH, Darmstadt, Germany 
General type scale MC1 LC 2200S Sartorious AG, Göttingen, Germany 
SDS-PAGE gel chamber, Mini-PROTEAN® Tetra 
Vertical Electrophoresis Cell 
Bio-Rad Laboratories GmbH, Munich, Germany   
Shaker, TH 15 Edmund Bühler GmbH, Hechingen, Germany 
Spectral photometer  NanoDrop, 2000c Thermo Fisher Scientific GmbH, Bremen, Germany   
Spectropolarimeter, J-720   Jasco, Tokyo, Japan 
Transilluminator, ChemiDoc™ MP System 
#1708280 
Bio-Rad Laboratories GmbH, Munich, Germany 
Vortex device, VF-2 IKA -Labortechnik, Staufen, Germany 
Waterbath, 1002  GFL GFL, Burgwedel, Germany 
Sonorex super ultrasonic bath Bandelin, Berlin, Germany 





Table 6. Commercial solutions/enzymes and kits  
Solution Supplier 
1 kb DNA Ladder (GeneRuler TM )   Fermentas Life Science, St. Leon-Rot, Germany 
6x DNA loading dye   Fermentas Life Science, St. Leon-Rot, Germany 
AccuPol DNA Polymerase VWR International GmbH, Darmstadt, Germany 
Amylose resin  New England Biolabs, Ipswich, MA, USA 
DNA clean and concentrator-5 kit Zymo Research, Irvine, CA, USA  
dNTPs (10 mM) Fermentas Life Science, St. Leon-Rot, Germany 
E.Z.N.A. Plasmid Mini Kit I VWR International GmbH, Darmstadt, Germany 
Fast Digest HindIII and Not I Fermentas Life Science, St. Leon-Rot, Germany 
GeneMATRIX Universal RNA Purification Kit EURx Ltd. Gdansk, Poland 
Immu-Mount  Thermo Fisher Scientific Inc., Waltham, MA, USA   
Lumi-Light Western Blotting Substrate   Roche Diagnostics GmbH, Mannheim, Germany 
Luminaris Color HiGreen qPCR Master Mix, high  
ROX qPCR Master Mix  
ThermoFisher Scientific, Waltham, MA, USA 
Maxima First Strand cDNA Synthesis Kit for RT- 
qPCR  
Thermo Fisher Scientific Inc., Waltham, MA,  
USA   
PageRuler Plus Prestained Protein Ladder   Thermo Fisher Scientific Inc., Waltham, MA, USA   
ProLong Gold Antifade Mountant Thermo Fisher Scientific Inc., Waltham, MA, USA   
SuperSignal West Femto Maximum Sensitivity  ThermoFisher Scientific, Waltham, MA, USA  
SYBR Safe DNA gel staining solution (10000x  
concentrated in DMSO) 
Invitrogen GmbH, Darmstadt, Germany 
T4-DNA-ligase   Promega, Madison, WI, USA 
Talon Superflow Metal Affinity Clontech Laboratories, Mountain View, CA, USA 
Taq DNA Polymerase + Buffer  Roboklon GmbH, Berlin, Germany 
Tissue-Tek  VWR International GmbH, Darmstadt, Germany 
ZR Plasmid Miniprep TM -Classic    Zymo Research Corp, Irvine, CA, USA   
 
Table 5. Consumables Supplier 
1µ-Slide 8 Well Glass Bottom Ibidi, Martinsried, Germany 
Amicon Ultra-15 Centrifugal Filter Device (30K, 
100K)  
Merck Millipore, Billerica, MA, USA 
BD Falcon (polystyrene Round-Bottom)   BD, Dickinson, Franklin Lakes, NJ, USA 
Cell culture flask, CellBIND Surface   Corning,  NewYork, USA  
Cell culture flask, Cellstar     Greiner Bio-One Frickenhausen, Germany 
Cover glasses 24x50 mm  Roth, Karlsruhe, Germany 
Coverslips (diameter 12 and 30 mm)    Menzel GmbH, 15 Braunschweig, Germany  
Cryogenic vial 1.2 mL Corning, NewYork, USA 
Dako Pen, Delimiting pen Agilent, Santa Clara, CA, USA 
Direct Detect Assay-free Cards Merck Chemicals GmbH, Darmstadt, Germany 
ECIS chip 8W10E+ Ibidi GmbH, Planegg / Martinsried, Germany 
Electroporation cuvette Peqlab, Biotechnologie GmbH, Erlangen Germany 
Filter, Millicell (CM)       Merck Millipore, Darmstadt, Germany  
Filter, Millicell (PCF) Merck Millipore, Darmstadt, Germany 
MicroAmp  Fast Optical 96-Well Reaction Plate   Life Technologies GmbH, Darmstadt, Germany 
MicroAmp Optical Adhesive Film  Life Technologies GmbH, Darmstadt, Germany 
Mini-PROTEAN TGX 4–20%  Protein Gel Bio-Rad Laboratories GmbH, Munich, Germany 
Nitrocellulosemebrane, Hyband-ECL, 0,45 µm GE Healthcare, Little Chalfont, UK 
Omican 100 insulin syringes B. Braun Vet Care GmbH, Tuttlingen, Germany 
Pall Nanosep centrifugal device with Omega mem-
brane 10 kDa 
Sigma-Aldrich Chemie GmbH,  Steinheim, Germany   
Quarz cuvette, 100-QS   Hellma Analytics, Müllheim, Germany 
Super frost ultra plus object slide   Menzel GmbH, 15 Braunschweig, Germany 
Tissue culture plate, 48 wells Corning,  NewYork, USA 
Tissue culture plate, 6-, 24- , 96 wells   TPP, Trasadingen, Germany 
ZipTip, C18 columns   Merck Millipore, Darmstadt, Germany 




IF, immunofluorescence; WB, western blot; IHC, immunohistochemistry; STED, stimulated emission deple-
tion. 
 
Table 7. Antibodies    
Primary antibodies Species Concentration  Supplier 
Anti-Tricellulin 
# 48-8400 
rabbit 0.25 mg/ml; IF 1:150, 
STED 1:100  IHC 1:75, 
WB:1:1000 





rabbit 0.5 mg/ml; IF 1:150, 
STED 1:100, WB 1:1000 





mouse 0.5 mg/ml; IF: 1:150, IHC: 
1:100, STED 1:100, WB 
1:1000 





rabbit 0.25 mg/ml 
WB: 1:1000 
STED, IF: 1: 100 
























mouse 0.5 mg/ml 
STED: 1:100 





rat 0.5 mg/ml  
STED 1:100 
BIOZOL Diagnostica 




mouse 50 µg/ml IF: 1:150 IHC: 
1:50 WB: 1:500 









Secondary antibodies Species Concentration  Supplier 
Anti-Rabbit  Atto 488 
#18771 







goat 1 mg/ml 
IF 1:250 
Invitrogen, Thermo Fisher 
Scientific, Schwerte, 
Germany 
Anti-Rabbit HRP  
#1708241 
goat 0.8 mg/ml 
WB: 1:1000 
Bio-Rad Laboratories Inc.,  
Hercules, CA, USA 
Anti-Mouse HRP  
#1706516 
goat 0.8 mg/ml 
WB: 1:1000 
Bio-Rad Laboratories Inc., 
Hercules, CA, USA 
Alexa fluor 594  anti-rabbit IgG 
Ref # A11072 
goat 2 mg/ml 
STED 1:300 
Life Technologies, 
Eugene, Oregon, USA 
Alexa fluor 594 anti-rat IgG  
Ref# A11007 
goat 2 mg/ml 
STED 1:300 
Life Technologies, 
Eugene, Oregon, USA 
Alexa fluor 594  F(ab’)anti-mouse IgG 
Ref#A11020 
goat 2 mg/ml 
STED 1:1000 
Life Technologies, 
Eugene, Oregon, USA 
Abberior STAR 635P anti mouse IgG 
#2-0002-007-5 
goat 1 mg/ml 
STED  1:300 
Abberior GmbH, 
Göttingen, Germany  
 
Abberior STAR 635P anti rabbit IgG 
#2-0012-007-2 
goat 1 mg/ml 
STED 1:300 
Abberior GmbH, 
Göttingen, Germany  













Table 8. Plasmids 
Plasmid Characteristics Reference 
pEYFP-C1-Tric   5.3 Kb; Ampr/Neor, SV 40 ori, 
pUC ori, PCMV  
IE; EYFP(reporter) N-terminal, tric 
O. Huber, Charite-Berlin, 2009, 
Germany 
pECFP-C1-Tric 5.3 Kb; Ampr/Neor, SV 40 ori, 
pUC ori, PCMV  
IE; ECFP(reporter) N-terminal, tric 
O. Huber, Charite-Berlin, 2009, 
Germany 
pEYFP-C1-Occl 5.3 Kb; Kanr/Neor, SV 40 ori, pUC 
ori, PCMV 
IE; EYFP(reporter) N-terminal, 
occludin 
C. Bellmann, FMP-Berlin, 2010, 
Germany 
 
pECFP-C1-Occl 5.3 Kb; Kanr/Neor, SV 40 ori, pUC 
ori, PCMV  
IE; ECFP(reporter) N-terminal, 
occludin 
C. Bellmann, FMP-Berlin, 2010, 
Germany 
 




J. Cording, FMP-Berlin, 2011, 
Germany 




M. Balda, UCL-London, UK 
pETRQ-C1-Cld1 5.3 Kb; Kanr/Neor, SV 40 ori, pUC 
ori, PCMV 
IE; EYFP(reporter) N-terminal, 
Cld1 
N. Gehne, FMP-Berlin, 2013, 
Germany 
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Table 9. Primers used for qRT-PCR 
Primer  Sequence (5’→3’)  
 fw  rev 
hActb  GGACTTCGAGCAAGAGATGG AGCACTGTGTTGGCGTACAG 
hTric  AGGCAGCTCGGAGACATAGA TCACAGGGTATTTTGCCACA 
hOcln  TCCAATGGCAAAGTGAATGA GCAGGTGCTCTTTTTGAAGG 
hMarveld3  GGACCCGGAGAGAGACCAG CTCCGAAGGGGGTTCACT 
hLSR GTGACCCTGCCCTGTACCTA TCAACGTAGGGGTTGTAGCC 
hZO1  GAACGAGGCATCATCCCTAA CCAGCTTCTCGAAGAACCAC 
hCldn1  CGATGCTTTCTGTGGCTAAAC GAGGGCATCACTGAACAGATAG 
hCldn5  GAGGCGTGCTCTACCTGTTT GTACTTCACGGGGAAGCTGA 
mActb  TTTGAGACCTTCAACACCCC ATAGCTCTTCTCCAGGGAGG 
mTric  GAGAATCCTGGGTGTGGTGG TTTCGATGACAACGACGGGT 
mOcln  ACTCCTCCAATGGCAAAGTG CCCCACCTGTCGTGTAGTCT 




mCldn1  GATGTGGATGGCTGTCATTG CGTGGTGTTGGGTAAGAGGT 
mCldn5  CTGGACCACAACATCGTGAC GCCGGTCCAGGTAACAAAGA 
mCldn12  AACTGGCCAAGTGTCTGGTC AGACCCCCTGAGCTAGCAAT 
mCldn25  CTACATGGCGGCCTCCATAG CGATGCCGCTATTGTGGTTG 





Table 11. Primers used for amplification of recombinant proteins 
Primer  Sequence (5’→3’)  







Primers used for MBP-hTric ECL2 
Primer  Sequence (5’→3’)  







   
 
 
Table 10. Primers used for mutagenesis PCR of hTric ECL2  
Primer  Sequence (5’→3’)  









F326A CCGTTAGCGAATACACCAGTG TGTATTCGCTAACGGATAGTAGCA 
F334I GCAGTGATATGCCGGGTAGAAGGA CCGGCATATCACTGCATTCACTGG 




Different biological samples were listed in Table 12. In addition, C57BL/6 mice obtained 




Table 12. Eukaryotic cells and bacteria 
Cell type/bacteria Description Source 
bEND.3 Mouse brain endothelial cell line Zwanziger et al., 2012b 
Caco-2 Human epithelial colorectal 
adenocarcinoma cells 
Bayer Pharma AG, Berlin, 
Germany 
HEK-293 Human embryonic kidney cells ATCC, Manassas, VA, USA 
HT29/B6 Human epithelial colon 
adenocarcinoma cells 
S. Krug, Charite–Berlin, Germany 
MDCK-II Madin-Darby canine kidney cells ATCC, Manassas, VA, USA 





Table 13. Fluorescent size markers for permeation experiments  
Size marker for permeation Supplier Fluorescence properties 
FD10, 10 kDa Sigma-Aldrich Chemie 
GmbH, Steinheim, Germany 
λex = 485 nm, λem = 520 nm 
FD40, 40 kDa Sigma-Aldrich Chemie 
GmbH, Steinheim, Germany 
λex = 485 nm, λem = 520 nm 
Lucifer Yellow, 0.4 kDa Sigma-Aldrich Chemie 
GmbH, Steinheim, Germany 
λex = 425 nm, λem = 520 nm 
Sodium fluorescein Sigma-Aldrich Chemie 
GmbH, Steinheim, Germany 
λex = 460 nm, λem = 515 nm 









Table 15. Software  
Program Manufacturer / Source 
BIOVIA Discovery-Studio, version 4.5  Accelrys, San Diego, USA 
BLAST NCBI, Rockville Pike, USA 
Huygens Professional  Scientific Volume Imaging, Hilversum, The Netherlands 
ImageJ, version 1.49k  W. Rasband, National Institutes of Health, Maryland, USA 
I-TASSER Roy et al., 2010; Zhang, 2008 
Leica Application Suite X (LAS X) Leica Mikrosysteme Vertrieb GmbH, Wetzlar, Germany 
Mendeley  Elsevier, New York City, NY, USA 
MS Office 2010 Professionel Microsoft, Unterschleißheim, Germany 
PEP-FOLD Shen et al., 2014; Thevenet et al., 2012 
Prism 5, version 5.04  GraphPad, San Diego, USA 
Spectra Manager, version 1.54.03  Jasco, Tokyo, Japan 
StepOne Software version 2.2.1  Applied Biosystems, Foster City, USA 
Zeiss LSM Image Browser, version 4.2.0.121  Carl Zeiss, Jena, Germany 
ZEN 2010B SP1  Carl Zeiss, Jena, Germany 
Table 14. Other colored markers   
Type of marker Supplier Fluorescence properties 
Ethidium bromide solution, 1% Carl Roth, Karlsruhe, 
Germany 
λab = 210 or 285 nm 
Hoechst 33342  Thermo Fisher Scientific, 
Schwerte, Germany 




GmbH, Steinheim, Germany 
λab = 570 nm 
Fluorescein sodium Sigma-Aldrich Chemie 
GmbH, Steinheim, Germany 
λex = 460 nm, λem = 515 nm 
Neutral red solution, 0.5 % in acetic 
acid pH 5.2 
Sigma-Aldrich Chemie 
GmbH, Steinheim, Germany 
λab = 540 nm 
TAMRA  Thermo Fisher Scientific, 
Schwerte, Germany 
λex = 543 nm, λem = 560 nm 
Tricellulin-YFP fusion protein  λex = 514 nm, λem = 516-537 nm 
Occludin-CFP fusion protein  λex = 442 nm, λem = 480-520 nm 
Claudin-1-TRQ fusion protein  λex = 458 nm, λem =462-494 nm 
TAMRA, (5-(and-6)-Carboxytetramethylrhodamine); YFP, yellow fluorescent protein; CFP, cyan fluorescent 
protein, TRQ, turquoise fluorescent protein; λab, wavelength of the absorption; λex, excitation wavelength; λem, 
emission wavelength. 





3.2.1. Peptide design and synthesis 
Peptides were synthesized automatically by peptide chemistry facility (FMP-Berlin, 
Germany) using 9H-fluoren-9-ylmethoxycarbonyl (Fmoc) chemistry. Identity and quality 
of peptides were verified by high-performance liquid chromatography and mass 
spectrometry, showing a purity of ≥95% (220 nm) and the expected masses. Trictide 
(Table 16) comprises extracellular loop 2 (ECL2) of human tricellulin-a (Tric313–336); 
Cys321 and Cys335 were replaced by Ser to avoid unspecific oligomerization. As a 
control, a scrambled variant (scrambled peptide, Table 16) was used. Peptides were 
amidated at the C-terminus. Trictide was labelled N-terminally with 5,6-
carboxytetramethylrhodamine (TAMRA) (Table 16).  
 
 
3.2.2. Cell Culture 
3.2.2.1. Routine cell culture work 
The cells (Table 12) were incubated at 37 °C and 5% or 10% CO2 in cell-specific medium 





, DPBS-/-) and dissociation with 
trypsin/ethylenediaminetetraacetic acid (EDTA) solution at 37 °C, they were resuspended 
in the new medium and centrifuged (150xg, 4 min). The pellet was taken up in new 
medium, resuspended and transferred on cell culture flasks (Table 17) or tissue culture 
plates (Table 5).  
Table 16. Peptide sequences 
  
Peptide Description Sequence 
Trictide ECL2 of human 
tricellulin, 313–336 
NDTNRGGLSYYPLFNTPVNAVFSR-NH2 
Scrambled trictide Control peptide DNLNRGGASYTPFYLNVPNFVTSR-NH2 
TAMRA-trictide  TAMRA-
NDTNRGGLSYYPLFNTPVNAVFSR-NH2 





Table 17. Culturing conditions of eukaryotic cells 
Cell type Medium compositions CO2 Culture flask Cell dissociation 
bEnd.3 DMEM, 4.5 g/l glucose, 10% 
FCS, 100 U/ml penicillin, 100 
µg/ml streptomycin 
10% Cellstar# 0.25%Trypsin/0.02% 
EDTA 
Caco-2 DMEM, 1 g/l glucose, 20% 
FCS, 100 U/ml penicillin, 100 





HT29/B6 RPMI 1640 Medium with 
stable L-glutamine, 10% FCS, 
100 U/ml penicillin, 100 µg/ml 
streptomycin 




DMEM, 1 g/l glucose, 20% 
FCS, 100 U/ml penicillin, 100 
µg/ml streptomycin* 
10% Cellstar# 0.25%/0.05% Trypsin 
/0.02% EDTA 
* after transfection cultured with geneticin (final 0.5 µg/ml); DMEM, Dulbecco's modified eagle-medium; 
EDTA, ethylenediaminetetraacetic acid; FCS, fetal calf serum albumin; NEAA, non-essential amino acids; 
RPMI, Roswell Park Memorial Institute-Medium, %, (v/v); #, further information about products can be find in 




3.2.2.2. Cryopreservation and thawing of cells 
Almost confluent cells (around 85% conflueny) were washed (2x, DPBS-/-), dissociated 
with trypsin/EDTA (Table 17) and centrifuged at 150xg, 4 min. The cell pellet was 
resuspended in freezing medium (90% fetal calf serum (FCS), 10% DMSO) and aliquoted 
in cryotubes. The tubes were first cooled down to -20 °C at a cooling rate of 1 °C/min and 
finally stored in liquid nitrogen at -196 °C. 
For reactivation, the cryoculture was thawed in a 37 °C water bath and immediately 
resuspended in cell-specific medium (Table 17). This suspension was centrifuged (150xg, 
4 min) to eliminate DMSO in freezing medium. After centrifugation, the cell pellet was 
resuspended in new medium and transferred to a cell culture flask. 
 
3.2.2.3. Cell counting 
An aliquot of the cell suspension was diluted 1:2 with cell-specific medium. From that, 20 
μl were applied to a Neubauer counting chamber. After counting the 4 counting areas, the 
cell count/ml was calculated by taking the mean of cell number (total cell number/number 
of counted areas) and multiplied by 10
4
 and the dilution factor 2. 




3.2.2.4. Transfection and obtaining stable transfected cell lines 
Tissue culture plates (6 wells) were used for the preparation of stably transfected cell lines. 
Wells were coated with poly-L-lysine (PLL, 20 µg/ml in DPBS-/-) (1 h, 1.5 ml), washed 
(2x, DPBS-/-) and HEK-293/MDCK-II cells seeded there (2.2.2.1).  Medium was removed 
and transfection procedure was initiated at a confluency of 90%. The plasmid DNA (2 µg) 
as well as polyethyleneimine (PEI) (10 µl) were mixed separately with 250 µl Opti-
minimal essential medium per well and incubated for 5 min. Then the DNA and PEI were 
mixed (1:1) and left for 20 min of additional incubation before finally being added to the 
culture plates (3 ml transfection medium/10 cm
2
). The next day the selection antibiotic, 
geneticin (final 0.5 μg/ml), was added. After 48 h the transfection success was verified by 
microscopic analysis of the fluorescently tagged proteins. 
3.2.2.5. Cell cultivation on coverslips and filters 




) were coated 
with PLL (20 μg/ml in DPBS-/-) while for bEnd.3 cells the coverslips were coated with rat 
tail collagen (0.67 mg/ml in 0.2% acetic acid). For each coverslip 0.3 ml/cm
2
 of coating 
material is applied and incubated at 22 °C for 1.5 h. The coverslips were washed (DPBS-/-) 
prior to cell seeding of the cells. The cells were seeded on coverslips under the conditions 
described in 3.2.2.1.  
For Caco-2 cells, the filters were coated with 150 μl rat tail collagen (0.67 mg/ml in 0.2% 
acetic acid, 1:2 in DPBS-/-) per filter (type: CM, pore size 0.4 μm, Table 5) and dried 
overnight on a 37 °C hot plate. The washing (DPBS-/-) step was followed by equilibration 
of the filters with cell-specific medium (apical 400 μl, basal 600 μl, Table 17) for 2 h in the 
incubator. Then 18·10
4 
cells were seeded per filter (culture area: 4.2 cm
2
). 
HT-29/B6 cells were grown on permeable supports (type: PCF, 3 µm pore-size, Table 5) 
and left for monolayer differentiation for seven days.  
 
3.2.2.6. Application of peptide on cells 
The peptides (Table 16) were weighed by analytical balance (AT21 Comparator, Metler 
Toledo) and dissolved in cell-specific medium (Table 17)  at 37 °C. Before the peptide 
treatment, the medium was taken off and replaced by peptide-containing medium. 




TAMRA-labelled peptides are first dissolved in DMSO (1% of total volume) and then in 
cell-specific medium. 
3.2.3. Functional assays 
The tightness of the cell monolayer was determined by transcellular electrical resistance 
(TER) and paracellular permeation measurements. While TER reflects permeability to 
ions, permeation measurements enabled us to draw conclusions about the permeability of a 
cell barrier for molecules of different sizes (Table 13). The combination of both methods 
allows correlation of change, in the paracellular tightness and in the permeability for 
certain molecular sizes. 
3.2.3.1. Measuring transepithelial electrical resistance 
The TER of the Caco-2 filter cultures (Table 17) was measured every 24 h with chopstick 
electrodes (on a 37 °C hot plate, three measurements per filter, each value by 120°). Before 
treatment, filter cultures reached TER values of 205.2±10.6 Ω•cm2 (empty control 
subtracted, representative values of an experiment, n=21). For the calculation of TER, the 
average electrical resistance of the empty filter (ΩL) was extracted from the mean electrical 




𝑇𝐸𝑅 = (𝑅𝐶𝑒𝑙𝑙 𝑙𝑎𝑦𝑒𝑟  − 𝑅𝐸𝑚𝑝𝑡𝑦 𝑓𝑖𝑙𝑡𝑒𝑟) ∙ 𝐴                         (Ω∙cm
2
)          
 
𝑅𝐶𝑒𝑙𝑙 𝑙𝑎𝑦𝑒𝑟       Resistance of the cell layer between apical and basolateral compartment of cell containing 
filter   
𝑅𝐸𝑚𝑝𝑡𝑦 𝑓𝑖𝑙𝑡𝑒𝑟  Resistance of the cell layer between apical and basolateral compartment of cell-free filter 
𝐴               Culture area           
 
Filters were grouped leading to similar initial TER values and then were treated with 
scramble peptide or trictide. 




3.2.3.2. Permeation assays 
All steps were carried out with 37 °C pre-warmed solutions. Fluorescein isothiocyanate 
(FITC)–dextran 10 (FD10, 10 kDa), FITC-dextran 4 (FD4, 4 kDa), lucifer yellow (LY, 457 
Da) and FITC-dextran 40 (FD40, 40 kDa) were used as permeation markers (Table 13). 







𝐴 ∙ 𝐶𝑖 ∙ 60
                    (cm/s) 
 
dQ/dt    Amount of the diffused permeation marker  (µg/min) 
A          Growth area of filters                                     (cm
2
) 
Ci              Initial concentration of size marker (apical)  (µg/ml) 
60         Conversion factor min to s  
 
For experiments with Caco-2 cells, three filters were used per each condition. The filters 





 (HBSS+/+) (apical 400 μl, basolateral 600 μl). Then the 400 μl permeation 
solution (8 µM FD10, 0.4 mM FD4, 100 µM LY or 2.5 µM FD40 in HBSS +/+) was 
applied apically and 600 μl HBSS+/+ was applied basolaterally. During 30 min of 
incubation on 37 °C hot plate, every one filter from each condition was discarded every 10 
min. 3 aliquots of 150 μl were removed from basolateral section of each filter and placed 
on a tissue culture plate (96 wells).  The fluorescence intensities of fluorescence markers 
(Table 13) were measured with the fluorescence plate reader (Safire, Tecan). 
The permeability measurements of the HT-29/B6 cells were taken in multi-well plates in 
HEPES-Ringer containing unlabeled dextran 4 kDa (FD4; 0.4 mM) at 37 °C. After apical 
addition of FITC-labeled and dialyzed 4 kDa dextran, basolateral samples were analyzed 
for their FD4 concentration at 0, 20, 40, and 60, 120 min.  




3.2.3.3. Cell viability 
Cell culture plates (48 wells) were coated with PLL (20 μg/ml in DPBS-/-, 0.3 ml/well, 5 
h) and washed (DPBS-/-). Cells were seeded and grown until they became sufficiently 
confluent to be tested with substances. Subsequently, the cells were washed (DPBS-/-) and 
each well was treated with 200 μl of 2.3.5-triphenyltetrazolium chloride (MTT) solution 
(0.5 mg/ml in Dulbecco's modified Eagle's medium (DMEM), 1 g/L glucose, without 
phenol red) (Weyermann et al., 2005) or neutral red solution (0.005% in DMEM 1 g/l 
glucose, without phenol red). After 3 h in the 37 °C incubator, cells were washed with 200 
µl/well extraction solution (MTT: 5% Triton X-100, 2% 2N hydrochloric acid, 93% 
isopropanol; neutral red: 1% acetic acid, 50% ethanol). After 15 min on the vibrator, the 
absorbance of the homogenates was measured (MTT, 570 nm; neutral red, 540 nm) with a 
fluorescence plate reader (Safire, Tecan). 
 
3.2.3.4. Electric cell-substrate impedance sensing 
Initially, the electric cell-substrate impedance sensing (ECIS) arrays (ECIS chip 8W10E+) 
were cleaned by 10 mM L-cysteine (200 μl/well) and incubated for 10 min. This treatment 
constitutes a hydrophilic layer and prepared the surface for protein adsorption. Furthermore 
it reduces the variation between ECIS wells and improves reproducibility.  After washing 
(3x with cell-specific culture medium), cell-specific culture medium was added to the 
arrays (200 μl/well) and a high current (3 mA), high frequency (64 kHz) pulse was applied 
to clean the electrodes (electrical stabilization). The bEND.3 (5·10
4
/well) and Caco-2 
(15·10
4
/well) cells were seeded into disposable 8-well electrode arrays of the ECIS and 
placed in an incubator at 37 °C and 10% CO2 while the electrical resistance was recorded. 
When stable TER values were reached [for bEnd.3 cells 1504±206 Ω·cm2 (n=8, peptide-
free medium controls) and for Caco-2 cells 1351±34 Ω·cm2 (n=10, peptide-free medium 
controls) compared to the cell-free control with 311 ± 4 Ω × cm2], cells were treated with 
trictide (50-150 µM), scrambled trictide (150 µM) or peptide-free medium only. The 
transcellular electrical resistance (TER) was recorded over time (70-100 h) with 1 h 
intervals, at multiple frequencies (between 100 and 80000 Hz) but 4000 Hz was used to 
evaluate the TER.  




3.2.4. Histological methods 
3.2.4.1. Obtaining cryosections 
C57BL/6N mice between 8 and 20 weeks of age were sacrificed, their brains removed and 
immediately frozen in 2-methylbutane on dry ice for 5 min. Unless the brains were 
intended for immediate use, they were stored at -80 °C. Before cryosectioning, brains were 
embedded in Tissue-Tek (Table 6) on a metal disc and adapted to -18 °C. 8 μm sections 
were cut using a microtome blade (MX35 Ultra, ThermoFisher Scientific) at -18 °C. The 
cut sections were transferred to super frost ultra plus object slides (Table 5) and let stand at 
room temperature to eliminate excess water. The slides were stored at -80 °C. 
The human cortical cryosections were already provided by AMS Biotechnology 
(Abingdon, United Kingdom) as embedded in Tissue-Tek. They were prepared the same 
way as mouse brains. 
3.2.4.2. Immunohistochemistry of cryosections 
Mounted cryosections were taken from -80 °C, fixed with methanol at -20 °C for 10 min. 
After washing step (1x 0.5% BSA in DPBS-/-) for 5 min and 1x sterile water for 3 min) on 
a shaker at room temperature, brain sections were circled with water-repelling pen (Dako 
Pen).  100 µl of primary antibodies (Table 7) were diluted in 0.5% BSA in DPBS-/-, added 
either together or separately, and left for overnight incubation at 4 °C. The slides were 
washed again (3x 0.5% BSA in DPBS-/- for 5-10 min and 1x DPBS-/- for 3 min) on a 
shaker. The secondary antibodies (Table 7) were diluted in DPBS-/-, 100 µl of antibody 
solution was added on top of brain sections and left at room temperature for 1 h in a dark 
place. The slides were washed (3x DPBS-/- for 5-10 min) on a shaker and then treated with 
Hoechst 33342 (16.23 µM in DPBS-/-) for 10 min in the dark. Finally the slides were 
washed (1x sterile water for 3 min), mounted with Immu-Mount (Table 6), and left for 30 
min incubation on 37 °C hot plate. The immunostained slides were stored at 4 °C. For 
STED microscopy, secondary antibodies were exchanged with STED specific antibodies 
(Table 7).  Cells were mounted in Prolong Gold Antifade (Table 6) and left for 24 h at 
room temperature before STED microscopy session.  




3.2.5. Microscopic investigation 
Unless stated otherwise, laser scanning microscopy (LSM 780 &710 Plan-Apochromat 
63x/1.4 or 100x/1.4 oil lenses) was used together with ZEN 2010B SP1 software to 
conduct the experiment. The settings were selected according to the fluorescence 
properties of the secondary antibodies (Table 7) and markers (Table 14). 
3.2.5.1. Immunocytochemistry on cover glasses and filters 
The coverslips were placed in a 24-well-tissue culture plate and coated with PLL (20 μg/ml 
in DPBS-/-, 0.3 ml/well, 1 h, for Caco-2 and MDCK-II cells) or rat tail collagen (0.67 
mg/ml in 0.2% acetic acid, 50 µl/well, for bEND.3 cells). Cells were seeded and grown 
until they became fully confluent. Before fixation, cells were washed twice with ice-cold 
DPBS-/-. The coverslips were placed into a staining tray with ice-cold acetone for 5 min 
and ice-cold ethanol for 1 min. After washing for 1 min with ice-cold DPBS-/-, samples 
were treated with blocking buffer (1% bovine serum albumin (BSA), 0.05% tween20 in 
DPBS-/-) for 15 min in order to prevent unspecific binding. Cells were incubated with a 
primary antibody (Table 7) diluted in the blocking buffer for 1 h at room temperature and 
in a humid chamber. The coverslips were washed (4x 2 min with DPBS-/- then 1x  2 min 
with blocking buffer) and the cells were incubated with a fluorophore coupled secondary 
antibody (Table 7), diluted in the blocking buffer for 30 min at room temperature and in a 
dark humid chamber. Finally the coverslips were washed (4x 2 min with DPBS-/- then 1x 
2 min with sterile water) and mounted with Immu-Mount and left for 30 min incubation on 
37 °C hot plate.  
For cells on filters, cells were first washed twice by addition of ice-cold DPBS-/- into 
apical and basal compartments. The same fixation protocol as explained above was applied 
by addition of fixing agents into apical compartments of the filters.  Filters were then taken 
out by cutting with a blade and treated with primary and secondary antibodies the same 
way as the coverslips. Details related to microscopy techniques can be found in chapter 
3.2.5.4. 
3.2.5.2. Live cell imaging 
The cells cultured on 9.6 cm
2
 coverslips (3.2.2.5) were washed 3 times with HBSS+/+, 
microscoped in HBSS+/+ and kept in 37 °C chamber. The staining of the cell nuclei was 




carried out with Hoechst 33342 (5 μM in HBSS+/+, ≥10 min). For the live cell imaging 
with spin disk confocal microscopy (Nikon_CSU, Germany), glass bottom 8-well cuvette 
was coated with PLL (20 μg/ml in DPBS-/-, 0.3 ml/well, 1 h). YFP-occludin MDCK-II 
cells were seeded on glass bottom 8-well cuvettes in (1:3, 0.3 ml/well, in no-phenol red 
cell specific medium) and waited until they became confluent.  
Plan-Apochromat 40x air objective was utilized, and the microscope was adjusted to zoom 
automatically. Cells were kept inside a regulated chamber (37 °C and 5% CO2), and every 
15 min an image was taken from each pre-saved position and condition over the course of 
15 h. TAMRA-trictide was dissolved first in DMSO and then in cell-specific medium 
[final 10 µM peptide concentration and 1% DMSO (v/v)].  Afterwards TAMRA-trictide 
was added in wells (30 µl/well from 100 µM stock peptide solution) after the first image. 
3.2.5.3. Fluorescence resonance energy transfer 
The measurement of the fluorescence resonance energy transfer (FRET) is a distance 
dependent, radiationless transfer of energy from an excited donor fluorophore to a suitable 
acceptor fluorophore. FRET is only possible if the molecules are less than 10 nm apart 
(Sekar and Periasamy, 2003). For analysis of cis-interactions between TJ proteins along the 
cell membrane at cell–cell contacts, HEK cells growing on coverslips (9.6 cm2) were co-
transfected with plasmids encoding Cldn1–YFP and Cldn1-TRQ,  YFP–Occl and CFP–
Occl, YFP–Tric and CFP–Tric, and  CFP–MD3. After 48 h, transfectants were treated with 
peptide-free medium, 50 µM scrambled peptide- and 50 µM trictide-containing medium, 
respectively. After another 24 h, living cells were transferred into HBSS +/+ and analyzed 
by ZEISS LSM 510 META NLO microscope using a PlanNeofluar 100x/1.3 oil objective. 
For FRET at bTJs, acceptor photobleaching principle was applied (Cording et al., 2013; 
Kenworthy, 2001). Photobleaching of YFP was performed using 30–40 pulses of the 514 
nm argon laser line at 100% intensity (Table 14). Before and after acceptor bleaching, CFP 
intensity (Table 14) images were recorded to calculate changes in donor fluorescence in 
the area of cell-cell contacts.  We always measured areas with similar CFP and YFP 
fluorescence intensities. The FRET efficiency (EF) was calculated as below: 
 
 









EF  FRET efficiency 
Ia   CFP fluorescence intensity after photobleaching 
Ib   CFP  fluorescence intensity before photobleaching 
 
MDCK-II cells were used for FRET measurements in three-cell contacts and treated with 
peptide-free medium, 50 µM scrambled peptide-, 50 µM and 100 µM trictide-containing 
medium, respectively. 
3.2.5.4. Stimulated emission depletion microscopy (STED) 
The coverslips were placed in a 24-well-tissue culture plate and coated with PLL (20 μg/ml 
in DPBS-/-, 0.3 ml/well, 1 h, for Caco-2 and MDCK-II cells) or rat tail collagen (0.67 
mg/ml in 0.2% acetic acid, 50 µl/well, for bEND.3 cells). Cells were seeded and grown 
until they became fully confluent. Before fixation, cells were washed three times with ice-
cold DPBS-/-. The coverslips were placed into a staining chamber with 4% 
paraformaldehyde (PFA) for 15 min at room temperature. After washing three times with 
ice-cold DPBS-/-, samples were treated with permeabilization buffer (0.1% Triton X-100 
in DPBS-/-) for 10 min. Afterwards, the coverslips were rinsed three times with DPBS-/- 
and left to incubate with blocking buffer (2% BSA in DPBS-/-) for 1 h at room 
temperature. Cells were incubated with primary antibody dilutions (Table 7) (1% BSA in 
DPBS-/-) overnight in a humid chamber at 4 °C. The coverslips were washed (3x 5 min 
with DPBS-/-) and the cells were incubated with a STED-specific fluorophore coupled 
secondary antibody (Table 7) (diluted in DPBS-/-) for 1 h in a dark humid chamber at 
room temperature. Finally the coverslips were washed (3x 10 min with DPBS-/- then 2x 10 
min with sterile water) and mounted with Prolong Gold Antifade (Thermo Fischer 
Scientific) and left for 24 h incubation at room temperature before time gated STED 
(gSTED) microscopy. STED imaging with time-gated detection was performed on a Leica 
SP8 TCS STED microscope (Leica Microsystems) equipped with a pulsed white light 
excitation laser (NKT Photonics). 




Dual-channel STED imaging was performed by sequentially exciting Atto647N and Alexa 
594 at 646 nm and 598 nm, respectively. Both dyes were depleted with a 775 nm STED 
laser. One optical section as acquired with an HC PL APO CS2 100x/1.40-N.A. oil 
objective (Leica Microsystems) (a scanning format of 1.024x1.024 pixel, 8 bit sampling 
and 6 fold zoom) can yield a pixel dimension of 18.9x18.9nm. Time-gated detection was 
set from 0.3–6 ns for all dyes. Fluorescence signals were detected sequentially by hybrid 
detectors at the appropriate spectral regions separated from the STED laser. To minimize 
thermal drift, the microscope was housed in a heatable incubation chamber (LIS Life 
Imaging Services). The effective lateral resolution of the SP8 TCS STED microscope was 
previously determined using 40 nm fluorescent beads (Life Technologies; 
excitation/emission maxima at 505/515 nm or 660/680 nm) to be 45 nm for the 647 nm 
channel (Grauel et al., 2016). Raw data obtained from gSTED imaging were deconvolved 
using Hygens Professional (Scientific Volume Imaging, Netherlands) software and 
analyzed by custom macro (ImageJ).  
3.2.6. Protein biochemistry methods 
3.2.6.1. Cell lysis of eukaryotic cells 
Cells were washed with ice cold DPBS-/- and, after removal of DPBS-/-, they were 
scraped off with DPBS-/- (600 µl/9.6 cm
2 
well). The remaining cells were collected with 
additional 600 µl of DPBS-/- and transferred into an eppendorf tube. The tube was 
centrifuged (150xg, 4 min, 4 °C) and DPBS-/- was removed from cell pellet. Extraction 
buffer (Table 18, 90 µl/per tube) was added on cell pellet.  Cells were resuspended 3-5 
times with a pipette and left for incubation on ice for 20 min. Following incubation, the 
tube was centrifuged (13000xrpm, 1 min, 4 °C) and extraction buffer was discarded. The 
pellet was homogenized with benzonase-mixture (5 µl/tube) (Table 18) again with a 
pipette and placed in thermomixer at 37 °C for 10 min. After 10 min, the mixture was 
homogenized well with a pipette (200 µl pipette tip) and mixed with solubilization buffer 
(16.6 µl/per well) (Table 18). The mixture was incubated with a thermomixer (Table 4) at 
97 °C for 3 min. Finally the extraction buffer (11.7 µl/tube) was added, protein 
concentrations of the samples were measured (chapter 3.2.6.2) and stored at -80 °C. 
 





Table 18. Ingredients of cell lysis buffers 
Extraction-buffer 25 mM HEPES, 150 mM NaCI, 1% Triton X-100, 1:10 
protease inhibitor (freshly added), pH 7.4 
Solubilization-buffer 50 mM Tris, 5 mM EDTA, 1% SDS, pH 8.8 
Benzonase-mixture 1.5 M Tris, 25 mM MgCI2, 35 U/ml benzonase, pH 8.8 in 
ddH2O. 
HEPES, (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); EDTA, ethylenediaminetetraacetic acid;  
SDS, sodium dodecyl sulfate; dd, double distilled. 
3.2.6.2. Determination of protein concentration 
The protein concentration was measured by Direct Detect Spectrometer system (Merck 
Chemicals GmbH) that measures amide bonds in protein chains and determines an intrinsic 
component of every protein without relying on amino acid composition, dye binding or 
redox potential. For that purpose, 2 µl of the sample was loaded as triplicates on Direct 
Detect assay-free card (Table 5). A mixture of solubilization-extraction buffer and 
benzonase solutions (Table 18) was used as blank. The mean of measurements from 
triplicates was taken as final protein concentration (mg/ml). 
3.2.6.3. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
The samples were prepared as 30 µg protein/well in a 25 µl mixture of 1x loading buffer 
and ddH2O per well. The separation of cell lysates was carried out by SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) in 12% Tris-gycine gels (Table 19) at 100 V and 22 °C. 
For optional checking of the purity of the purified proteins, the SDS gel was then stained 
with Coomassie staining solution (0.2 g Coomassie Brilliant Blue G250, 25 ml 95% 
ethanol, 17 ml 96% perchloric acid per 400 ml distilled water). 
Table 19. SDS-PAGE 
Running buffer 25 mM Tris-HCl, 192 mM Glycine, 0.1% SDS pH 8.3 
Stacking gel buffer 1.5 M Tris-HCl pH 8.8 
Separating gel buffer 0.5 M Tris-HCl pH 6.8 
 12% Tris-glycine-gel 
Stacking gel 3.4 ml ddH2O, 0.63 ml stacking gel buffer, 0.83 ml 30% 
Acrylamide/Bisacrylamide, 50 μl 10% SDS, 50 μl 10% APS, 5 μl TEMED 
Separating gel 3.3 ml ddH2O, 2.5 ml separating gel buffer, 4 ml 30% 
acrylamide/bisacrylamide, 100 μl, 10% SDS, 100 μl 10% APS, 4 μl TEMED 
5x SDS Loading buffer 225 mM Tris/HCl (pH 6.8), 5% (w/v) SDS; 50% (v/v) 
glycerol, 0.25 M DTT; 0.05% (w/v) bromophenol blue 
Tris-HCl, tris (hydroxymethyl) aminomethane hydrochloride; APS, ammonium peroxodisulfate; SDS, sodi-
um dodecyl sulfate; TEMED, tetramethylethylenediamine; sizes were determined in comparison to PageRul-
er Plus prestained protein ladder (Thermo Fischer Scientific) (5 μl/well). 
 




3.2.6.4. Western blot 
For the specific detection of a protein in a protein mixture, a Western blot analysis was 
performed. After equilibration of the nitrocellulose membrane and the SDS gel for 10 min 
in transfer buffer (25 mM Tris-HCl, 190 mM glycine, 20% methanol, pH 8.3), protein 
transfer was carried out in a wet blot apparatus (Bio-Rad) at 4 °C for 1 h at 100 V. The blot 
was blocked with 5% milk powder (Table 3) in TBST [50 mM Tris-HCl, 150 mM NaCl, 
0.05% Tween-20 (Table 3), pH 7.4] for 1 h at room temperature on a shaker (Table 4). 
Incubation with the primary antibodies was carried out in a suitable dilution (Table 7) 
overnight at 4 °C. The peroxidase-coupled secondary antibody (1:1000 in 1% milk 
powder, Table 5) was incubated after washing the membrane (6x, TBST) for 1 h at 22 °C. 
After another washing step (6x, TBST), chemiluminescence detection of the proteins took 
place: the membrane was wetted with 500 µl of developer solution [SuperSignal West 
Femto Maximum Sensitivity Substrate (Table 6), luminol/enhancer solution and stable 
peroxide solution were 1:1 mixed] for 5 min, and chemiluminescence in transilluminator 
(Table 4) detected. The band intensities were analyzed by ImageJ. 
3.2.6.5. Peptide detection in blood plasma 
TAMRA-trictide (10 µM) was dissolved in 1% DMSO and completed with mouse blood 
plasma (see chapter 3.2.7.2 for preparation). The blood plasma was incubated up to 48 h at 
37 °C. At hour zero, as well as after 2, 4, 8, 12, 13, 24 h, and 48 h, 160 μl aliquots were 
taken and precipitated with 60 µl of acetonitrile/99% ethanol (1:1) (30 min, 4 °C). After 
centrifugation (20000xg, 15 min, 4 °C), supernatant was  taken and filtered through 
Nanosep 10K Omega filters (Table 5) by centrifugation (5000xg, 10 min, 17 °C) and 
analyzed by SDS-PAGE. For the separation of the peptides with SDS-PAGE, 10 µl of the 
filtrate was resuspended in 5x loading buffer (Table 19), denatured (5 min, 95 °C), cooled 
on ice and separated in mini-protean TGX gel  at 100 V and 22 °C  (Table 4). The 
fluorescence of TAMRA (Table 14) was detected in the gel documentation system and 
measurement of band intensities quantified by the ImageJ software (Table 15).  
Parallel to this experiment, stability of trictide in blood plasma was investigated. 
Additional samples were prepared with trictide (800 µM) incubated [dissolved firstly in 
DPBS-/- (10x)] in mouse blood plasma up to 48 h. After the separation of supernatant, 
samples were filtered through 22 microns pipette tip filters (ZipTip C18 columns, Table 5) 
and analyzed by mass spectrometry. 




3.2.6.6. Expression and purification of maltose-binding protein tagged proteins 
Recombinant proteins were fused N-terminally with maltose-binding protein (MBP) for 
affinity purifications. For Tric ECL2, amino acid residues 312–339 of the human sequence 
were used. Proteins were expressed in Escherichia coli BL21, harvested and resuspended 
in binding buffer (20 mM Tris/HCl, pH 7.4, 200 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid). Cells were lysed via sonication (sonorex super ultrasonic 
bath, 300 W) and centrifuged (39000xg), and the supernatant was incubated (1 h, 4 °C) 
with amylose resin. MBP-proteins were eluted with binding buffer containing 10 mM 
maltose.  
3.2.6.7. Purificaton of His-tagged proteins 
The recombinant N-terminally His-tagged C-terminal tail of human Tric was purified for 
further co-immunoprecipitation. Bacterial pellets were resuspended in lysis buffer (5 ml/g) 
(Table 20) and centrifuged (10000xg, 30 min, at room temperature). The supernatant was 
used for further purification. The columns (20 ml) were loaded with 2 ml Ni-NTA agarose 
matrix. The supernatant was added to the column and incubated with the column material 
for one hour at room temperature. The supernatant was run twice over the column. Then, 
the columns were washed three times with 10 mM imidazole  and finally eluted with 4 ml 
of 200 mM imidazole  (4x1 ml each) (Table 20). Elution was stored at -20 °C. Before 
concentrating the eluate, the protein concentration was measured. The samples were 
diluted into 10 mM imidazole with PBS -/- and then concentrated to 1 mg/ml protein 
concentration by centrifugal filter device (Amicon ultra-15, Table 5). 
Table 20. Buffer and solutions for protein purification  Ingredients  
Lysis Buffer  100 mM NaH2PO4∙H2O, 10 mM Tris-HCl,  
6 M guanidine hydrochloride in 1.8 Ω H2O, 
pH 8.0 (adjusted with NaOH)  
Washing solution  10 mM imidazole in DPBS-/- 
Elution solution  200 mM imidazole in DPBS-/- 






In order to analyze the binding between human Tric and recombinant N-terminally His-
tagged cytosolic C-terminal tail of human Tric (hTric363-558), proteins were co-precipitated. 
The columns were placed in a 2 ml tube (without closing the tip) and loaded with 500 μl of 
Talon Superflow Metal Affinity (Table 6). Then, the columns were washed (3x with 300 μl 




of 10 mM imidazole in DPBS-/-) before being loaded with 500 μl of the concentrated 
protein. The columns were completely sealed and left to incubate for 2 h at 8 °C. A 
protein-free control was included for each protein sample. Afterwards, the supernatant was 
removed and the columns were washed (3x with 300 µl of 10 mM imidazole). In the next 
step, the columns (controls and samples) were each loaded with 300 μl cell lysates, sealed 
and incubated overnight at 8 °C. The next day, the columns were washed (3x with 300 μl 
of 10 mM imidazole in DPBS-/-) and transferred to a new 1.5 ml closable tube and loaded 
with 80 μl of 200 mM imidazole for elution. The sealed columns were incubated at room 
temperature for 45 min. Subsequently, the solutions were centrifuged (13000xg, up to 2 
min, at room temperature) and the elution fraction was obtained. The final samples were 
prepared for SDS-PAGE gel electrophoresis. 
3.2.7. In vivo investigations in mice 
The studies on mice were approved by the Office for Health and Social Affairs of Berlin 
and carried out according to the valid German animal welfare regulations. 
3.2.7.1. Peptide injections and detection of fluorescent dyes 
C57BL/6N mice (10–19 weeks old, 18–23 g) were housed in MDC-Berlin animal facility, 
kept on 12:12 h dark–light, and fed standard diet ad libitum according to German animal 
welfare law in Berlin (G0030/13, LaGeSo).  
For dye-uptake studies in organs, 800 µM of trictide dissolved in DPBS+/+ (3.6 µmol/kg) 
were injected into the tail vein (i.v.). The injection volume was adjusted according to the 
weight of the animals (for 22 g adult mouse, 100 μl of the fluorescent dye solution). After 
4 or 24 h, 2% Na-fluorescein (376 Da, w/v, dissolved in DPBS+/+) was administered (i.v.). 
After 10 min, mice were anesthetized with i.p. injection of anesthesia mixture (0.18 mg/g 
ketamine and 0.024 mg/g xylazine in distilled water, 350 µl/mice). Under deep anesthesia, 
mice chests were opened, hearts were prepared by insertion of a butterfly cannula in left 
ventricle and perfused transcardially with 25 mL DPBS+/+ containing 6250 IU heparin 
(flow rate 1.5 ml/min). The harvested brain, kidney and a lobe of liver were frozen in 2-
methylbutane on dry ice for 7 min and stored at -80 °C until further use. 




For the biochemical detection of the fluorescent dyes, 100 mg of the perfused brain, kidney 
or liver were homogenized on ice in 250 μl DPBS+/+ (Dounce tissue homogenizer), 250 μl 
of 60% trichloroacetic acid were added, and the homogenate was left for overnight 
incubation at 4 °C. After centrifugation (18000xg, 20 min, 4 °C), the fluorescence intensity 
of the Na-fluorescein within the supernatant was measured in 96-well plates at the 
appropriate wavelength (Table 14) by a TECAN-reader (Table 4). A set of standard 
samples was included within the same plate, and a standard curve obtained from those 
samples was used to calculate the amount of Na-fluorescein uptake related to weight of 
organs (µmol/kg). 
3.2.7.2. Obtaining blood plasma 
C57BL/6 mice were sacrificed immediately after cervical dislocation, and cardiac blood 
was taken from the left ventricle. The blood was incubated with heparin (25 IU/ml) and 
immediately mixed and centrifuged (750xg, 15 min, at room temperature). The yellow 
fraction on top of the precipitate was transferred to a test tube and immediately used for 
investigations of peptide stability as first use preference. Otherwise the fraction was stored 
at -20 °C for later use. 
3.2.8. Molecular biological methods 
3.2.8.1. Quantitative real time polymerase chain reaction 
Total RNA was isolated from tissue or eukaryotic cells by using the Universal RNA 
Purification Kit (Table 6), transcribed into cDNA (complementary DNA) using the 
Maxima First Strand cDNA Synthesis Kit (Table 6) for quantitative real time polymerase 
chain reaction (qRT-PCR) and stored at -20 °C. The mouse- or human-specific primers 
(Table 9) were designed by Philipp Berndt and tested for its binding specificity using Blast 
(Table 15). 
qRT-PCR was carried out in the StepOne Real-Time PCR System (Life Technologies 
GmbH), according to the cycling protocol in Table 19, using the Luminaris Color HiGreen 
high ROX qPCR Master Mix. The Master Mix contained a Taq polymerase that emits a 
fluorescent signal upon binding to the double stranded cDNA. During qRT-PCR the 
detected fluorescence increases proportionally to the DNA accumulation.  




20 μl of the reaction mix were pipetted according to Table 21 in each well of a MicroAmp 
Fast Optical 96-well reaction plate (Table 5). For data analyses and export the StepOne 
Software v2.2.1 (Table 15) was used. In order to evaluate the data, the cycle threshold (Ct) 
value was set to 0.4, within the linear phase of the logarithmic amplification plot for all 
tested primers.  Ct value gives the number of cycles completed in order to detect a real 
signal from the samples.  Threshold is determined as a level above background 
fluorescence. In order to calculate relative expression of the examined genes, Ct values 
were normalized to β-actin (Actb, as a housekeeping gene): Actb (ΔCt = Cttarget - CtActb). 
To compare the expression between two groups, ΔΔCt (ΔΔCt = ΔCtB - ΔCtA) was 
calculated. cDNA amplification during the PCR is exponential. A single peak at the 
calculated temperature indicated specific amplification of cDNA; therefore, unspecific 
products were identified by melting curves. 
 
Table 21. qRT-PCR protocol 
Component Concentration Cycling protocol 
Luminaris Color HiGreen 
qPCR Master mix (2x) 
1x Step Temperature 
(°C) 
Time Number of 
cycles 
Primer (fw) 0.3 µM Uracil-DNA 
glycosylase 
pre-treatment 
50 2 min 1 
Primer (rev) 0.3 µM Initial 
denaturation 
95 10 min 1 







qRT-PCR, quantitative real time polymerase chain reaction; fw, forward; rev, reverse; cDNA, 
complementary DNA. 
 
3.2.8.2. Molecular cloning 
A thermocycler (Bio-Rad Laboratories GmbH) was used to clone recombinant N-
terminally His-tagged cytosolic C-terminal tail of human Tric (hTric363-558) DNA from 
N-terminally YFP-tagged human Tric cDNA using primers (Table 11). The composition of 
PCR mixture and the thermal cycling conditions for a reaction volume of 30 μl are shown 
in Table 20. The PCR product was purified using the DNA Clean and Concentrator-5 kit 
(Table 4) according to the supplier’s manual. The concentration was photometrically 
determined using the NanoDrop 2000c (Thermo Fisher Scientific GmbH). 
 





Table 22. PCR protocol 
Component Concentration Cycling protocol 
10x key buffer 1x Step Temperature 
(°C) 
Time Number of 
cycles 
dNTP mix 0.2 mM Initial 
denaturation 
95 2 1 
Template DNA 0.5 ng/µl Denaturation 95 30 s 35 
Primer (fw) 0.5 µM Annealing 65 45 s 
Primer (rev) 0.5 µM Elongation 72 1  
Taq DNA 
Polymerase 
1 µl  Final 
elongation 
72 5  1 
PCR, polymerase chain reaction; dNTP, deoxynucleotide fw, forward; rev, reverse; cDNA, complementary 
DNA. 
 
In order to ligate PCR product with the pET-28a (+) expression vector (Addgene, USA), 
both DNA and target vector were digested with Hind III and Not I fast digest restriction 
enzymes (Table 6). The restriction was performed in a volume of 40 μl for the PCR 
product or 30 μl for the plasmid DNA (Table 23) at 37 °C for at least 4 h. After restriction, 
the PCR product and the plasmid DNA were separated by agarose gel electrophoresis. 
Agarose gel bands that were observed at the expected size were cut out. The DNA was 
extracted using the Zymoclean Gel DNA Recovery Kit (Table 6) following the product 
protocol. The concentration and the degree of purity of the extracted DNA were 
determined by photometric measurement of the absorption at 260 and 280 nm using the 
NanoDrop 2000c. 
 
Table 23. Protocol of DNA restriction  
Restriction of the PCR product Restriction of the plasmid product 
Component Amount Component Amount 
PCR product 30 µl Plasmid DNA 20 µl 
Fast digest buffer (10x) 4 µl Fast digest buffer (10x) 3 µl 
Fast digest enzyme (HindIII) 2 µl Fast digest enzyme (HindIII) 2 µl 
Fast digest enzyme (NotI) 2 µl Fast digest enzyme (NotI) 2 µl 
PCR, polymerase chain reaction. 
 
The ligation of the PCR product and the linearized plasmid DNA was performed in 20 μl 
of reaction mix (Table 24) for 14 h at 16 °C. The ligase was inactivated by heating at 65 °C 
for 10 min. 




Table 24. Protocol of Ligation  
Component  Concentration 
Ligase buffer (10x) 1x 
Plasmid DNA 5 ng/µl 
PCR product Molar ratio of 5:1 plasmid DNA 
T4 DNA ligase 20 units/µl 
 
3.2.8.3. Preparation of electrocompetent bacteria 
An E. coli BL21 culture in 500 ml LB medium was grown (200xg, 37 °C, without 
antibiotic) until it reached an OD 600 nm=0.6. After cooling for 30 min on ice and 
centrifuging (3000xg, 10 min, 4 °C), the pellet was resuspended in 160 ml ice-cold 
distilled water, divided into four portions and centrifuged again (1500xg, 15 min, 4 °C). 
Supernatants were discarded and pellet was resuspended with 40 ml of ice-cold distilled 
water and centrifuged (1500xg, 15 min, 4 °C). The pellet was resuspended in 10% 
glycerol. After centrifugation for the last time (1500 g, 15 min, 4 °C), it was resuspended 
in 1 ml of ice-cold 10% glycerol, aliquoted and stored at -80 °C. 
3.2.8.4. Transformation of electrocompetent bacteria 
An aliquot of 150 μl of electrocompetent bacteria was thawed on ice and transferred into 
an electroporation cuvette together with 0.5 μl of the plasmid DNA. The bacteria were 
exposed to 1.8 kV, allowing the cells to take up the plasmid. The transformed bacteria 
were immediately incubated with 500 μl LB medium at 37 °C for 1 h. Selection of positive 
clones was provided by kanamycin (100 μg/ml) containing agar plates. The bacteria was 
plated on agar plates and incubated overnight at 37 °C. The next day we picked positive 
clones from single colonies. Mini-cultures (5 ml of LB medium with 100 μg/ml 
Kanamycin) were inoculated and left for overnight incubation (200xg, 37 °C). Those mini-
cultures were either used for preparation of glycerol stocks or purification of plasmid DNA 
by DNA purification kits (Table 6). 
 
3.2.8.5. Site directed mutagenesis 
Aromatic residues in tricellulin extracellular loop 2 (Y322, Y323, F326, F334) were 
mutated into alanine or isoleucine (Chapter 4.3.8). Primers that carry the modified codon 
were given in Table 10. The PCR master mix with a volume of 80 μl (Table 25) contained 
an AccuPOL DNA Polymerase (Table 6) with high proofreading capacity for replication of 
the plasmid DNA. Gradient PCR program (51, 51.3, 52.5, 54.2, 56.5, 59.1, 61.8, 64.5, 67, 




69.1, 70.6, 71.5 °C) was applied due to high variation between the melting temperatures of 
primers. The PCR product was purified using the DNA Clean and Concentrator-5 kit 
(Table 6) following the product instructions.  
 
Table 25. Gradient PCR protocol 
Component Concentration Cycling protocol 
AccuPol buffer 
(10x) 
1x Step Temperature 
(°C) 
Time Number of 
cycles 
dNTP mix 0.2 mM Initial 
denaturation 
95 2 min 1 
Template DNA 500 ng/rxn Denaturation 95 1 min 35 
Primer (fw) 0.2 µM Annealing 51-71.5 °C 30 s 
Primer (rev) 0.2 µM Elongation 72 11 min  
Taq DNA 
Polymerase 
0.025 U/µl Final 
elongation 
72 5 min 1 
PCR, polymerase chain reaction; dNTP, deoxynucleotide; rxn, reaction; fw, forward; rev, reverse; cDNA,  
complementary DNA. 
3.2.9. Biophysical methods 
3.2.9.1. Circular dichroism spectroscopy 
The circular dichroism (CD) spectroscopy was applied to detect possible structural 
differences between effective and ineffective peptides. The technique is based on optically 
active substances absorbing different degrees of circularly polarized light. Therefore, 
tricellulin peptides (50 μM) were dissolved in phosphate buffer (10 mM, pH 7.2) in order 
to determine the proportion of secondary structural elements (α-helix, β-sheet, β-loop). The 
remaining portion was considered disordered. By adding the surfactant SDS (0.5 mM in 
phosphate buffer) below the critical micelle concentration (9-10 mM, (Niraula et al., 2014), 
a possible induction of β-sheet structures should be examined (Zhong and Johnson, 1992). 
Above the critical micelle concentration, SDS led to the induction and stabilization of α-
helices (Gopal et al., 2012). Trifluoroethanol (60% TFE in phosphate buffer) has the 
property of favoring induction of α-helices (Buck, 1998). The measurements were taken 
with the spectropolarimeter J-720 (Table 4), at 22 °C, from 190-260 nm, in 0.1 cm quartz 
cuvettes (Table 5). Per measurement, 8 accumulations were made with a resolution of 0.1 
nm and a measuring speed of 20 nm/min. For analysis, the data was subtracted from the 
buffer-based spectrum.  Molar residual ellipticity [θ] was calculated considering the amino 
acid number using the Spectra Manager program (Corrêa and Ramos, 2009): characteristic 




of α-helical elements in L-AS peptides are ellipticity minima at 208 and 222 nm, and a 
maximum at 192 nm. For β-sheet structures, there is a minimum at 217 nm and a 
maximum at 195 nm. Unordered elements show a minimum <200 nm (Greenfield and 
Fasman, 1969). The secondary structural components of the peptides were determined with 
the Spectra Manager using reference spectra (Yang, Wu & Martinez, 1986). 
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10 ∙𝐶 ∙𝑑
                               (deg∙ 𝑐𝑚2  ∙ 𝑑𝑒𝑐𝑖𝑚𝑜𝑙−1)  
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𝜃    Ellipticity (mdeg) 
C   Molar concentration (mol·l
-1
) 
d   Layer thickness of the cuvette (cm) 
n   Number of the amino acids 
 
3.2.9.2. Three-dimensional structure prediction of peptides 
3D-structure model of trictide peptides was prepared using the program Pepfold 
(http://bioserv. rpbs.univ-paris-diderot.fr/PEP-FOLD/) (Shen et al., 2014)Thévenet et al., 
2012). Different models varying in their 3D-structure were obtained; models ﬁtting best to 
experimental data were selected for further analysis. To gain insight into the binding 
mechanism of trictide, we created docking models of the Pepfold trictide model to the 
iTasser (Table 15) model of human Tric ECL2. The suggested binding surfaces were based 
on the hydrophobic potentials of the two structures and were depicted using Discovery 
Studio Visualizer (Table 15). 
 




3.2.9.3. Mass spectroscopic detection of peptides in the blood plasma 
For mass spectrometric detection of TAMRA peptides in blood plasma, samples were 
prepared according to procedures detailed in chapter 3.2.6.5, concentrated (rotary vacuum 
concentrator, 45 °C, 5.5 torr/min vacuum), and dissolved in 5% acetonitrile/0.1% TFA in 
an ultrasonic bath (Table 4). The sample was desalted and re-concentrated using ZipTip 
C18 columns (Table 5). After washing (3x, 50% acetonitrile, 0.1% TFA) and equilibration 
(3x, 0.1% TFA, pH 7.0), the columns were loaded with the sample by pipetting 10 times. 
After washing (3x, 0.1% TFA, pH 7.0), the sample was eluted in 1.5 µl 65% 
acetonitrile/0.3% TFA directly on an Opti-TOF 384er plate (Thermo fischer scientific). For 
each sample, 0.5 μl of α-cyano-4-hydroxycinnamic acid (5 mg/ml in 75% acetonitrile/0.3% 
TFA) was added. Peptides were detected with the mass spectrometer (AB SCIEX TOF / 
TOF 5800, SCIEX, Germany). 
3.2.10. Statistsics 
Data analysis and generation of graphs were achieved by employing GraphPad Prism® 
5.04 and Microsoft Excel 2010 (Table 15). Results are given as mean±SEM. One-way 
analysis of variance (ANOVA) followed by Dunn’s multiple comparison test were used to 
determine significant difference between two groups. The two-way ANOVA test followed 
by Bonferroni’s comparison test was used to determine significant differences between 
more than two groups. Differences were considered significant if p≤0.05 for n ≥4 (* 












4. RESULTS  
 
4.1. TRICELLULIN IS HIGHLY EXPRESSED IN KIDNEY AND COLON 
For selection of suitable model systems for tricellulin derived peptidomimetic research, the 
expression of tricellulin was compared among different organs. Tric mRNA levels were 
quantified in several organs isolated from WT mice: brain (cortex and whole), eye, kidney 
(cortex and medulla), heart, lung, liver, testis, spleen, jejunum, duodenum, ileum and colon 
(Table S1). The lowest Tric expressing organs were spleen, brain cortex, testis and whole 
brain. Organs expressing Tric at medium levels were heart, ileum, jejunum, lung and 
duodenum. Colon was the highest Tric expressing organ, followed by kidney medulla, 
kidney cortex, liver and eye (Fig. 4.1). Due to high expression in the colon, we chose colon 
carcinoma cell line (Caco-2) as a cell culture model for modulating barrier permeability.  
Fig. 4.1 Tricellulin is highly expressed in most of the epithelial tissue dominant organs and less in 
endothelial tissue dominant organs of mice.  Messenger RNA (mRNA) expression of wild-type mice 
organs was given. Four organs with the lowest tricellulin expression were given as blue bars, and the rest of 
the organs expressing tricellulin at higher levels were given as red bars. mRNA normalized to β-actin  (Actb) 






4.2. TIGHT JUNCTION PROTEINS WERE DETECTED IN MOUSE AND 
HUMAN BRAIN SECTIONS 
The aim of the following experiment is to observe tricellular cell-cell contacts particularly 
in mouse brain capillaries to reveal localization of Tric with respect to other TJ proteins. 
Imaging of Tric in brain tissues is an unsolved problem due to the low expression levels 
and the unique morphology of tricellular contacts of capillary endothelial cells in general 
and of brain capillary specifically. Human and mouse brain slices were immunostained to 
observe localization of Tric (3-cell TJ marker), Cldn5 (2-cell TJ marker), Occl (2-cell TJ 
marker), ZO-1 (general junction marker) and LSR (3-cell TJ marker). Occl and Cldn5 
expression are well-described at the BBB, and their expression was known to be higher 
than that of other TJ proteins (Mariano et al., 2013; Pan et al., 2017). That is why they 
were used as co-staining for confirmation of brain capillaries.  
 
Fig. 4.2 Tricellulin localizes throughout cell-cell contacts and is enriched at tricellular contacts in Z-
direction of the mouse brain capillaries. (A) Immunohistochemical images of brain slices (8 µm 
cryosections) were given. Brain capillaries from region of forebrain cortex were stained with rabbit anti-
tricellulin (Tric), mouse anti-occludin (Occl) and mouse anti-claudin5 (Cldn5) antibodies. Tricellular contact 
points (white arrows). (B) 3D reproduction of Z-stacks. Tricellulin signal extends via Z-direction (see 





Both Occl-Tric and Cldn5-Tric co-stainings gave signal along the bicellular contacts of the 
capillary. Tric signal (green) was stronger at points where three capillary contacts join 
together (Fig. 4.2A, white arrows). Three-dimensional reproduction using Z-stack images 
demonstrated the extension of dot-like Tric signals (yellow) through the Z-direction at 
tricellular contact of the capillaries (Fig. 4.2B, insets). 
The second objective of this chapter was to visualize localization of tricellular TJ markers 
in human brain microvessels. Tric and LSR both localize at tricellular contacts (Iwamoto 
et. al., 2014; Sohet et al., 2015) while Occl and ZO-1 proteins localize to bicellular 
capillary contacts. Tric was expressed and observed at tricellular contacts with dot-like 
structure (Fig. 4.3A, white arrows). Labelling with LSR-ZO1 antibody combination 
revealed that LSR was also expressed and localized precisely at tricellular contacts of brain 
capillaries (Fig 4.3A, green arrows).  
 
Fig. 4.3 Tricellulin and lipolysis stimulated lipoprotein receptor (LSR) are expressed in human brain 
capillaries and localize in contacts between tricellular membrane surface patches. Immunohistochemical 
images of human brain cortex slices (8 µm cryosections) were stained with mouse anti-occludin (Occl), 
rabbit anti-tricellulin (Tric), rabbit anti-LSR and rat anti-zonula occludens protein 1 (ZO-1) antibodies. (A) 
Co-staining of Occl and Tric: tricellular Tric localization (white arrows), co-staining of LSR and ZO-1: 
tricellular LSR localization (green arrows). (B) 3D reproduction of Z-stacks. Tricellulin (white arrow) and 






After the three-dimensional reproduction using Z-stack images, the distinct tricellular 
localization of LSR (green arrows) and enrichment of Tric (white arrows) extending in Z-
direction was observed relative to the bicellular capillary contacts (Fig. 4.3B).  Imaging TJ 
proteins within healthy brain tissues enabled us to compare their localization and 
expression pattern to tissues of the peptide administered animals.  
4.3. TRICELLULIN PEPTIDOMIMETIC TO PERMEABILIZE CELL BARRIER 
4.3.1. Recombinant tricellulin extracellular loop two affects barrier integrity 
Recombinant MBP fused ECL2 of Tric was used to investigate its effect on the 
transepithelial electrical resistance (TER) of Caco-2 cells. MBP treated cells (negative 
control) displayed a non-significant decrease of TER to 78 ± 18%, and furthermore 90 µM 
MBP-Tric ECL2 treatment decreased to 78 ± 10%. However, 280 µM MBP-Tric ECL2 
clearly dropped TER to 53 ± 6% after 24 h (Fig. 4.4A).  
In order to identify changes at protein level in parallel to the TER changes, transwell filters 
were investigated immunocytochemically. MBP-Tric ECL2-free media treated samples 
showed typical Occl localization at bicellular contacts and Tric localization at tricellullar 
contacts (Fig. 4.4B, green arrowheads). Confocal microscopy resolution did not enable 
distinct localization of Occl and Tric at tricellular contacts (see chapter 4.3.5.2). That is the 
reason for the overlapping (yellow) signal of Occl (red) and Tric (green) at tricellular 
contacts (Fig. 4.4B, see enlarged images). Occl staining was sharp and continuous in the 
bicellular area. Samples treated with 280 µM MBP did not change normal localization of 
both proteins. 90 µM MBP-Tric ECL2 treatment resulted in internalization of vesicles and 
submembranous attachment of Occl protein along bicellular regions of cells. Tric signals 
were localizing at bicellular cell membrane (Fig. 4.4B, green arrows) and also at 
internalized vesicles (yellow arrows). But there were still Tric molecules localizing at 
tricellular contacts (Fig. 4.4B, green arrowheads). 280 µM MBP-Tric ECL2 increased the 
degree of internalization for both Occl and Tric. Occl was observed at internalized vesicles 
together with Tric (Fig. 4.4B, yellow arrows) and its signal was decreased at cell 
membrane compared to the untreated sample. Tric localization was also observed at 





4.4B). Due to the clear effect of recombinant Tric ECL2 on paracellular localization 
tightness reduction, Tric ECL2 region has been selected as an approach for overcoming 
cellular barriers at bTJs and tTJs, with the potential to improve drug delivery transiently. 
Fig. 4.4 Administration of the recombinant extracellular loop 2 (ECL2) of human tricellulin (Tric) 
causes redistribution of Tric and occludin (Occl) from the plasma membrane to the cytosol and 
weakens the paracellular barrier of human colon carcinoma epithelial (Caco-2) cells. (A) 
Transepithelial electrical resistance (TER) after 24 h of incubation with MBP (maltose binding protein) or 
MBP–Tric ECL2.  One-way ANOVA test was applied prior to Dunnett’s comparison post hoc test. 
Mean±SEM, n=3, * P < 0.01 relative to untreated control. (B) Immunocytochemistry showed effects of 
MBP–Tric ECL2 compared with MBP-Tric ECL2-free (untreated) and MBP treatment alone; incubation 
time: 24 h. Green arrowheads indicate tricellular localization of Tric; yellow arrows indicate intracellular 
Tric and Occl; green arrows indicate dot-like localization of Tric at the bicellular plasma membrane. 
 
4.3.2. The synthetic peptide trictide affects human epithelial colorectal 
adenocarcinoma cell line 2 
The experiments with MBP-Tric ECL2 showed promise for further development of a Tric 
ECL-based approach to cell barrier modulation. Trictide, a synthetic peptide, was derived 





of trictide was investigated in a variety of epithelial and endothelial cell lines chosen 
according to their TJ protein expression profile. Caco-2 cells were used preferentially in 
this chapter for trictide investigations due to their high Tric and broad transmembranous TJ 
protein’s expression profile (Berndt, 2017).  
4.3.2.1. Trictide has a concentration dependent effect on cell barrier tightness and a 
small concentration-difference between cytotoxicity and barrier opening 
A variety of trictide concentrations were tested in filter experiments in order to analyze 
trictide’s concentration dependency on tightness of cell barrier. TER was measured after 
16 h of incubation with the peptide. TER values relative to the untreated sample (194±7 
Ω·cm2) are given in Fig. 4.5A.  
50 µM trictide showed insignificant increase (11.3%) and absolute TER value of 216±9 
Ω·cm2. 100 µM trictide decreased TER to 90% (174±8 Ω·cm2). 125 µM trictide exhibited 
80% of TER (154±2 Ω·cm2). Only 150 µM trictide and 200 µM trictide significantly 
decreased TER to 56% (109±13 Ω·cm2) and 21% (154±2 Ω·cm2), respectively. 150 µM 
scrambled trictide displayed TER of 94% (181±7 Ω·cm2) (Fig. 4.5A). Consequently, a 
remarkable trictide action was recorded with concentrations ≥ 150 µM. 
Fig. 4.5 150 µM non-cytotoxic trictide concentration weakens the paracellular barrier of filter-cultured 
human colon carcinoma epithelial (Caco-2) cells after 16 h of incubation. (A) Transcellular electrical 
resistance (TER) values of trictide and scrambled trictide are given in comparison to peptide-free control 
(untreated). n=6. (B) Cell viability measurement with MTT [3-(4.5-dimethylthiazol-2-yl)-2.5-
diphenyltetrazolium bromide] was applied for cells that were treated with the same concentrations as for TER 
measurements. As positive control, Triton X-100 was included, n=4. (A-B) One-way ANOVA test was 





In order to measure cell viability levels after peptide administration, MTT assay was used. 
Percentages of cell viability compared to untreated control were: 50 µM (104±2%), 100µM 
(107±2%), 125 µM (106±3 %), 150 µM (90±2%), 200 µM (64±2%), scrambled trictide 
(105±7%), and 0.1% triton (37±4%) (Fig. 4.5B). Therefore, ≤150 µM trictide as well as the 
scrambled peptide were not cytotoxic, and higher concentrations of trictide should be 
avoided as they might be toxic. 
4.3.2.2. The effect of trictide on the impedance of the cell barrier 
Changes in cell impedance due to trictide administration were measured by electric cell-
substrate impedance sensor (ECIS) over time, which allowed calculation of TER. 150 µM 
trictide exhibited an increasing resistance up to 163±17% over 16 h, and then the TER 
drastically decreased to 104±16% after 47 h. 100 µM of trictide caused increase in TER 
between 16 and 47 h from 110±2 % to 142±4%.  Resistance after scrambled trictide 
remained almost the same at 0 h (86±4%), 16 h (82±7%) and 47 h (83±8%). Thus, trictide 
appeared to be active after 16
 
h of incubation; scrambled trictide did not show any effect 
on the resistance during the same period of time (Fig. 4.6). 
 
Fig. 4.6 Trictide reversibly influences the barrier of human colon carcinoma epithelial (Caco-2) cells. 
Effect on transcellular electrical resistance (TER) upon 100 µM and 150 µM trictide and 150 µM scrambled 
trictide administration compared to peptide-free medium (untreated). Measurements were taken by electric 
cell-substrate impedance sensor allowing calculation of TER. The graph initiated with peptide 
administration; at 47 h peptide containing medium was exchanged for peptide-free medium. Total incubation 
time, 70 h; dotted lines, time points of statistical calculations; two-way ANOVA test was applied prior to 
Bonferroni’s comparison post hoc test; mean±SEM; n=4; ** P ≤ 0.01 (47 h compared to 16 h), *** P ≤ 0.001 






At 47 h, the recovery process was initiated, by exchanging the peptide-containing medium 
for peptide-free medium. The 150 µM trictide treated sample exhibited an increase of TER 
up to 136±30% at 69 h. This finding is an indicator of cell barrier recovery followed by 
removal of peptide. The 100 µM trictide group exhibited slight decline of TER from 142% 
at 47 h to 138 ± 9% at 70 h. Scrambled trictide did not show any change in TER after the 
addition of peptide-free medium (Fig. 4.6).  
The data displayed unexpected TER increase at 16 h, which would indicate barrier 
tightening. ECIS measures cellular impedance that reflects transcellular resistance in an 
alternating current circuit. The dissimilarity between chopstick measurements and ECIS 
could be due to this technical difference. Repetition of experiment is necessary to confirm 
this effect. 
4.3.2.3. Trictide opens the cellular barrier for molecules up to 10 kDa. 
Filter experiments always showed the reduction of transcellular electrical resistance by 
trictide. Permeation measurements were performed in order to reveal the size of the 
opening in the barrier. Earlier, the tricellular central sealing tube was calculated as a radius 
of approximately 5 nm, which allows for the passage of globular macromolecules with a 
molecular weight of up to 10 kDa (Krug, et. al. 2009; Staehelin, 1973). Paracellular 
permeability for passage of small molecules and large molecules was measured with 
fluorescent tracers (LY, 0.45 kDa; FD10, 10kDA, FD40, 40 kDa).  
It was observed that 100 µM trictide non-significantly reduced the passage of small 
molecules to 60±11%. 125 µM trictide showed no change in permeability (106±29%).  
Passage increased up to 225±26% with 150 µM trictide. 150 µM scrambled trictide did not 
considerably affect permeability (78±9%). Untreated sample showed basis permeability 
coefficient for small molecules at 31±5·10
-10 
cm/s throughout the observation (Fig. 4.7A). 
Paracellular permeability measurements for large molecules like FD10 showed for 100 µM 
trictide 65±15% passage of larger molecules, which is not significant relative to untreated 
control. 125 µM trictide (92±32%) and 150 µM scrambled trictide 98±22% did not affect 
passage at all.  However, the degree of paracellular permeability for 10 kDa sized 
molecules increased to 221±54% with 150 µM trictide, which was more than 2 times the 
permeability of the untreated control. Untreated cells showed control permeability 
coefficient for the passage of large molecules at 13±2·10
-10 





The degree of paracellular permeability for much larger molecules like FD40 was 
measured as: 100 µM trictide (53±34%), 125 µM trictide (66±21%), 150 µM trictide 
(108±30%), and 150 µM scrambled trictide (120±49%). None of the concentrations 
significantly affected permeability towards 40 kDa molecules. The untreated sample 
exhibited a permeability coefficient of 1.4±1·10
-10 
cm/s for those much larger molecules 
(Fig. 4.7C).  
 
Fig. 4.7 150 µM of trictide opens the paracellular barrier of human colon carcinoma epithelial (Caco-2) 
cells for small and larger molecules up to 10 kDa. (A) Effect of trictide and scrambled trictide on 
paracellular permeability coefficient of lucifer yellow (0.4 kDa). (B) FITC (fluorescein isothiocyanate) 
Dextran 10 kDa. (C) FITC Dextran 40 kDa.  Values were related to substance-free control (untreated) and 
given as percentage; total incubation time: 16 h; ns, non-significant. One-way ANOVA test was applied prior 
to Dunnett’s comparison post hoc test. Mean±SEM, n=5, ** P < 0.01, *** P < 0.001 
 
Consequently, 150 µM was the only concentration that caused a significant increase in 
permeability of small and larger molecules. However, there was no opening for a 40 kDa 
molecule to pass.  
4.3.2.4. D-amino acid derivative of trictide is not effective. 
Substitution of physiological L-amino acids with non-physiological D-amino acids might 
decrease the substrate recognition and binding affinity by proteolytic enzymes (Di, 2015) 
and may increase stability of respected peptide. For that reason, a trictide with D-
conformation was synthesized. Initial experiments were executed with higher 
concentrations than used for L-trictide such as 200 and 300 µM. Even those high 
concentrations did not cause any drop of TER or any barrier opening activity (Fig. 4.8A). 
Likewise paracellular permeability of 10 kDa molecules did not increase due to the 






Fig. 4.8 D-amino acid trictide (D-trictide) does not have an effect on transcellular barrier tightness  of 
human colon carcinoma epithelial cells. (A) Transepithelial electrical resistance (TER) (B) Paracellular 
permeability of FITC (fluorescein isothiocyanate) Dextran 10 kDa. (A-B) Values were related to substance-
free medium (untreated). Total incubation time: 16 h. One-way ANOVA test was applied prior to Dunnett’s 
comparison post hoc test. Mean±SEM, n=3, ns: non-significant, versus untreated control. 
 
4.3.2.5. Trictide affects bicellular and tricellular tight junction proteins 
In order to be acquainted with alterations at protein level and to investigate how individual 
TJ proteins were affected by trictide, immunocytochemistry was applied. It was 
stimulating to examine alterations of Occl and Tric together due to their compensating 
regulation over each other (Raleigh et al., 2010) Occl-Cldn1 and Tric-Cldn1 co-stainings 
were selected due to information in the literature that affirms the contribution of Cldn1 to 
the enrichment of Occl and Tric at cell-cell contacts (Cording et al., 2013). Tric-LSR co-
staining was included considering that both LSR and Tric molecules are required for 
normal tTJ formation and barrier integrity (Masuda et al., 2011). As described in detail in 
chapter 4.3.2.1, 150 µM trictide was the active concentration in barrier opening of Caco-2 
cells. But at cellular level, we observed that this concentration was altering localization of 
TJ proteins too drastically and making it impossible to observe small modifications of 
individual proteins (Fig. 4.9). That is why mainly 100 µM of trictide was applied as a 











Fig. 4.9 Proteins related to the tricellular tight junctions are strongly affected by 16 h treatment with 
trictide. (Continuation of A and B from page 11) Human epithelial colorectal adenocarcinoma cells were 
grown until confluency and then incubated with peptide-free (untreated), scrambled peptide and trictide 
containing medium. Z-stack images were taken by confocal laser scanning microscopy and maximum 
intensity Z-projection method was performed. (A) Occludin (Occl) and tricellulin (Tric) co-stainings: In the 
untreated and scrambled trictide treated sample, Tric was localized to tricellular tight junctions (tTJs) (yellow 
arrowheads), whereas Occl was localized to bicellular tight junctions (bTJs). After 100 µM trictide treatment, 
Occl and Tric were internalized (white arrows). Tric localization was extended to bTJs after both 100 and 
150 µM trictide treatments (green arrowheads). (B) Lipolysis-stimulated lipoprotein receptor (LSR) and Tric 
co-stainings: In the untreated and scrambled trictide treated sample, Tric and LSR localized exclusively to 
tTJs (yellow arrowheads). Trictide addition led to co-internalization of Tric and LSR (white arrows), and to 
extended signals of Tric and LSR towards bTJs (green arrowheads). (C) Occl and claudin-1 (Cldn1) co-
stainings: In the untreated and scrambled trictide treated sample, Cldn-1 and Occl localized exclusively to 
bTJs (green arrowheads). After trictide treatment, Cldn-1 and Occl co-internalized (white arrows), and 
concentrated signals appeared around tTJs (red arrowhead).  
 
In untreated samples, Tric localizes as a dot-like structure where 3-cells come together, 
while Occl localizes mainly at cell borders where 2-cells meet (Fig. 4.9A, yellow 
arrowheads). After treatment with 100 µM trictide for 16 h, immunocytochemical stainings 
revealed discontinuous Occl staining and elongated Tric staining through bicellular plasma 





LSR and Tric signals of untreated and scrambled trictide treated samples were observed as 
yellow dots at tricellular contacts (Fig. 4.9B, yellow arrowheads). Samples labelled with 
LSR and Tric exhibited co-internalization of both proteins (white arrows) and signals 
extending from tTJs to bTJs when cells were administered with 100 µM or 150 µM trictide 
(Fig. 4.9B, green arrowheads). 
In untreated samples, Occl and Cldn1 co-stainings showed yellow co-localizing signals 
along cell-cell contacts (Fig. 4.9C, green arrowheads). Only with scrambled trictide, the 
green signal was more abundant than the yellow signal that indicates reduction of Occl and 
increase of Cldn1. The distribution of Occl and Cldn1 along the entire cell surface was 
different. The reason for that is Caco-2 cells growing upwards in various degrees, resulting 
in variable cell heights. These variations cause maximum intensity projected Z-stacks to 
reveal different amounts of Occl and Cldn1 at different levels. After 100 µM trictide, 
Cldn1 remained near the tricellular area (Fig. 4.9C, red arrowhead) and Cldn1 signal was 
reduced at bicellular area. Occl was dispersed discontinuously throughout bTJs, and 
proteins were co-internalized after 100 and 150 µM of trictide (Fig. 4.9C, white arrows). 
To sum up, 100 µM of scrambled trictide did not cause considerable changes to the typical 
localization of Tric, LSR, Occl, and Cldn1 (Fig. 4.9A, B, C, second column). After 
treatment with 150 µM trictide, alterations in the localization of these TJ proteins were 
intensiﬁed due to the presence of the greater concentration of the peptide (Fig. 4.9A, B, C, 
fourth column). In this chapter, it was confirmed that the mechanism of trictide affecting 
cell barrier integrity also modifies localization of tricellular and bicellular TJ proteins. 
4.3.2.6. Trictide mainly causes down-regulation of tricellulin and occludin 
The remarkable effect of trictide on barrier integrity and increase of permeability of the 
barrier raised the question of what happens at expression levels of TJ proteins. Therefore, 
mRNA expressions of TAMPs, LSR, Cldn1, Cldn5 and ZO-1 were analyzed by qRT-PCR 
in Caco-2 cells (Table.S2). mRNA values (2
ΔCt
) (see chapter 3.2.8.1) of proteins expressed 
in untreated controls were: Tric (12±0.7•10-3), Occl (18±3•10-3), MD3 (7±0.7•10-4), LSR 
(16±2•10-3), Cldn1 (4±0.1•10-3), Cldn5 (30±6•10-7), and ZO-1 (7±1•10-3).  
Thus, incubation with 150 µM trictide decreased mRNA expression of several TJ proteins 
significantly compared to untreated control. As expected, trictide reduced Tric mRNA 





(MD3) and scrambled peptide, MD3 mRNA was reduced by both scrambled trictide 
(51±6%) and trictide (37±8%). Cldn1 expression was decreased to 58±10%; Cldn5 
expression was similarly decreased (60±13%) by trictide (Fig. 4.10A). The latter result 
directed trictide investigation to work on a cell line with higher Cldn5 expression level 
because Caco-2 cells do not express high levels of Cldn5 (see chapter 4.3.3.3). 
 
Fig. 4.10 Trictide down-regulates expression of tricellulin, marvelD3, occludin and claudins in human 
colon carcinoma epithelial cells. (A) Effect on messenger RNA (mRNA) of designated proteins upon 
trictide and scrambled trictide treatment compared to untreated control (2
ΔΔCt
) (blue dotted line). mRNA 
normalized to β-actin  (Actb) (ΔCt = Ctjunction protein - Ctactin); Ct, Cycle threshold; total incubation time, 16 h; 
two-way ANOVA test was applied prior to Bonferroni’s comparison post hoc test; mean±SEM; n=10; * P ≤ 
0.05, ** P ≤ 0.01, *** P ≤ 0.001 versus untreated control. (B) Effect on tight junction protein expressions 
upon trictide treatment compared to peptide-free medium (untreated). Expression levels were determined by 
Western blotting followed by densitometry analysis of protein band intensities. Expression levels were 
normalized to GAPDH (Glyceraldehyde 3-Phosphate Dehydrogenase) and compared to untreated control. 
Total incubation time, 16 h; one-way ANOVA test was applied prior to Dunnett’s comparison post hoc test; 
mean±SEM; n ≥5; * P ≤ 0.05 versus untreated control. (C) Examples of Western blotted TJ protein bands 
were given. Expected protein sizes are:  tricellulin (Tric), 64 kDa; occludin (Occl), 65 kDa; marvelD3 
(MD3), 45 kDa; anti-lipolysis stimulated lipoprotein receptor (LSR), 71.4 kDa; claudin-1 (Cldn1), 23 kDa.  






Protein expressions of TAMPs, LSR and Cldn1 were measured to examine whether mRNA 
changes were reflected in protein quantities. As a result of 150 µM trictide administration, 
Tric expression decreased to 40±11% and Occl expression decreased to 42±8%. The rest of 
the proteins exhibited expression levels such as: MD3 (50±10%), LSR (77±22%) and 
Cldn1 (80±18%) (Fig. 4.10B). Only Tric and Occl were down-regulated significantly 
compared to the untreated control samples, and stated effects can be also observed in the 
given protein bands (Fig. 4.10C).  
4.3.3. Effect of trictide on claudin-5 rich endothelial cells forming blood-brain 
barrier 
In chapter 4.3.2.6, it was stated that Cldn5 mRNA expression of Caco-2 cells was affected 
by trictide treatment. Thus, trictide investigations were performed with mouse brain 
endothelial cells (bEnd.3) expressing high Cldn5 amount. Unfortunately, bEnd.3 cells 
express limited numbers of TJ proteins in high amounts such as: Occl, Cldn5, Cldn12 
(Berndt, 2017). That is why it was not possible to investigate interplay between Cldn5 and 
Tric.  
4.3.3.1. Trictide weakens the paracellular barrier of mouse brain endothelial cells 
The ECIS measurements in Fig. 4.11 showed TER change relative to the untreated sample 
plotted against the time, starting with peptide addition. Effects of each condition were 
statistically calculated compared to untreated cells. Before treatment, all cells reached a 
stable TER of 1077.8±44.4 Ω·cm2 (n=4). Untreated control cells showed TER of 
1503.7±206.5 Ω·cm2 after 21 h of administration. 50 µM trictide (95±9%) and scrambled 
trictide (98±7%) had no effect on TER during the administration time.  
Significant effect of 100 µM trictide on TER started at 9 h (75±8%) and developed further 
at 10 h (66±9%) and 11 h (58±1%). At the end of the incubation time TER was decreased 
to 16±1%. On the other hand, 75 µM trictide decreased TER gradually and significantly 
starting from 14 h (62±3%) and decreased further at 15 h (57±3%), 16 h (51±2%), 17 h 
(46±2%) and 18 h (42±2%) of incubation (Fig. 4.11).  
Trictide was known to open epithelial cell barriers after 16
 
h of incubation (see chapter 





transcellular resistance significantly from 9 h with 100 µM and from 14 h with 75 µM of 
trictide. 
 
Fig. 4.11 Trictide weakens the paracellular barrier of mouse brain endothelial cells starting from 9 h of 
incubation. Effect on transcellular electrical resistance (TER) upon 50-100 µM trictide and 150 µM 
scrambled trictide administration compared to peptide-free medium (untreated). Measurements were done by 
electric cell-substrate impedance sensor. The graph initiated with peptide administration; total incubation 
time, 21 h; dotted lines, time points of statistically significant changes; two-way ANOVA test was applied 
prior to Bonferroni’s comparison post hoc test; mean±SEM; n=4; ****P ≤ 0.0001 versus untreated control.  
 
4.3.3.2. Up to 75 micromolar, trictide is not cytotoxic for mouse brain endothelial cells 
In order to measure cell viability after peptide treatment, neutral red uptake assay was 
used. The bEnd.3 cells were incubated with peptide-free medium (untreated) and a variety 
of trictide concentrations. Scrambled trictide was used as negative and 0.01% triton X-100 
containing medium was used as positive control. Thus, cell viability values were observed 
for: 50 µM (118±10%), 75µM (98±10%), 100 µM (50±23%) and 150 µM of trictide 
(13±4%), 150 µM of scrambled trictide (124±12%), and 0.01% triton X-100 (10±3%) (Fig. 
4.12). Even though Triton X-100 concentration was maintained 10 times less compared to 
experiments with Caco-2 cells, much lower cell viability was detected. Taken together, 75 
µM trictide was not cytotoxic within the duration of the experiment (16 h), and bEnd.3 
cells were more sensitive for trictide administration. For further studies, 75 µM trictide was 







Fig. 4.12 ≤75 µM trictide is not cytotoxic for mouse brain endothelial cells (bEnd.3).  Effect on cell via-
bility upon 50-150 µM trictide, 150 µM scrambled trictide (negative control), and 0.01% Triton X-100 (posi-
tive control) treatment compared to peptide-free medium (untreated). Cell viability was measured with neu-
tral red uptake assay. Total incubation time, 16 h; one-way ANOVA test was applied prior to Dunnett’s com-
parison post hoc test; mean±SEM; n=7; *** P < 0.001 versus untreated control. 
 
4.3.3.3. Trictide down-regulates claudin-1, lipolysis stimulated lipoprotein receptor and 
occludin in mouse brain endothelial cells 
The mode of action of trictide affecting individual junctional proteins and leading to 
disruption of barrier integrity was not fully understood. mRNA expressions of Tric, Cldn5, 
Cldn1, LSR, ZO-1, Occl and Cldn25 were analyzed upon 75 µM trictide and 100 µM 
scrambled trictide administration compared to peptide-free medium (untreated) (Table S3). 
mRNA investigations of TJ proteins were started with 100 µM trictide concentration (Fig. 
S5) but reduced to 75 µM due to better cell viability. Cldn25 was included as a non-barrier 
forming control because it does not exhibit classical claudin TJ function with barrier 
tightening (Ohnishi et al., 2017). To date there is no information about interaction between 
Cldn25 and Tric available. 
Incubation with 75 µM trictide significantly decreased mRNA expression of Cldn1 
(36±8%), LSR (26±4%) and Occl (50±6%) (Fig. 4.13A). In fact, bEnd.3 cells expressed 
only a few junctional proteins in high levels, with exemplary delta Ct values (2
ΔCt







) and ZO-1 (21±0.8·10
-3
). Tric 











exhibited greater expression compared to Tric but were still expressed less compared to 
Cldn5, Cldn25, Occl and ZO-1. 
Protein expression level of Cldn5 upon 75 µM trictide application was tested to inspect 
whether mRNA change was reflected by protein amount and compared to untreated 
control. Cldn5 was up to 177±75% up-regulated, but this effect was insignificant due to 
high variation among samples (Fig. 4.13B). An example of analyzed protein bands can be 
observed in figure 4.13C.  
 
Fig. 4.13 Trictide down-regulates mRNA expression of claudin-1, LSR and occludin in mouse brain 
endothelial cells. (A) Effect on messenger RNA (mRNA) of designated proteins; upon trictide and 
scrambled trictide treatment compared to untreated control (2
ΔΔCt) (red dotted line). mRNA normalized to β-
actin  (Actb) (ΔCt = Ctjunction protein - Ctactin); Ct, Cycle threshold; total incubation time, 16 h; two-way 
ANOVA test was applied prior to Bonferroni’s comparison post hoc test; mean±SEM; n≥8; * P ≤ 0.05, *** P 
≤ 0.001, ****P ≤ 0.0001 versus untreated control. (B) Effect on claudin-5 (Cldn5) expressions upon trictide 
treatment compared to peptide-free medium (untreated). Expression levels were determined by Western 
blotting followed by densitometry analysis of protein band intensities. Expression levels were normalized to 
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) and compared to untreated control. Total incubation 
time, 16 h; student’s t-test was applied prior to Mann Whitney post hoc test; mean±SEM; n=4. (C) Examples 
of Western blotted Cldn5 (22 kDa) protein bands were given. Cldn1, claudin-1; Tric, tricellulin; LSR, anti-
lipolysis stimulated lipoprotein receptor; Cldn25, claudin-25; ZO-1, zonula occludens protein-1; Occl, 





4.3.3.4. Trictide concentrates claudin-5 and ZO-1 around tricellular contacts 
It was demonstrated that trictide affects endothelial cell barrier and down-regulates several 
TJ proteins (chapter 4.3.3.1). Cldn5 is of specific interest for trictide administration in 
brain endothelial cells because of its status as the highest expressed TJ protein and the 
main paracellular tightener. The localization changes were displayed after 16 h of 75 or 
100 µM trictide treatments (Fig. 4.14). Cells treated with peptide-free medium and 75 µM 
scrambled trictide containing medium were included as negative control. Cells were 
labelled with anti-Cldn5 (TJ marker) and anti-ZO-1 (junctional marker) antibodies. Both 
75 and 100 µM trictide concentrations were included to visualize gradual effect of the 
peptide.  
Fig. 4.14 Claudin-5 (Cldn5) and zonula occludens protein-1 (ZO-1) are enriched close to tricellular 
area after trictide treatment. Mouse brain endothelial cells (bEnd.3) were grown until confluency and then 
incubated with peptide-free (untreated), scrambled and trictide containing medium. Z-stack images were 
taken by confocal laser scanning microscopy and maximum intensity Z-projection method was performed. 
Untreated cells: Cldn5 localized at bicellular contacts (white arrow) and intracellularly (yellow arrowheads). 
ZO-1 also localized at bicellular contacts. 75 µM scrambled trictide: No major changes were observed. 
Cldn5 and ZO-1 located at bicellular contacts (white arrow). 75 µM trictide: Cldn5 was clustered around 
tricellular contacts (yellow arrows) and ZO-1 was still localizing at bicellular contacts. 100 µM trictide: 
Cldn5 and ZO-1 were localized stronger around tricellular area (yellow arrows). Incubation time, 16 h; 





Untreated samples showed staining at bicellular contacts for both Cldn5 (green) and ZO-1 
(red) (Fig. 4.14, white arrow). Cldn5 antibody also showed intracellular staining around 
cell nucleus. After scrambled trictide (75 µM) treatment, signals were dominantly observed 
at bicellular contacts (Fig. 4.14, white arrows). In the 75 µM trictide treated samples, 
bicellular localization of Cldn5 was reduced and green signal was redistributed to 
concentrate around tricellular contacts (Fig. 4.14, red arrows). At those points, the signal 
manifested itself yellow due to the fact that ZO-1 protein also moved close to tricellular 
contacts. 100 µM trictide caused greater alterations compared to 75 µM. The staining of 
Cldn5 as well as ZO-1 at bicellular contacts was severely reduced. A greater part of the 
signals was concentrated as a yellow signal around tricellular areas (Fig. 4.14, yellow 
arrows).  
 
Fig. 4.15 Claudin-5 (Cldn5) and occludin (Occl) are internalized and enriched close to tricellular area 
after trictide treatment. Mouse brain endothelial cells (bEnd.3) were grown until confluency and then 
incubated with peptide-free (untreated) and trictide containing medium. Z-stack images were taken by 
confocal laser scanning microscopy and maximum intensity Z-projection method was performed. Untreated 
cells: Cldn5 and Occl localized at bicellular and tricellular contacts (white arrows). 100 µM trictide: both 
Cldn5 (green arrows) and Occl (red arrows) were internalized and observed at subcellular areas. Cldn5 and 
Occl were redistributed from bicellular contacts to intracellular area and clustered around tricellular contacts 





Modifications of Cldn5 and Occl localizations were further observed after trictide 
administration. Untreated cells exhibited sharp staining of Cldn5 (green) and Occl (red) at 
bicellular contacts that overlapped also at tricellular contacts (Fig. 4.15, white arrows). 
After 100 µM trictide treatment, Occl was highly internalized and detected also at 
subcellular areas (Fig. 4.15, red arrows) that were likewise close to tricellular contacts 
(Fig. 4.15, yellow arrows). Although Cldn5 was internalized to a lesser degree compared to 
Occl, it can be still found at bicellular contacts (Fig. 4.15, green arrows). Just like Cldn5 
and ZO-1 stainings, Cldn5 and Occl signals were concentrated around some tricellular 
contacts. 
 
Fig. 4.16 Claudin-5 (Cldn5) is concentrated around tricellular area after trictide treatment. Mouse 
brain endothelial cells (bEnd.3) were grown until confluency and then incubated with peptide-free (untreated) 
and trictide containing medium. Individual cell contacts were imaged using confocal microscopy and STED 
super-resolution microscopy. The deconvoluted STED image showed further background reduction. 
Untreated cells: Cldn5 and ZO-1 localized at bicellular and tricellular contacts (yellow arrows). 100 µM 
trictide: Cldn5 and ZO-1 were clustered around tricellular contacts (enlarged). ZO-1 could also be observed 
at bicellular contacts (red arrowheads). Incubation time, 16 h; enlarged images, zoom: 6.0; 100x objective. 
 
 
The opening of the mouse endothelial cell barrier was clearly demonstrated according to 
results in chapter 4.3.3.1.  But it was not yet understood if the barrier was open exclusively 
at tricellular or additionally at bicellular areas. However, immunocytostainings of trictide 





Occl as they tend to concentrate around the tricellular contacts. To comprehend detailed 
structure of the tricellular area, images with stimulated emission depletion (STED) super-
resolution microscopy were taken. The cells were treated with 100 µM trictide-containing 
and peptide-free medium (untreated).  
Untreated cells showed typical localization of Cldn5 and ZO-1 at bicellular junctions. 
Confocal microscopy pictures of Cldn5 (green) and ZO-1 (red) showed overlapping signals 
(orange-like) along the plasma membrane. However, STED images enabled to present 
distinct signals of Cldn5 and ZO-1 at cell contacts.  Deconvoluted STED images further 
decreased the background noise at bicellular contacts and demonstrated organization of 
individual junctional proteins (Fig. 4. 16, yellow arrows).  
Consequently, 100 µM trictide treated cells revealed reduced signal of Cldn5 at the plasma 
membrane and formation of clustering Cldn5 signals at the periphery of tricellular 
contacts. ZO-1 signal remained at bicellular contacts (Fig. 4. 16, red arrowheads). 
Deconvoluted STED images revealed an opening in the centre of the tricellular region. 
This strong modulation of highly barrier forming TJ protein Cldn5 indicates opening of 
endothelial cell barriers tricellularly. 
4.3.4. Tricellulin knockdown confirms the tricellulin dependent function of trictide 
As a control experiment, TER and the permeability for FD4 were investigated in Tric 
knockdown cells. Thus, human colon epithelial adenocarcinoma cell line HT 29/B6 was 
transfected with either a vector containing shRNA sequence targeting Tric (shTric) or the 
empty vector. Two clones of shTric were used: shTric20= 20% and shTric50 = 50% of 
initial tricellulin expression (Fig. 4.16C). Cells were seeded on filters and treated with 150 
µM trictide or 150 µM scrambled trictide for 24 h. Cells transfected with the empty vector 
and administered with scrambled trictide constructed the control group.  
Cells transfected with the empty vector and treated with trictide showed significant 
decrease of TER compared to the scrambled trictide treatment. The shTric50 clone also 
displayed significant decrease of TER after trictide, compared to scrambled trictide 
administration. However, the shTric20 clone did not demonstrate any difference in TER 





barrier was already leaky due to only 20% of Tric expression, and therefore trictide had no 
additional effect on the barrier in the absence of Tric. 
Trictide treatment significantly increased the paracellular permeability of the cells 
transfected with the empty vector compared to scrambled trictide treatment. Both 
scrambled trictide administered shTric50 and shTric20 clones were permeable for 4 kDa 
molecule, compared to the control group. Trictide increased the permeability of both 
clones only slightly (Fig. 4.17B). In conclusion, the shTric50 and shTric20 Tric 
knockdown clones showed decreased TER down to 50% and 25%, thus underlining the 
importance of Tric in cellular barrier tightness. Moreover, Tric knockdown clones show 
that the effect of trictide depends on the presence of Tric 
 
 
Fig. 4.17 Tricellulin (Tric) knockdown cells confirmed that trictide function depends on the presence of 
Tric. Human colon epithelial adenocarcinoma cells (HT 29/B6) were transfected with vector containing a 
sequence for short hairpin RNA (shRNA) that targeted Tric (shTric) or the empty vector. Cells were seeded 
on filters and apically treated with 150 µM trictide or scrambled trictide for 24 h. (A) Transcellular electrical 
resistance (TER) of cells after peptide administrations (B) Permeation of 4-kDa FITC (fluorescein 
isothiocyanate) dextran (FD4) after peptide treatments (basolateral determination of FD4 concentrations at 0, 
20, 40, 60 and 120 min). (C) Vec, empty vector transfected cells; shTric50/shTric20, clones showing 
50%/20% Tric expression. Two-way ANOVA test was applied prior to Bonferroni’s comparison post hoc 
test; mean±SEM; n=6. *** P ≤ 0.001 versus scrambled trictide (control peptide). Experiments were 





4.3.5. Effect of trictide on Madin-Darby canine kidney and human embryonic 
kidney cells 
Since HEK cells are embryonic cells, they do not express TJs. Hence, experiments 
conducted with HEK cells enable analysis of proteins without interference from other TJ 
proteins. Fluorescence resonance energy transfer (FRET) assay was used to determine the 
cis-interactions for different TJ proteins and to define specific binding sites of trictide at 
the molecular level. MDCK-II cells express TJ proteins endogenously and form a 
paracellular barrier. They were used to examine interactions between Tric-Tric after 
trictide administration. MDCK-II cells were also ideal for STED due to their homogenous 
propagation over microscopic cover glasses that reduced background and uneven 
deposition of cells. 
4.3.5.1. Trictide affects tight junction protein-protein interactions 
The association of TJ proteins along the plasma membrane is termed cis-interaction. To 
study this association, FRET efficiencies between CFP and YFP-labelled proteins were 
measured.  Possible alterations of interactions between TJ proteins caused by 50 µM 
trictide and 50 µM scrambled trictide treatments in comparison to the peptide-free medium 
in HEK cells after 24 h were investigated. Subsequently, FRET efficiencies were measured 
by LSM microscopy (Fig. 4.18).  
The strong bicellular homophilic cis-interaction of Cldn1  was not changed by either the 
scrambled peptide or trictide (Cording et al., 2013). Similarly, bicellular heterophilic cis-
interactions for Cldn1–Occl and Cldn1-MD3, that do not involve Tric, were not affected. 
As expected, cis-interactions in Tric-containing protein combinations were reduced by 
trictide. The cis-interaction of Cldn1 with Tric was disrupted by 50%; Tric with MD3 
completely disappeared after incubation with trictide (Fig. 4.18 B). Fluorescent images of 
cell-cell contacts between co-transfected Tric and Cldn1 expressing cells showed 
localization of both proteins at bicellular contacts after peptide administrations (Figure 
4.18A). It is usual to observe Tric at bicellular area in the TJ protein transfected HEK cell 
systems (Cording et al., 2013).  
Occl localization was strongly affected from trictide application in Caco-2 cells (see 





measured after trictide and scrambled trictide. Accordingly, the data showed that 
homophilic cis-interaction of Occl decreased to 47% after trictide treatment compared to 
untreated control (Fig. 4.18B).  
 
 
Fig. 4.18 Trictide interferes with protein interactions of tricellulin (Tric) and with Occl (occludin)-Occl 
association (A) Human embryonic kidney (HEK-293) cells transiently expressing Claudin-1 (Cldn1)-YFP 
and CFP-Tric were treated with peptide free, scrambled trictide or trictide-containing medium. Both proteins 
localized at bicellular contacts (orange arrowheads). (B) cis-Interactions of homo- and heterophilic protein 
combinations as determined by fluorescence resonance energy transfer (FRET) in co-transfected HEK cells 
after treatment with 50 µM of trictide or scrambled trictide. The protein pairs were transfected as YFP- and 
CFP-fusion proteins, respectively. (C) Co-transfected Madin-Darby canine kidney cells (MDCK-II) 
transiently expressing CFP- and YFP-Tric treated with scrambled trictide or trictide; the proteins were 
localized at tricellular contacts (yellow arrowheads). Due to overexpression of Tric, signals were also 
observed in cytosol.  (D) Trictide treatment leads to a loss of Tric-Tric cis-interaction, as demonstrated by 
FRET in co-transfected MDCK-II cells. (B-D) MD3, marvelD3; YFP/CFP, yellow/cyan fluorescent protein; 
total incubation time, 24 h; one-way ANOVA test was applied prior to Dunnett’s comparison post hoc test; 






Homophilic cis-interactions of Tric were measured at tTJs in co-transfected MDCK-II 
cells. Tric mostly localized to the tTJs and showed relatively strong FRET signals 
(11.6±2.3) (Fig. 4.18C). 50 µM trictide decreased the homophilic tricellular Tric cis-
interaction to 55% while 100 µM trictide reduced it to 14% (Fig. 4.18D). Consequently, 
Tric containing homophilic and heterophilic cis-interactions and Occl-Occl cis-interactions 
was significantly affected by trictide administration.  
4.3.5.2. Super resolution microscopy revealed opening of the tricellular sealing tube 
To understand the detailed structure of the tricellular junctions, STED super-resolution 
microscopy was applied on MDCK-II cells. This method also enabled us to detect 
alterations in the assembly of TJ proteins after trictide treatment.  
 
Fig. 4.19 Trictide treatment opens tricellular tight junctions by removing tricellulin (Tric) and 
occludin (Occl) from the tricellular cell contact area. (A) Madin-Darby canine kidney (MDCK-II) cells 
immunostained against Occl and Tric. Individual cells were imaged using confocal microscopy (top) and 
stimulated emission depletion (STED) super-resolution microscopy (middle); the deconvoluted STED 
images showed further background reduction (bottom). The enlargement (white box, merge) suggests only 
partially co-localized Tric and Occl signals (white arrowhead). Under control conditions, Tric localized at 
tricellular junctions (yellow arrowheads). (B) MDCK-II cells were treated with trictide. Tric spread out to the 
bicellular tight junctions (green arrowheads) and left a tricellulin-free area (white dotted arrow and circle, 






Untreated cells exhibited typical localization of Occl at bicellular and Tric at tricellular 
junctions. Confocal microscopy pictures of Occl (red) and Tric (green) showed yellow 
points at tricellular junctions (Fig. 4.19A, yellow arrowheads). These could be interpreted 
as co-localization of both proteins at tTJs (Fig. 4.19A, upper row). However, STED 
pictures showed cell junctions with less background, and it was possible to detect TJ 
proteins aligning along the cell membrane with 50 nm resolution (Fig. 4.19A, middle row). 
Deconvoluted STED images further decreased the background noise at tricellular junctions 
and demonstrated that Tric and Occl co-localized only partially at tTJs (Fig. 4.19A, lower 
row). Tric stands in the center and Occl surrounds it from three bicellular contact ends 
(Fig. 4.19A, enlarged image, white arrowhead).  
100 µM trictide treated cells revealed elongated signals of Tric from tTJs to bTJs in 
confocal images (green arrowheads) (Fig. 4.19B, upper row). STED, in particular 
deconvoluted images, revealed a Tric-free area in the center of the tricellular region (Fig. 
4.19B, enlarged image, white dashed circle and arrow). The absence of Tric suggests that 
tricellular sealing tube is open and could enable paracellular passage of molecules through 
tricellular contact. It also supports the argument that trictide binds Tric and affects 
tricellular area preferentially. However, we should also consider other mechanisms like 
internalization and down-regulation of Tric as potentially leading to localization changes. 
4.3.5.3. Trictide redistributes occludin from bicellular junctions progressively during 15 
h of incubation 
Our objective was to observe the time course of cellular modifications caused by trictide 
and fluorescently labelled TAMRA-trictide. Spin disk confocal microscopy was used for 
live-cell imaging in long-term time-lapse. This technique is useful for imaging 
fluorescence samples for longer durations without being bleached. Therefore YFP-Occl 
transfected MDCK-II cells were used to emphasize cellular borders with TJ marker protein 
Occl. This enabled us to track the effect of trictide without using any other marker that 
might disturb the monolayer after long-lasting treatment.  
Untreated cells maintained continuous and linear cell membrane and tricellular contacts 
throughout the experiment (Fig. 4.20A, yellow arrows). 100 µM of trictide caused 
disruption and redistribution of Occl at cellular borders. Occl signals were reduced at some 





images (Fig. 4.20B, white arrowheads). Between 12 h and 15 h, it became clear that YFP-
Occl signal was weakened at bicellular contacts progressively and finally enriched 
intracellularly (Fig. 4.20B, white arrows).  
Cells administered with 10 µM TAMRA-trictide containing medium had two different 
fluorescent signals: YFP-Occl (green) and TAMRA-trictide (red). This combination 
allowed the investigation of peptide’s mode of action by comparison of the influence on 
cellular borders and peptide’s localization. The lesser concentration was used to avoid 
saturated fluorescence intensity of TAMRA and to maintain TJ visibility before Occl is 
removed from the cell junctions.  It was observed that starting from 6 h of peptide 
treatment, YFP-Occl signal deteriorated  at tricellullar contacts (Fig. 4.20C, dotted circles), 
and these areas (central-tube like) were filled with fluorescently labelled trictide (Fig. 
4.20D, red arrows). From 12 h, the effect on cell contacts was further expanded to 2-cell 
contacts that caused accumulation of TAMRA-trictide in greater amounts up to 2 µm deep 
submembranously. After 15 h of treatment, fluorescent peptide was localizing 
intracellularly around most of the bicellular contacts and causing disappearance of cell 
contacts.  
The internalization and enrichment of Occl protein around tricellular contacts after trictide 
was presented in chapter 4.3.3.4. Furthermore it was found that Occl expression is 
significantly down-regulated consequent to trictide administration. So the outcome of this 
live-cell imaging (Fig. 4.20) is in accordance with previous chapters and enabled us to 
acquire more information about the mode of action. Trictide first affects tTJs, then starts 
transfer of TJ proteins to bicellular contacts, and finally causes internalization of proteins. 
Even though trictide’s binding mechanism is not fully understood, it evidently disturbs 
association of TJ proteins in a way that alters their localization and affects the integrity of 













4.20 Live-cell imaging for 15 h reveals that trictide and TAMRA-trictide alter localization of occludin 
and cause its redistribution from 2-cell contacts to cytosol. YFP-Occl (occludin with yellow fluorescent 
protein) transfected MDCK-II (Madin-Darby Canine Kidney) cells were treated with peptide-free medium, 
trictide and TAMRA-trictide. First image (0 h) was taken before the treatment.  Every 15 min, an image was 
taken to record each condition. Cells were kept in a 10% CO2 controlled environment at 37 ºC. (A) Untreated 
cells have continuous and sharp cellular borders (yellow arrows). (B) 100 µM trictide caused disappearance 
of Occl from bicellular contacts and enrichment around tricellular area (white arrow heads); and starting from 
12 h, relocalization to cytosol begins under the cell membrane (white arrows). (A-B) Black and white was 
used to create better contrast for images with single channel. (C) YFP-Occl signals observable alterations at 
cellular borders. From 6h, tricellular contacts were the first to disappear gradually (dotted circles). (D) 
Merged images of YFP and TAMRA signals. At 3 h, TAMRA signal was observed particularly at 3-cell 
contacts. At 6 h, some tricellular contacts became invisible (dotted circles) and these zones were filled with 
TAMRA signal (red arrows). This effect increased in time and, starting from 12 h on,  a greater amount of 
TAMRA signal was localized at cellular contacts (red arrows), which caused complete loss of some 3-cell 
borders (dotted circles) as well as submembranous uptake.  
4.3.6. In vivo effect of trictide 
4.3.6.1. Trictide can be detected in mouse blood plasma up to 48 hours 
Before starting in vivo use of trictide, its degradation curve was obtained to study how long 
trictide is stable in mouse blood. Blood plasma contains peptidases that play a role in 
peptide stability (Di, 2015). In order to investigate the half-life of peptide, TAMRA-
trictide (3.1 kDa) was dissolved in mouse blood plasma at 37 °C and incubated for 48 h. 
TAMRA fluorescence was observed at about 10 kDa band of the protein marker and at the 
bottom of the gel (Fig. 4.21A).  A possible reason is that the samples were separated with 
the gradient SDS-PAGE gel, and 10 kDa was the smallest size of that protein marker.  
After densitometry analysis of bands on SDS-PAGE gel, 2 h, 4 h, 8 h, 12 h, 13 h, 24 h and 
48 h samples have respectively shown 82%, 68%, 59%, 50%, 42%, 30% and 14% of 
fluorescence intensity. Taken together, TAMRA-trictide’s half-life in blood plasma was 
detected as 12 ± 1.9 h (Fig. 4.21B). 4 h and 24 h time points were chosen for further in vivo 
experiments because of the in vitro effect observed at 16 h and in order to check the effect 







Fig. 4.21 TAMRA-trictide (human) has a half-life of 12 h in mouse blood plasma. 10 µM of TAMRA-
trictide was dissolved in mouse blood plasma and incubated at 37 ºC up to 48 h. (A) Fluorescence image of 
gradient SDS-PAGE gel bands pertaining to the indicated incubation times. First sample was blood plasma 
without fluorescent peptide (negative control). Bands were observed close to the level of 10 kDa marker 
protein. (B) Fluorescence intensity of bands was assessed by densitometry analysis. Dashed blue line 
indicates half-life of the peptide at about 12 h. Red line indicates intensity of a 4 h sample that was 
preferentially selected for the experiments described in the following chapters. Values were relative to the 0 h 
sample (as 100% of fluorescence intensity); mean ± SEM; n=3. 
 
4.3.6.2. Junction proteins in mouse brain and kidney are highly affected by trictide 
Brain and kidney barriers were both essential targets to be examined when the effect of 
trictide was tested as a potential drug enhancer. The primary objective was to measure 
changes in several junctional proteins at mRNA level. For this purpose, 800 µM trictide 
(3.6 µmol/kg dissolved in phosphate-buffered saline) or phosphate-buffered saline (control 
group) was administered (100 µl/22 g mice) to mice which were sacrificed after 4 h or 24 
h. Absolute mRNA expressions (2
ΔCt
 values) of the junction proteins are given in Table 26 







Table 26. Messenger RNA (mRNA) expression of untreated mouse brain and kidney 
Absolute mRNA expressions (2
ΔCt






































mRNA normalized to β-actin (Actb) (ΔCt = Ctjunction protein - Ctactin); Ct, Cycle threshold; mean ± SEM; n 
≥4; Tric, tricellulin; LSR, lipolysis stimulated lipoprotein receptor; Occl, occludin; Cldn5, claudin-5; ZO-1, 
zonula occludens protein 1; Cldn12, claudin-12; Cldn25, claudin-25; MD3, marvelD3; Cldn1, claudin-1. 
 
In brain, 24 h after trictide administration, Cldn5 was up-regulated compared to 4 h after 
application (1.75 fold) and control group (1.4 fold). Tric was also up-regulated after 24 h 
compared to 4 h after application (1.9 fold) and control group (1.7 fold). On the other hand, 
LSR was down-regulated after 4 h of treatment compared to control group (58±5%) (Fig. 
4.22A).  
In kidney, Tric expression was reduced to 65±5% after 4 h and to 32±1% 24 h after trictide 
injections. MD3 expression was decreased to 38±9% 24 h after trictide administration. 
This effect was highly significant compared to both 4 h (94±8%) and control group mRNA 
levels. ZO-1 mRNA was first up-regulated 1.3 fold (131±11%) at 4 h, then down-regulated 
(94±1%) 24 h after the treatment (Fig. 4.22B). Cldn25 mRNA was expressed in kidney at 
almost the same level as in the brain (Table 26). Cldn25 was down-regulated to 58±1% 24 
h after the injections, and this down-regulation is statistically significant compared to 4 h 
after application (97±9%) and control group (Fig. 4.22B). The data of mRNA expressions 
suggests that trictide has a time-dependent gradual effect at mRNA level. Due to the strong 
alterations of important barrier-forming TJ proteins (Tric, Cldn5 and LSR), barrier 







Fig. 4.22 Trictide causes up-regulation of tricellulin (Tric) and claudin-5 (Cldn5), down-regulation of 
lipolysis stimulated lipoprotein receptor (LSR) in brain.  Trictide causes down-regulation of Tric, 
marvelD3 (MD3), zonula occludens protein 1 (ZO1) and claudin-25 (Cldn25) in kidney. Effect on 
messenger RNA (mRNA) of designated proteins (2
ΔΔCt
); upon 800 µM of trictide (3.6 µmol/kg) compared to 
phosphate-buffered saline (PBS) (red dotted line) intravenous injections (100 µl/ 22 g mouse). 4 h and 24 h 
after the administrations, animals were sacrificed and their brains and kidneys were isolated and prepared for 
quantitative real-time polymerase chain reaction.  (A) mRNA expression of junction proteins in trictide 
administered mouse brain. (B) mRNA expression of junction proteins in trictide injected mouse kidney. 
mRNA normalized to β-actin  (Actb) (ΔCt = Ctjunction protein - Ctactin); Ct, Cycle threshold; Cldn12, claudin-12; 
Cldn1, claudin-1; two-way ANOVA test was applied prior to Bonferroni’s comparison post hoc test; mean ± 
SEM; n≥4; * P ≤ 0.05, ** P ≤ 0.01, ****P ≤ 0.0001 versus PBS control.  
 
4.3.6.3. Trictide does not change Na-ﬂuorescein uptake of kidney and liver, while 
uptake in brain tends to be enhanced 
Tric was found to be highly expressed in mouse liver and kidney but low in brain (chapter 
4.1). Thus, in vivo experiments were performed to explore trictide’s effect on barrier 
properties of brain, liver and kidney. PBS or 800 µM of Trictide (3.6 µmol/kg) was 
administered to mice (100 µl/22 g mice) intravenously. After 4 h of peptide injection, mice 
were injected again intravenously with Na-ﬂuorescein (0.5 mmol/kg, 100 µl/22 g) and 
afterwards perfused for ~10 min.  The graphs below show comparison between Na-







Fig. 4.23 Na-ﬂuorescein uptake of kidney and liver does not change 4 h after trictide administration, 
but uptake in brain tends to be higher. 800 µM of trictide (3.6 µmol/kg) was injected (100 µl/22 g mice) 
intravenously and 4 h later the fluorescent dye Na-ﬂuorescein (376 Da; 0.5 mmol/kg, 100 µl/22 g mice) was 
injected. (A) Na-ﬂuorescein uptake in mouse kidney after trictide and phosphate-buffered saline (PBS) 
injection. (B) Na-ﬂuorescein uptake in brain. Na-ﬂuorescein was dissolved in PBS and treatments with only 
PBS were taken as untreated control. Absolute amount of Na-ﬂuorescein molecule was given as µmol/kg. 
Student’s t-test was applied prior to Mann-Whitney’s post hoc test versus PBS control. Mean ± SEM, n=9.  
 
In the kidney of trictide and phosphate-buffered saline (PBS) applied animals, we detected 
3.5±1 µmol/kg and 4±1 µmol/kg of Na-fluorescein, respectively. In the liver of trictide and 
PBS administered animals, Na-fluorescein was detected as 8±0.6 µmol/kg and 7±0.7 
µmol/kg, respectively. The liver was more permeable for Na-fluorescein compared to the 
kidney.  Neither kidney nor liver showed significant changes of Na-fluorescein levels as a 
result of trictide injections when compared to PBS (Fig. 4.23A).  
The microvessels of brains of the PBS administered animals were tighter and 200 times 
more impermeable by Na-fluorescein than kidney. In brain of the trictide and PBS applied 
animals, 0.05±0.01 µmol/kg and 0.02±0.015 µmol/kg of Na-fluorescein was detected, 
respectively (Fig. 4.23B). Brain uptake of Na-fluorescein in trictide injected animals 
demonstrated an increase, but due to high variation among data sets, this effect was 
statistically insignificant. Collectively, trictide tended to open the cerebral barriers for 
small molecules. However, more experiments would be necessary to confirm the tendency. 
 
4.3.6.4. Claudin-5 and occludin are altered in brain capillaries after trictide ad-
ministration 
Further information on TJ protein amount and localization was necessary to understand the 





PBS injected mice were cut as thin cryosections and labelled with anti-Cldn5, Tric, Occl 
and ZO-1 antibodies. Brain capillaries were imaged by STED microscopy to enable 
observation of changes, especially at 3-cell junctions on a molecular level.  
 
Fig. 4.24 Trictide injections caused slight alterations at the localization of claudin-5 (Cldn5) and 
tricellulin (Tric), and significant changes of the fluorescence intensity of Cldn5 and occludin (Occl) 
proteins. (A) Immunofluorescent STED images of brain capillary of phosphate-buffered saline (PBS) 
injected mice (control group). (B) Immunofluorescent STED images of brain capillaries after 800 µM (3.6 
µmol/kg) trictide treatment. Tric weakened at tricellular junctions and Cldn5 became poriferous. White 
arrows, Tric enrichment at tricellular contacts; dashed lines, representative capillary border; 8 µm brain 
cryosections; zoom: 6.0; 100x objective. (C) Fluorescence intensities of brain capillaries from PBS vs. 800 
µM trictide injected mice. Cldn5 was down- and Occl was up-regulated after trictide administration. Tric 
showed tendency of down-regulation. Zonula occludens protein-1, ZO-1; incubation time after injections, 4 
h; measurements were performed with ImageJ; two-way ANOVA test was applied prior to Bonferroni’s 






Cldn5 was included as dominant TJ marker of the BBB and ZO-1 as general cell-cell 
contact marker in order to confirm the structures displayed in the images as a brain 
capillary (Fig. 4.24A). No greater changes of the localization of Cldn5, ZO-1 and Occl 
were observed in the brain capillaries of the trictide group. However, the fluorescence 
intensity of Cldn5 and Occl appeared slightly altered in the 2-cell junctions. The Cldn5 
intensity was weakened and the contact line seemed to become poriferous (Fig. 4.24B). 
Tric signal was not only visible in tricellular but also at bicellular junctions (Fig. 4.24A). It 
was possible to distinguish specific Tric signal at tricellular junctions also after trictide 
administration. Nevertheless, decline of Tric signal occurred in 3-cell junctions after 
trictide treatment in some slices (Fig. 4.24B, white arrows).  
Since visual examination of microscopy images was insufficient to prove up- or down-
regulations of the latter proteins, fluorescence intensities of brain capillaries were 
quantified for Tric, Cldn5, Occl, and ZO-1. According to that analysis, Cldn5 signal was 
reduced and Occl signal increased significantly in brain capillaries of trictide injected 
mice. Tric tended towards reduction, while ZO-1 tended to increase (Fig. 4.24C). 
Although trictide has a 12 h half-time in blood plasma (Fig. 4.21B), trictide injections did 
not significantly increase permeability of brain, kidney and liver barriers (Fig. 4.23). In 
addition, there were significant mRNA expression alterations of Cldn5 and Tric in brain, 
and of Tric, MD3 and Cldn25 in kidney at 4 h and 24 h after trictide injections (Fig. 4.22). 
For further in vivo studies, more experimentation is necessary; barrier permeability and 
protein expressions should be more carefully studied approximately 12 h after the 
administration. 
4.3.7. Trictide structure is predicted as a β-sheet formed by two β-strands with 
surface-exposed aromatic residues. 
In order to understand trictide’s key structural components for its barrier opening function, 
trictide and scrambled trictide were analyzed with CD spectroscopy. The spectra were 
compared with reference spectra (Yang et. al., 1986) in order to determine the proportion 
of secondary structural elements. On the other hand, 3D structure models of peptides were 





Trictide and scrambled trictide mostly showed β–sheet followed by random coil propensity 
in phosphate buﬀer. Moreover, in micelles of SDS a pronounced β–sheet conformation was 
found for both trictide and scrambled trictide. TFE favored a weak α-helical secondary 
structure propensity, which was not different for trictide and scrambled trictide at 
representative wavelengths (Fig. 4.25A). Accordingly, the molar ellipticity (Θ) did not 
exhibit a statistically significant difference from characteristic ellipticity minimum (217 
nm for β-sheet, 208 and 222 nm for α-helix). 
 
Fig. 4.25. Trictide has mainly the potential to form β-sheet. (A) Circular dichroism spectrograms of 
trictide (50 μM) and scrambled trictide (50 μM) in diﬀerent solvents. Random coil propensity of the peptides 
in 10 mM phosphate buﬀer (PB) (pH 7.4). β-sheet propensity of trictide in PB with 0.5 mM sodium dodecyl 
sulfate (SDS) [minimum at 216 nm (red dotted line). Helical propensity of trictide in PB with 60% 2.2.2-
triﬂuoroethanol (TFE) (two minima expected between 207-222 nm (black dotted lines)], respectively. (B) CD 
spectroscopy data (mean±SEM; n=6) and prediction of secondary structural elements by PEP-FOLD. 
Abbreviations and conditions as in (A). CD spectroscopy was executed in collaboration with Christian Staat 
and Sophie Dithmer. 
 
Structural prediction analysis of trictide by CD spectroscopy revealed high β-sheet 
propensity in phosphate buffer (55%) combined with unstructured random domains (36%). 
Conditions promoting β-sheet formation (0.5 mM SDS) did not increase the propensity of 
peptide to form β-sheet (53%) or unstructured (35%) elements. TFE, an agent which 
supports α-helix formation in peptides, only slightly increased the α-helix content from 0 to 





prediction of secondary structural elements by 3D model of trictide with the highest 
thermodynamic stability showed a large β-sheet fraction (50%) accompanied by 
unstructured segments (33%), just like predictions obtained from CD spectroscopy 
(Fig.4.25B). 
Scrambled trictide also displayed high β-sheet content in phosphate buffer (54%) 
combined with random domains (37%). SDS buffer affected the scrambled trictide affinity 
to form β-sheet (43%) or unstructured (39%) elements. The α-helix content of scrambled 
trictide was also as low as trictide and did not increase significantly by TFE (Fig. 4.25B). 
Taken together, trictide’s β-sheet and random domains propensity obtained from CD 
spectroscopy was comparable to PEP-FOLD modeling. Molecular modeling of the 
scrambled trictide with the PEP-FOLD program revealed a remarkably greater amount of 
randomly arranged amino acids, a lower percentage of β-sheets, and no β-turns when 
compared to the trictide structure. α-Helices were not predicted, neither in trictide nor in 
the scrambled trictide model. Thus α-helice is not an essential factor for the structure of the 
trictide, but β-sheet is important. Since β-sheet is not a discriminating factor, it was not 
clear how the β-strands need to be arranged to enable its function.  
 
Fig. 4.26 Trictide structure is predicted as a β-sheet formed by two β-strands with surface-exposed 
aromatic residues. (A) PEP-FOLD model of trictide with the highest thermodynamic stability based on 
circular dichroism spectroscopic measurements. More than 50% of trictide showed β-sheet propensity of two 
β-strands (light blue) connected by a β-turn (green); the aromatic amino acids were localized sidewise of β-
sheet. (B) The PEP-FOLD model of the scrambled peptide exhibited three β-strands compared to trictide 
with two β-strands, no β-turn, and a greater amount of random structuring. (A, B) F13, -14, -20, -22, Y10, -





The importance of aromatic residues in trans-interaction for TJ proteins was previously 
revealed for Cldn5 ECL2 (Piontek et al., 2008b). Aromatic amino acids such as F14 and 
Y11 were concentrated at the β-turn of the trictide molecule, with outward directed side 
chains. Two further aromatic amino acids (Y10, F22) locate at the surface of the β-sheet or 
in its close proximity. The β-sheet is formed by two β-strands resulting in an elongated 
conformation (Fig. 4.26A). Secondary structure modeling of the scrambled trictide showed 
that the aromatic amino acids are randomly distributed along the peptide. Three β-strands 
form a more compact β-sheet compared to trictide (Fig. 4.26B). The outward directed 
aromatic amino acids are the most important structural difference between trictide and 
scrambled trictide.  This may account for trictide’s efficiency.  
Fig. 4.27 Potential aromatic binding mechanisms of trictide to the human tricellulin (Tric) 
extracellular loop two (ECL2). (A) Parallel interaction model proposing binding of Y323’-Y323 and F326’ 
(trictide) with F334 (Tric ECL2) while F334’ (trictide) binds to Y322. (B) Antiparallel interaction model 
proposing binding of Y323-Y323’, Y322 (Tric ECL2)-F326’ (trictide) and F326 (Tric ECL2)-F334’ 
(trictide). Blue, hydrophilic surface; brown, hydrophobic surface; asterisk, disulﬁde bridge between yellow 
thiol residues. Molecular modeling was executed in collaboration with Jimmi Cording. 
 
Two alternative mechanisms of trictide association with the ECL2 of Tric are shown in 
Fig. 4.27. In a parallel interaction mode, the aromatic residues Y323´, F326´ and F334´ in 
trictide form a hydrophobic surface at one side of the peptide structure. The postulated 
structure of the Tric-ECL2 exhibits a complementary hydrophobic surface formed by 
Y322, Y323 and F334 (Fig. 4.27A). Alternatively, Y323´, F326´and F334´ of trictide 
might bind in an antiparallel interaction mode to the hydrophobic binding surface at the 





To conclude, prediction of secondary structural elements did not point out important 
differences, but 3D modeling of the peptides highlighted the importance of tertiary 
structure and positions of aromatic amino acids.  
4.3.8. Single substitutions of aromatic residues in tricellulin extracellular loop 2 do 
not alter localization of tricellulin. 
The structure of trictide obtained from the molecular modelling approach, taken together 
with the ECL2 model of Tric, indicated the essential role of ECL2 aromatic amino acids in 
Tric. This prompted us to consider these amino acids as potential binding determinants. 
Aromatic residues in ECL2 region of Cldn5 were proven to play a major role in Cldn5’s 
trans-interactions and enrichment at Cldn5-contacts (Piontek et al., 2008b). In addition, 
Tyr and Phe (Y322, Y323, F326, F334) residues of Tric ECL2 were highly conserved 
among vertebrate species (human, chimpanzee, orangutan, bovine, rat, mouse, xenopus) 
(Cording et al., 2015). In order to examine individual contributions of Y322, F326 and 
F334 amino acids into trans-interaction of Tric, single amino acids were exchanged by 
hydrophobic Ala or Ile residues (Fig. 4.28A). Localization pattern of substituted 






Fig. 4.28 Tricellulin (Tric) extracellular loop 2 (ECL2) mutations do not change Tric’s tricellular 
localization. (A) Schematic illustration of Tric, sequence of Tric ECL2 and location of single aromatic 
amino acid mutations. (B) Madin-Darby canine kidney cells (MDCK-II) transiently expressing YFP-Tric that 
was modified by single amino acid exchange at Y322, F326, F334. Mutations did not change tricellullar 
localization of Tric. YFP, yellow fluorescent protein, enlarged images, 4x magnification; 63x objective. 
 
Because MDCK-II cells express Tric endogenously, typical Tric localization at tricellular 
contacts was observed between wild-type YFP-Tric transfected cells (Fig. 4.18C). Study of 
localization of YFP-Tric substitutes (Y322I, Y322A, F326A, F334I) revealed that Tric 
could still localize at tricellular contacts with its typical dot-like appearance. Replacement 
of aromatic residues did not alter typical Tric localization (Fig. 4.28B).  Further 
investigations of trans-interactions and paracellular tightness of cells expressing 
substituted recombinant Tric are required in order to fully understand the contributions of 
those aromatic residues to paracellular barrier tightening.  
4.3.9. Homophillic tricellulin interactions are mediated by its C-terminal tail 
The cytosolic C-terminal tail takes part in homophilic cis-interactions of Tric (Westphal, 
2010). We therefore analyzed the binding between human Tric and recombinant N-





after trictide administration. The purified protein was incubated with Caco-2 cell lysate for 
a co-immunoprecipitation assay. The eluted fraction of the bound proteins was analyzed by 
Western Blot. The blot was cut into two pieces. The upper part ≥ 55 kDa was incubated 
with anti-Tric antibody due to the larger size of the protein (64 kDa); the lower part was 
incubated with anti-His antibody (Fig. 4.29).  
The existence of N-terminally His-tagged C-terminal tail of human Tric (Tric C-term) 
construct was confirmed by recognition of anti-His antibody at the expected size (blue box, 
Fig 4.29). Furthermore, binding of the Tric C-term to full length Tric within the cell lysate 
was displayed by recognition of anti-Tric antibody (red box, Fig. 4.29). Co-
immunoprecipitation data proved that homophilic binding of Tric occurs also via its C-
terminal tail in addition to the extracellular domain (see chapter 4.3.5.1, Fig. 4.18D). The 
protein band surrounded by green box was observed in between 55 and about 40 kDa and 
interpreted as dimer of the Tric C-term construct. This dimer was observed in the upper 
part of the blot incubated with anti-Tric antibody that was designed to recognize C-
terminal tail of Tric. The control lane contained only Tric C-term construct without cell 
lysate, and therefore no protein band was observed. No considerable change in the amount 
of bound protein fractions (Tric + Tric C-term) was observed consequent to trictide 
treatment (Fig. 4.29).  However, it is essential to conduct more experiments to draw a 







4.29 Tricellulin (Tric) binds to Tric with its C-terminal tail. Recombinant N-terminally His 
(polyhistidine)-tagged C-terminal tail of human Tric (Tric C-term) was incubated with human colon 
carcinoma epithelial cells for 2 h and purified by co-immunoprecipitation method. Control (Cntrl) lane 
includes only Tric C-term construct and no cell-lysate. Mw, molecular weight; UT, untreated cell lysate; TT, 
150 µM trictide treated cell lysate; incubation time with trictide, 16 h. Upper part of the blot incubated with 
anti-Tric antibody, lower part of the blot incubated with anti-His antibody. Red box, full-length Tric (64 


























Tricellulin is a tight junction protein that mostly localizes at the tricellular tight junctions 
and constitutes a cellular barrier by restricting passage of macromolecules through the 
paracellular pathway (Ikenouchi et al., 2005; Krug et al., 2009). The ECL2 region of Tric 
is known to be involved in trans-association of two Tric proteins and extracellular binding 
of three Tric proteins at tTJs. A Tric ECL2 derived peptide called “trictide” was designed 
to modulate the tricellular structure, hence the paracellular tightness. Before trictide was 
developed, all peptide-based strategies for opening barriers were based on the modulation 
of bTJ proteins. Therefore this thesis focuses on revealing tricellular organization of TJ 
proteins and altering this organization to increase paracellular permeability.  
 
5.1.  TRICELLULIN DETECTED MOSTLY IN EPITHELIAL TISSUE 
DOMINANT ORGANS  
In previous studies, the Tric expression profile among several mice organs was 
investigated (Ikenouchi et al., 2005; Raleigh et al., 2010). Analysis of Tric mRNA 
expression in mice organs enabled us to compare epithelial versus endothelial dominant 
organs. Additionally, Tric expression in brain is compared to the rest of the covered organs 
including different parts of small intestine and colon.  
We found that colon is the highest Tric expressing organ and brain is one of the low Tric 
expressing endothelial dominant organs. When Tric was identified for the first time, it was 
found to be expressed in epithelial-derived tissues excessively (Ikenouchi et al., 2005; 
Schlüter et al., 2007). They detected high Tric expression especially in small intestine, 
kidney and lung. It was expressed at medium level in liver and at much lower level in testis 
and brain. Those results are consistent with the findings of this thesis, except the fact that 
parts of small intestine expressed at lower degrees compared to liver according to our 
examinations. Ikenouchi et al. (2005) used northern blotting whereas in this thesis qRT-





methods or other factors like sex and age differences etc. On the other hand, Raleigh and 
his colleagues (2010) used two different techniques to analyze mouse Tric in different 
organs. Chip-based analysis of transcript profiles demonstrated the highest Tric expression 
in kidney, stomach, liver and lung, relatively. Semi-quantitative RT-PCR showed the 
highest Tric expression in colon and jejunal epithelium (Raleigh et al., 2010). Tric 
expression in brain was mostly found at low levels in both studies (Ikenouchi et al., 2005; 
Raleigh et al., 2010). Their results were also consistent with the results of our study, which 
investigated Tric expression within mouse organs. Moreover, the greater part of our 
investigation is constituted on the stated value of Caco-2 cells as high Tric expressing cell 
models (Raleigh et al., 2010).  
Cerebral capillary endothelial cells contain TJs that seal between neighboring cells to form 
a continuous blood vessel. The volume of capillary and endothelial cell constitutes around 
1% and 0.1% of the whole brain tissue volume, respectively (Pardridge et al., 1990). Due 
to low percentage of capillary endothelial cells throughout the brain, expressions of TJ 
proteins within brain capillaries cannot be abundant. Even though Tric is detected in low 
levels in the whole brain, it is expressed higher in the peripheral nervous system compared 
to the central nervous system, according to mRNA analysis and immunohistostainings 
(Kikuchi et al., 2010). Tric was detected by immunofluorescence stainings of different 
frozen mice organ sections (Iwamoto et al., 2014). In mouse cerebrum and cerebellum, 
both Tric and LSR were observed at triendothelial contacts (Iwamoto et al., 2014). On the 
other hand, Mariano and her colleagues (2013) observed Tric localizing at cell membrane 
including both bicellular and tricellular regions, nuclear and perinuclear areas of cultured 
endothelial cells, and also co-localizing with Cldn5 in brain microvessels (Mariano et al., 
2013). The latter result is similar to our findings because Tric is observed at bicellular 
contacts and co-localizing with Occl and Cldn5 in mouse brain capillaries. In addition, we 
demonstrated localization of Tric at tTJs extending through Z-direction. In human brain 
microvessels, we observed Tric and LSR more precisely at tricellular contacts similar to 
previous findings (Iwamoto et al., 2014; Sohet et al., 2015). It is not possible to make a 
clear statement about Tric localization due to different results of ex vivo immunostainings 
of human and mouse brain. However, many factors determine the quality of an 
immunostaining; like antibody specificity and cross reactivity, low protein expression and 





experiment are consistent with previous results and can be improved when considering said 
factors.  
 
5.2. TRICTIDE OPENS CELL BARRIERS AND IMPROVES THE PASSAGE OF 
IONS AND MACROMOLECULES  
In previous studies, TJ peptidomimetics were only derived from Cldns or Occl and targeted 
to open the cellular barrier at bTJs. It was demonstrated that Cldn peptides have potential 
to modulate bTJ structure and paracellular barrier (Dithmer et al., 2017; Staat et al., 2015; 
Zwanziger, Hackel, et al., 2012). For the first time with this study, we focus on opening 
paracellular barrier at tricellular contacts. Thus, Tric has been selected as a target because 
it was the first TJ protein discovered at tTJ which contributes to paracellular tightness 
(Ikenouchi et al., 2005; Krug et al., 2009). Trictide does not show any homology to parts of 
other TJ proteins. That is why, trictide is assumed to bind Tric more specifically at a 
certain region of the TJ mainly the tTJs. On the other hand, there is limited knowledge of 
pathways and mechanisms behind transcriptional regulation of Tric (see chapter 1.3.2.3) 
which makes it difficult to evaluate the acquired data. 
The ECL parts of two opposing TJ proteins were known to play role in trans-interactions 
(Piontek et al., 2008). Similarly, Cys residues in Tric’s ECL2 are found to be involved in 
its trans-interactions (Cording et al., 2015). As first-step of trictide, a recombinant protein 
was produced from the ECL2 region of human Tric fused with the purification tag MBP. 
MBP-Tric ECL2 opens the human colorectal adenocarcinoma cell (Caco-2) barrier for ions 
and causes localization changes of TJ proteins. Occludin is observed at submembranous 
region and internalized within intracellular vesicles. Tric is also internalized, mostly 
together with Occl and shifted to bicellular area. These effects are detected progressively 
depending on the increasing concentration of the construct. It is unlikely to see a clear 
effect on Occl because an earlier experiment showed that Occl and Tric do not interact 
directly (Raleigh et al., 2010). This effect is further investigated by measuring cis-





Recombinant protein MBP-Tric ECL2 has provided promising results regarding the 
modulation of TJ proteins and opening of a cell barrier. This is the reason why trictide (2.7 
kDa), a chemically synthesized peptide, has been designed from the ECL2 part of human 
Tric313–336. Using a synthetic peptide is preferred to a recombinant protein because it is 
cheaper, more reproducible, and allows for easier pharmaceutical applications.  
In order to investigate functional alterations like barrier opening and permeability for ions 
and macromolecules, and to use a homologous human system for the human trictide, Caco-
2 cells with high Tric expression were used primarily (Berndt, 2017). In previous studies, 
peptides were applied for 24-48 h (Dithmer et al., 2017; Sauer et al., 2014; Staat et al., 
2015; Zwanziger, Hackel, et al., 2012). We incubated the cells with trictide for 16 h 
because significant effects were obtained at this time. Trictide has a concentration-
dependent effect on both epithelial and endothelial cell lines. The encompassed 
concentrations are also tested for cytotoxicity. For Caco-2 cells, 150 µM of trictide is the 
preferred working concentration because this concentration increases ion permeability 
significantly without causing cytotoxicity. Previous studies also used similar 
concentrations in vitro such as 200 µM (Staat et al., 2015) and 100 to 300 µM (Zwanziger, 
Hackel, et al., 2012) of Cldn1; and 300 µM of Cldn5 (Dithmer et al., 2017) 
peptidomimetics. The working concentration of Cldn5 peptide was also not cytotoxic, 
similar to trictide (Dithmer et al., 2017).  
The trictide effect is also sequence specific because scrambled trictide does not change any 
of the barrier properties. The permeability is increased for molecules up to 10 kDa in 
addition to ions. This finding is consistent with that of previous studies undertaken without 
peptidomimetics or other treatments.  These results proved that Tric selectively tightens for 
molecules 4 to 10 kDa (Krug et al., 2009). Hereby we show that by altering Tric’s 
function, molecules with 0.4 and 10 kDa are able to pass through central sealing tube while 
much bigger sizes (≥40 kDa) cannot. The minimum radius of tTJ central sealing tube was 
estimated as 5 nm, (Staehelin, 1973) and the Stokes radius of 10 kDa molecules is 2.3 nm 
(Staehelin, 1973). Therefore, a 10 kDa molecule can permeate through tTJ central sealing 
tube. Earlier studies using Caco-2 cells and markers of identical size (0.4 and 10 kDa) 
reported similar significant increase in paracellular permeability for those markers in 





Interestingly, we saw that 100 µM of trictide decreases permeability compared to untreated 
control. ECIS measurements also support this finding with slowly increasing TER of 100 
µM trictide. The same effect is observed with 50 µM trictide at filter experiments. Taken 
together, a threshold concentration between 50 and 100 µM of trictide is assumed to be 
effective. Cells’ recovery from trictide is analyzed by ECIS. We observed that after 21 h of 
exposure to trictide (at 47 h), medium is exchanged and the decreasing slope of TER 
changes to an increasing slope. This reversal can be interpreted as cell recovery.  
D-amino acid derivative of trictide is also considered in this study. Non-physiological D-
amino acids are proven to be degraded slower compared to L-amino acids because of their 
reverse conformation (Di, 2015; Werle et al., 2006). Besides, my colleagues obtained 
stronger barrier opening with D-amino acid derivative of a Cldn5 peptidomimetic in vivo 
(Dithmer et al., 2017). Unfortunately, we did not see any effect of D-trictide in vitro, even 
when double concentrations of trictide were administered. D-trictide was therefore 
excluded from in vivo experiments. The reason for non-functioning D-trictide could be an 
improperly formed tertiary structure. This may be clarified by CD spectroscopy 
experiments in the future. 
Trictide causes alteration of Cldn5 mRNA expression in Caco-2 cells (see chapter 5.3), 
which prompted in vitro investigations of endothelial cells. Cldn5 is expressed in a much 
lower amount in Caco-2 cells (Table S2) compared to mouse brain endothelial cells (Table 
S3). Besides, it is important to understand the potential of trictide at blood-brain barrier 
focused applications. Therefore, once trictide’s efficacy was determined, it was 
administered to mouse brain endothelial cells and barrier propertiesafter trictide has been 
investigated. Trictide opens the endothelial cell barrier with 75 µM and 100 µM 
concentrations starting from 9 h of incubation. When mouse brain endothelial cells were 
treated with Cldn5 (300 µM) derived peptides, the TER was reduced to a steady-state after 
24 h (Dithmer et al., 2017). In addition, toxicity tests of Cldn5 derived peptides displayed 
higher viability compared to trictide, which exhibits cell toxicity starting from 100 µM. 
Taken together with the cell cytotoxicity results, it can be stated that the therapeutic 
window of trictide is much narrower compared to Cldn5 derived peptides. 50 µM of 
trictide does not have an effect, while 100 µM is highly toxic for cells. The working 
concentration of Cldn5 derived peptides is also four times higher than trictide without any 





Earlier, LSR, Tric and Occl were knocked down to reveal their involvement in barrier 
formation and possible interplays between Tric-Occl and LSR-Tric (Ikenouchi et al., 2005; 
Ikenouchi et al., 2008; Masuda et al., 2011). According to our research, the tightness of 
cell barrier decreases with decreasing Tric expression as it was stated at the discovery of 
Tric (Ikenouchi et al., 2005). So trictide does not cause an additional effect on that already 
leaky barrier, and the effect of trictide depends on the presence of Tric. 
 
5.3. TRICTIDE MODULATES LOCALIZATION AND EXPRESSION OF 
TRICELLULIN AND OTHER TIGHT JUNCTION PROTEINS 
Our investigations of barrier functions revealed the fact that both epithelial and endothelial 
cell barriers open after trictide administration. However, it is important to recognize which 
molecular modulations cause this aperture in order to understand the contribution of 
individual TJ proteins in barrier formation and the mechanism of barrier opening. There 
are two scenarios that may explain the process through which trictide binds to Tric. The 
first scenario assumes that trictide binds to the ECL2 part of Tric and speciﬁcally interferes 
with the trans-interactions between the proteins that form tTJs (Cording et al., 2015). The 
trictide inﬂuences the barrier function and eases paracellular passage of compounds 
through epithelial and endothelial monolayers. Previous research asserts that after 
synthesis, Tric-Occl complexes are transported together to the edges of elongating 
bicellular junctions and get separated when tricellular contacts are formed (Westphal et al., 
2010). Thus, the second scenario suggests that trictide binds to Tric ECL2 at bicellular 
contacts just after synthesis and before it reaches tricellular contacts. Therefore our 
experiments were designed to visualize localization of several TJ proteins and test their 
expression at mRNA and protein levels.  
We observed that in epithelial cells, Tric is elongated from tTJs to bTJs. This effect is 
similar to what is observed under pathological conditions like hypoxia (Cording et al., 
2015). Either by disturbing trans-interactions between the ECL2 parts of Tric or by being 
bound to Tric before reaching tTJs, trictide disrupts trimerization and destabilizes 
tricellular contacts. Interestingly, Occl is highly affected by trictide treatments. The typical 





expression of both mRNA and protein is also down-regulated. It was previously stated that 
Occl is highly dynamic at cell membrane. External factors like temperature and the amount 
of cholesterol at cell membrane affect the mobile fraction of Occl. Thus, the membrane 
fluidity is important for Occl and determines barrier function in parallel (Shen et al., 2008). 
In order to understand trictide’s effect on Occl, we conducted FRET analysis to test 
whether Occl-Occl cis-interactions are affected. According to FRET, Occl-Occl 
interactions are highly affected and results are consistent with microscopic investigations. 
Nevertheless it was stated in previous studies that Occl and Tric do not bind directly 
(Raleigh et al., 2010). That is why we assume that this must be an indirect effect like the 
previously revealed interplay between Occl and Tric (Ikenouchi et al., 2008). Occl 
transfected MDCK-II cells are treated with trictide and observed live with spin-disk 
microscopy for 15 h. Consequently, we found that Occl is moved towards tTJs 
progressively. At 12 h, internalization is visible especially from tricellular contacts. The 
internalization increases over time and bicellular signal is severely decreased. The current 
investigation also tests fluorescently labelled TAMRA-trictide. As expected, TAMRA 
signal is concentrated at tricellular area and loss of Occl signal overlaps with increasing 
TAMRA signal. Based on these data, a claim can be made that the peptide acts first at tTJ, 
which is then followed by bTJ, and interferes with the membrane fluidity of Occl - a 
determiner of barrier properties. 
In epithelial cells, LSR is also elongated from tTJs to bTJs acting together with Tric. 
Previously, LSR was reported to interact with Tric directly or indirectly through its 
cytoplasmic domain. In addition, Tric knockdown cells did not show any alteration at 
localization of LSR (Masuda et al., 2011). However, in our study Tric has changed its 
localization after trictide that might have caused LSR to elongate towards bTJs together. 
LSR expression at mRNA level is also highly affected by trictide treatment just like Tric.  
Cldn1 and Cldn5 are known to improve enrichment of Occl and Tric at cell–cell contacts 
(Cording et al., 2013). We observed that Cldn1 is translocated to tricellular contacts and 
led to a concentrated signal around tricellular area as a result of peptide administration. 
Furthermore, it is highly internalized and down-regulated at mRNA level. In previous 
studies, it was observed that a Cldn1 derived peptide similarly reduces membrane-
localization of Cldn1(Mrsny et al., 2008). FRET analysis shows that Cldn1-Tric 





after trictide. Cldn5 is examined with endothelial cells due to high expression levels. Just 
like Cldn1, Cldn5 signal is decreased at bTJs but increased around tTJs and extremely 
internalized. Cldn5 mRNA is 40% down-regulated in epithelial cells and 35% decreased in 
endothelial cells. Detection of Cldn1 and Cldn5 at tricellular contacts can be explained 
either by compensatory mechanisms (Cording et al., 2015; Breitkreuz-Korff, 2018) or shift 
of TJ proteins to unstabilized tricellular area.  
The mRNA of ZO-1 is not affected by trictide in epithelial cells and only insignificantly 
decreased in endothelial cells. It is not expected to see a vast effect of trictide on ZO-1 
protein. However, we observed that ZO-1 is also internalized and lessened at bicellular 
contacts. In addition, STED images confirmed that typical localization of ZO-1 is disturbed 
and, additionally, ZO-1 is assembled like a circle at tricellular contacts. Similar results are 
obtained with STED images of Tric and Occl proteins in MDCK-II cells. Both results can 
be interpreted as a confirmation of the opening of unstabilized tricellular contacts, which 
increase permeability of small and large molecules.  
FRET measurements confirmed that generally Tric involving protein-protein interactions 
are affected by trictide except Occl-Occl interactions, which are possibly affected 
indirectly by compensatory mechanisms (Ikenouchi et al., 2008). This strengthens the 
argument that Tric is specifically modulated directly from trictide applications. 
Nevertheless, other TJ proteins are also found to change their localization and down-
regulate their expression as a result of an indirect or direct trictide influence.  The reason 
for these modulations is not completely understood. 
To sum up, both scenarios are supported by the acquired data, such as elongated signals at 
tTJs, disturbed TJ signals at bTJs, and unstabilized tricellular contacts. Indeed, microscopic 
investigations revealed the fact that tricellular area is preferentially and highly affected by 
trictide. Moreover, Tric is modulated at every expression level, and trictide’s action 
depends on Tric’s presence. Most of the affected proteins have direct or indirect relations 
with Tric, except Occl. It is also important to acquire more information about 
transcriptional regulation of TJ proteins in order to explain down and up-regulations of 






5.4. TRICTIDE DOES NOT MODULATE PROPERTIES OF TISSUE BARRIERS 
CONSIDERABLY 
During in vitro studies, concentration and incubation time are optimized, and the effect of 
peptide is examined using various methods. Our objective was to test the drug passage 
through tissue barriers of several organs. Trictide is administered via intravenous injections 
to avoid the first-pass effect that greatly reduces a drug’s concentration before it reaches 
systemic circulation. We selected the highest dose (800 µM) that is soluble without a 
solubility enhancer. The administered dose is well tolerated by the animals, weight gain 
continues, no behavioral differences are observed compared to control group, and no 
edema are observed. Trictide increases the permeability significantly after 16 h in vitro. 
However, the proteolytic degradation by plasma proteins plays an additional role in blood 
stability and exposure time of the peptide (Werle & Föger, 2018). Ex vivo peptide stability 
tests within blood plasma demonstrated that peptide is still detectable up to 48 h, and its 
half-life endures approximately 12 h. Therefore, exposure time is expected between 4 h to 
24 h. Unlike in previous studies (Sauer et al., 2014; Zwanziger, Hackel, et al., 2012), 
exposure time is kept shorter in order to observe a short-term effect (4 h) in addition to a 
long-term effect (24 h) . On account of the plasma half-life being determined ex vivo, the 
further metabolic and excretion processes responsible for elimination of the peptides are 
not considered (Diao & Meibohm, 2013). 
After 4 h and 24 h of injections, mRNA expression of several TJ proteins is investigated in 
the organ of interest (brain) and the organ with higher Tric expression (kidney). TJ proteins 
are selected and grouped for different organs according to their expression levels. In brain, 
Cldn5 and Tric are highly up-regulated after 24 h of trictide injections, compared to the 
PBS control. These two proteins are important because Cldn5 is the dominant TJ protein in 
BBB, and Tric is the target protein of trictide. Interestingly, both proteins are slightly 
down-regulated after 4 h as a short-term effect. LSR is also significantly down-regulated 
after 4 h. We expected to see in vivo effect of trictide much earlier compared to in vitro, 
considering previous studies (Dithmer et al., 2017). Tric, Cldn1, Cldn5 (in colonic 
epithelial cells) and LSR, Cldn1, Occl (in mouse endothelial cells) are down-regulated 
after trictide administrations (16 h) during the in vitro experiments. When in vivo and in 





time after peptide injections has a similar influence on mRNA expressions of TJ proteins 
with 16 h of peptide incubation. The overexpression of Cldn5 and Tric found after 24 h of 
trictide can be an indicator of compensatory mechanism between TJ proteins. Similar 
mechanisms are observed between Cldn1-Cldn3 (Breitkreuz-Korff, 2018),  Tric-Occl 
(Cording et al., 2015; Ikenouchi et al., 2008) and Tric-LSR (Masuda et al., 2011). On the 
other hand, previous studies demonstrated that when Cldn1 targeting peptides were 
injected into perineurium, the permeability of small and macromolecules was enhanced 
and Cldn1 was down-regulated even after 48 h (Sauer et al., 2014; Zwanziger, Hackel, et 
al., 2012). Since the outcomes of both in vivo peptidomimetics are different, the reason 
behind Cldn5 and Tric up-regulations cannot be totally understood.  
In kidney, Tric and MD3 are down-regulated gradually from 3 h to 24 h of trictide 
exposure. Tric is highly expressed in mouse kidney as well as in colon (see chapter 4.1). 
Therefore, it is reasonable to state that Tric and MD3 are affected in a similar way as 
during in vitro experiments. Besides, the effect of trictide on a high Tric expressing organ 
is quite comparable to the findings of previous peptidomimetic studies (Dithmer et al., 
2017; Sauer et al., 2014; Zwanziger, Hackel, et al., 2012). Taken together, these findings 
show that trictide affected kidney in a more progressive and consistent way, and much 
earlier, which can be explained by the peptide’s water-soluble characteristic. 
Cldn25 is a recently discovered TJ protein and known to be expressed in brain cerebellum 
abundantly (Ohnishi et al., 2017). Cldn25 is used as a control protein in our mRNA 
examinations because its sequence is not similar to Tric, (Berndt, 2017) and to date there is 
no information about the interaction of Cldn25 and Tric. Surprisingly, Cldn25 is not 
affected by trictide in brain, yet it is significantly down-regulated after 24 h of trictide 
exposure in kidney. The expression level of Cldn25 in different organs is unknown, and 
that is why we are interested by prospects of future studies on Cldn25 expression in 
kidney. 
The most important part of in vivo investigation is fluorescent uptake of the tissue barriers 
after trictide. Therefore, animals were injected with Na-fluorescein (376 Da) after 4 h of 
trictide injections. The preliminary tests at 4 h and 24 h intervals did not reveal any 
meaningful difference.  A significant effect was obtained at the 4 h interval in previous 





Na-fluorescein uptake of kidney and liver is not enhanced by trictide injections. Brain has 
a tendency to increase the uptake after trictide administration, but the effect is insignificant 
due to high variability among datasets. Nevertheless, by increasing the number of 
experiments and by applying further optimizations, trictide’s potential for increasing BBB 
permeability can be revealed to a greater extent. C5C2, a Cldn5 peptide, was also 
administered intravenously  at nearly the same dosage (3.5 µmol/kg). The D-amino acid 
derivative of C5C2 triggered the strong barrier opening and significant increase of the 
brain uptake (Dithmer et al., 2017). Another peptide derived from Cldn5 is also 
administered intravenously (2.9 µmol/kg).  Evaluations have determined that this peptide 
increases Na-fluorescein uptake of brain only if it is applied three times: at 0 h, 18 h and 21 
h (Breitkreuz-Korff, 2018). Thus, the applications of trictide can be optimized similarly in 
order to enhance the brain’s Na-fluorescein uptake.  
The brain sections of trictide injected animals have been prepared for microscopic 
investigations. There were no major alterations in the localization of TJ proteins on brain 
microvessels that can be spotted visually. Similarly, the immunohistochemical stainings of 
brain cryosections of mice treated with Cldn5 derivative did not show a clear peptide-
mediated effect on Cldn5 localization in the TJs (Breitkreuz-Korff, 2018). However, the 
Cldn5 signal of brain microvessels from the trictide injected group is detected as more 
porous, and total fluorescence is quantified as weaker compared to that of the PBS group. 
Furthermore, the tricellular localization of Tric on brain capillaries is slightly decreased 
after trictide injection. Surprisingly, the total fluorescence of Occl is quantified as 
intensifying significantly in trictide injected animal brains. Unfortunately, 
immunohistochemical stainings of trictide injected brain sections cannot provide much 
information. More evident changes can be observed within 24 h trictide exposed animal 
brains.  Since brain is the only organ that shows a tendency of increasing Na-fluorescein 
uptake, it was stimulating to examine possible TJ protein modulations in brain. And yet, 






5.5. DETERMINATION OF TRICTIDE’S SECONDARY STRUCTURE AND 
INTERACTION WITH TRICELLULIN 
The structure of trictide is proposed by CD spectroscopy and molecular modeling as an 
elongated β-sheet composed of two β-strands with aromatic residues located at the surface 
of the peptide. The scrambled peptide exhibits three β-strands in a more compact 
organization and with numerous randomly structured sequence fragments. The aromatic 
amino acids are positioned in a totally different orientation compared to the trictide 
structure. The notable difference between the two structures can be the reason of the lack 
of efﬁcacy of the scrambled peptide. Earlier studies have described how trans-interactions 
between ECLs of Cldns are mediated by hydrophobic interactions of aromatic amino acids; 
we suggest a similar binding mechanism for trictide (Krause et al., 2008; Suzuki et al., 
2014). 
The sequence of trictide was not modified to optimize its function like the Cldn5 derived 
peptidomimetic (C5C2). When the α-helical propensity of C5C2 is reduced by C-terminal 
truncation, this reduction remarkably eliminates barrier-opening function. Distinct from 
Tric ECL2 and trictide binding mechanism, hydrogen bond association was proposed 
between ECL2 of Cldn5 and C5C2 (Dithmer et al., 2017).  
Like trictide, Cldn1 derived peptide has mostly β-sheet propensity, which is important for 
its function (Zwanziger, Hackel, et al., 2012). The conserved aromatic residues among 
classical claudins (Piehl et al., 2010); Phe and Tyr are suggested as binding elements 
between Cldn1 ECL2 and the peptide (Suzuki et al., 2014, Staat, doctoral dissertation 
2015). Similarly, the highly conserved amino acids of Tric ECL2, among vertebrate 
species, (Cording et al., 2015) are understood to play a role in trictide association  
In order to conﬁrm this mechanism, the aromatic core amino acids of Tric ECL2 are 
exchanged one by one with amino acids, which are again hydrophobic and smaller in size. 
MDCK-II cells are transfected with those recombinant proteins. The typical localization of 
Tric remains unchanged, which suggests complete trans-interactions between ECL2s and 
stable tricellular contacts. Further investigation of the barrier properties of Tric ECL2 
mutated cells is necessary to understand binding mechanism better. Instead of exchanging 





four amino acids, can be replaced. Until now only the C-terminal coiled-coil domain part 
of Tric crystal structure has been revealed (Schuetz et al., 2017). Additional data relevant 
to Tric’s 3D structure will stimulate this line of scientific inquiry. 
In earlier studies, the structure of Tric ECL2 did not show considerable secondary structure 
elements (Cording et al., 2015). The structure of Tric ECL2 and trictide has been modelled 
by different methods. The detected differences should be caused by the missing disulﬁde 
bond in trictide. The docking model presents two possible binding mechanisms, 
considering that the interactions occur between the hydrophobic surfaces. These binding 
mechanisms may explain the disruption of tricellular trans-interactions and the opening of 






















Tricellulin (Tric) is a tricellular tight junction (TJ) protein that establishes a barrier by 
sealing the intercellular cleft between tricellular cell-cell contacts. We have only limited 
information about the exact structure, function and transcriptional regulation of Tric. This 
study was conceived in order to better understand the contribution of Tric and other TJ 
proteins to the formation of the tricellular contact and maintenance of the proper barrier 
function.  
Trictide, a synthetic peptide derived from the second extracellular loop of Tric, has been 
developed to affect Tric for modulating paracellular tightness to initiate temporary opening 
of cell barriers. The functional, structural and molecular changes caused by the peptide 
have been examined in order to understand its mode of action and its potential for 
pharmacological use. With this work, for the first time tricellular TJs are targeted by using 
Tric peptidomimetics for a transient opening.  
When all functional and molecular alterations are considered together, it can be stated that 
trictide administration opens the cellular barrier transiently for small molecules and 
macromolecules until 40 kDa, concentration- and time-dependently. Furthermore, the 
disruption of tricellular contacts is revealed by various microscopy techniques such as laser 
scanning confocal, gated stimulated emission depletion (STED) and spin disk confocal 
microscopy. So it has became clear that destabilization of tricellular contact organization 
takes place together with the barrier opening.  
However, the molecular alterations at tricellular contacts may not be the only reason for 
the trictide-induced barrier opening. Because occludin (Occl) - a bicellular TJ protein - is 
shown to be highly internalized at the cell membrane, it is down-regulated at both mRNA 
and protein level and the homophilic cis-interaction of  Occl is highly decreased after 
trictide. Since there is no information to date about direct interaction between Tric and 
Occl, trictide’s influence on Occl is assumed as an indirect or unspecific effect. 
Additionally, MD3, LSR, Cldn1 and Cldn5 are down-regulated at mRNA but not at protein 
level. Therefore, they are not considered as direct targets. Considering long-term (15 h) 





contacts, the alteration of other tricellular or bicellular TJ proteins should be a secondary 
effect. 
The determined working concentration of the peptide was not toxic for cells. Since the 
therapeutic window of trictide is relatively narrow, concentrations between 125 and 150 
µM would be worth for further investigations of the barrier opening activity. 
Trictide has been implemented into in vivo experiments in order to modulate tissue 
barriers. We only observed a tendency of increased intake of small molecules into the 
brain. In vivo investigation of trictide still needs further optimization of administration as 
well as for the modification of the peptide. To optimize the pharmacokinetic profile of 
trictide and to minimize its recognition by peptidases, the peptide should be PEGylated or 
modified by fatty acids. The use of D-amino acids has been another option to increase 
trictide’s stability and availability in the blood. However, D-trictide does not efficiently 
alter barrier properties, most probably due to its conformational problems.  
Moreover, trictide should be modified, as successfully applied in previous studies for 
claudin peptidomimetics (Dithmer et al., 2017) for instance by extension. Moreover, basic 
amino acids such as arginine, histidine and lysine should be introduced, which is known to 
enhance cell penetration of the peptide and gain admission into the cell (Madani et al., 
2011). Most importantly, aromatic amino acids that are proposed to form the binding core 
should be exchanged to prove their importance in trictide’s efficacy.  
Due to its unique structure and function, Tric is expressed among all tissue barriers of all 
organs, unlike Cldn5, which is abundantly expressed only in a few organs, for instance in 
the capillaries of the brain. As Tric appears in ubiquitary distribution in all barriers, 
systemic administration is impossible to modulate a specific barrier selectively. Therefore, 
local administration is recommended. A drug combined with trictide could be given 
directly to the artery of a certain organ, like intra-arterial use of some chemotherapeutics in 
treating retinoblastoma (Yamane et al., 2004). The opening of the tissue barrier and the 
facilitated uptake of a certain drug by trictide will provide advantages in treatment 
protocols. Trictide’s usage in tissues with tighter barriers like the brain and eye is 
particularly beneficial. Because by facilitating intracellular uptake of the drug, the dose of 





The general relevance of this dissertation is found in its novel revelations about molecular 
modifications of the addressed TJ proteins triggered by trictide-induced Tric modulation. 
The barrier opening for molecules smaller than 40 kDa and destabilization of tricellular 
contacts is the proof of mechanism that trictide interferes with the interaction between the 
opposing extracellular regions of Tric contributing to the paracellular tightness. We 
propose trictide as a drug enhancer to increase the permeability of TJ-based tissue barriers 
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SUPPLEMENTARY MATERIAL  
 
Table S1 Messenger RNA (mRNA) expression of tricellulin (Tric) in different wild type (WT) mouse 
organs  

















































5.4±1.2 3.8±0.5 4.3±0.7 7±0.5 
Table contains numerical values from Fig. 4.1. mRNA expression of Tricellulin (Tric) in C57BL/6 mouse  





Table S2 Messenger RNA (mRNA) expression of designated proteins in human colon carcinoma epi-
thelial cells after peptide-free medium, 150 µM scrambled trictide and 150 µM trictide administra-
tions. 






















































































Table contains absolute values (ΔCt) of Fig. 4.10. mRNA expressions normalized to β-actin (Actb) (ΔCt = 
Ctjunction protein  - Ctactin); Ct, Cycle threshold; Tric, tricellulin; Occl, occludin; MD3, marvelD3; LSR, anti-
lipolysis stimulated lipoprotein receptor; Cldn1, claudin-1; Cldn5, claudin-5; ZO-1, zonula occludens protein 






Table S3 Messenger RNA (mRNA) expression of designated proteins in mouse brain endothelial cells 
after peptide-free medium, 100 µM scrambled trictide, 75 µM and 100 µM trictide administrations. 


















































































































Table contains absolute values (ΔCt) of Fig. 4.13 and Fig. S 1. mRNA expressions normalized to β-actin 
(Actb) (ΔCt = Ctjunction protein  - Ctactin); Ct, Cycle threshold; Tric, tricellulin; Occl, occludin; LSR, anti-
lipolysis stimulated lipoprotein receptor; Cldn1, claudin-1; Cldn5, claudin-5; Cldn25, claudin-25; ZO-1, 





Table S 4 Messenger RNA (mRNA) expression of designated proteins in wild type (WT) mouse brain 
and kidney upon phosphate-buffered saline (PBS) and 4 h and 24 h after 800 µM of trictide (3.6 
µmol/kg) administrations.  































































































































































































































































Table contains absolute values (ΔCt) of Fig. 4.22. mRNA expressions normalized to β-actin (Actb) (ΔCt = 
Ctjunction protein  - Ctactin); Ct, Cycle threshold; Tric, tricellulin; Occl, occludin; MD3, marvelD3; LSR, anti-
lipolysis stimulated lipoprotein receptor; Cldn1, claudin-1; Cldn5, claudin-5; Cldn12, claudin-12; Cldn25, 









Fig. S5 Trictide down-regulates mRNA expression of claudin-5, LSR, occludin and up-regulates 
Cldn25 and ZO-1 in mouse brain endothelial cells. (A) Effect on messenger RNA (mRNA) of designated 
proteins; upon trictide and scrambled trictide treatment compared to untreated control (2
ΔΔCt
) (red dotted 
line). mRNA normalized to β-actin (Actb) (ΔCt = Ctjunction protein  - Ctactin); Ct, Cycle threshold; total incubation 
time, 16 h; two-way ANOVA test was applied prior to Bonferroni’s comparison post hoc test; Mean ± SEM; 
n =10; ** P ≤ 0.01, *** P ≤ 0.001 versus untreated control. Cldn1, claudin-1; Cldn5, claudin-5; Cldn25, 
claudin-25; Tric, tricellulin; Occl, occluding; LSR, anti-lipolysis stimulated lipoprotein receptor; ZO-1, zonu-
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